EXHIBIT 8





2200 Sixth Avenue, Suite 425, Seattle, WA 98121 • 206.389.9321 • Toll Free: 855.329.0919



2208 North 30th Street, Suite 202, Tacoma, WA 98403 • 253.627.6401 • Toll Fee: 800.649.2034

ONE-WEEK TRANSCRIPT TURNAROUND

Digital Transcripts • Internet Realtime • HD Legal Video • Picture-in-Picture Depositions Remote Depositions • Designation Editing • Nationwide Scheduling • HD Videoconferencing

Thank you for choosing BA Litigation Services for your court reporting, legal video, and deposition technology needs. It is always our goal to provide you with exceptional service. If there is anything we can do to assist you, please don't hesitate to let us know.

Sarah Fitzgibbon, CCR Vice President



The Premier Advantage[™] PDF transcript bundle contains:

- Full-size and condensed transcripts
- Printable word index
- Hyperlinked selectable word index
- Embedded printable exhibit scans
- Hyperlinked selectable exhibit viewing
- Common file formats: txt, lef, mdb accessed via *paperclip* icon

1 UNITED STATES DISTRICT COURT 2 WESTERN DISTRICT OF WASHINGTON 3 WESTERN DISTRICT OF WASHINGTON 4 AT SEATTLE 5 _____) STATE OF WASHINGTON, et al.,) NO.2:25-cv-00244-LK 6 7 Plaintiffs,) 8 v.) 9 DONALD J. TRUMP, in his) 10 official capacity as President) 11 of the United States, et al.,) 12 Defendants.) 13 _____) 14 Washington, D.C. 15 Thursday, April 3, 2025 16 17 Deposition of MICHELLE G. BULLS, a witness herein, was called for examination by counsel for 18 19 Plaintiffs in the above-entitled matter, pursuant to 20 notice, the witness being first duly sworn by 21 BESS A. AVERY, a Notary Public in and for the 22 District of Columbia, taken at the offices of B&A 23 Litigation Services, 1029 Vermont Avenue, N.W., Washington, D.C., commencing at 9:06 a.m., when 24 25 were present on behalf of the respective parties:



1	APPEARANCES
2	ON BEHALF OF THE PLAINTIFF STATE OF WASHINGTON:
3	WILLIAM MCGINTY, ESQ.
4	LAURYN K. FRAAS, ESQ.
5	Assistant Attorneys General
6	Attorney General of Washington
7	800 Fifth Avenue, Suite 2000
8	Seattle, Washington 98104-3188
9	(360) 709-6027
10	william.mcginty@atg.wa.gov
11	lauryn.fraas@atg.wa.gov
12	ON BEHALF OF THE DEFENDANTS:
13	VINITA B. ANDRAPALLIYAL, ESQ., SR. COUNSEL
14	CHRISTIAN S. DANIEL, ESQ., TRIAL ATTORNEY
15	ROBERT BOMBARD, ESQUIRE
16	UNITED STATES DEPARTMENT OF JUSTICE
17	Civil Division, Federal Programs Branch
18	1100 L Street, NW
19	Washington, DC 20530
20	(202) 305-0845
21	Vinita.B.Andrapalliyal@usdoj.gov
22	Christian.S.Daniels@usdoj.gov
23	
24	ALSO PRESENT: Miranda Berge, Esq HHS
25	Anna Jacobs, Esq HHS



1	INDEX	
2	Witness: Page	
3	MICHELLE G. BULLS	
4	Examination by Mr. McGinty 6	
5	Examination by Ms. Andrapalliyal 184	
6	Further Examination by Mr. McGinty 204	
7		
8		
9		
10		
11	EXHIBITS	
12		
13	Bulls Deposition Exhibits Page	
14	Exhibit 1 Subpoena Duces Tecum	
15	Exhibit 2 Resume of Michelle G. Bulls 33	
16	Exhibit 3 Presidential Documents from the 49	
17	Federal Register Vol. 90, 1/20/2025	
18	Exhibit 4 Termination letter, dated 2/28/25 66	
19	Exhibit 5 Exhibit 5, article from journal 77	
20	Nature	
21	Exhibit 6 NIH Grants Management Staff 91	
22	Guidance - Award Assessments for	
23	Alignment with Agency Priorities -	
24	3/2025	
25		

1	EXHIBITS (Continued)
2	
3	Exhibit 7 Memo from NIH to Institute and 99
4	Centers Chief Grants Management
5	Officers, 2/13/2025
6	Exhibit 8 Memo from NIH to Institute and104
7	Center Chief Grants Management Officers,
8	2/12/2025
9	Exhibit 9 Exhibit B - Notices of Awards106
10	Exhibit 10 HSS Notices of Award
11	Exhibit 11 NIH Office of Extramural Research118
12	letter to Patrick Donnell, 3/12/2025
13	Exhibit 12 NIH Office of Extramural Research122
14	letter to Julie C. Tang, 3/18/2025
15	Exhibit 13 NIH Office of Extramural Research125
16	letter to Garrett M. Steed, 3/21/2025
17	Exhibit 14 E-mail from Office of Sponsored126
18	Programs to Carol Rhodes
19	Exhibit 15 NIH letter to Carol Rhodes,129
20	3/18/2025
21	Exhibit 16 NIH letter to Lester Warnac132
22	Villaflor, 3/20/2025
23	Exhibit 17 NIH letter to Carole Rhodes,134
24	3/12/2025
25	



Case 1:25-cv-10787-BEM Document 38-8 Filed 04/25/25 Page 7 of 246

1	EXHIBITS (Continued)
2	
3	Exhibit 18 E-mail from UW-AOR to Carol Rhodes,136
4	3/21/25
5	Exhibit 19 NIH letter to Carol Rhodes,139
6	3/20/2025
7	Exhibit 20 NIH Grants Policy Statement141
8	Exhibit 21 Spreadsheet of terminations
9	Exhibit 22 Revised version of Exhibit 21182
10	
11 12(13 14 15	all exhibits retained)
16 17	
18	
19 20	
21	
22	
23	
24	
25	



7	
1	PROCEEDINGS
2	
3	(Bulls Deposition Exhibit 1 was
4	premarked.)
5	Thereupon,
б	MICHELLE G. BULLS,
7	was called as a witness by counsel for Plaintiffs,
8	and, having been duly sworn by the Notary Public,
9	was examined and testified as follows:
10	EXAMINATION
11	BY MR. McGINTY:
12	Q Could you state your name and spell your
13	last name for the record, please.
14	A Sure. Michelle Bulls, B-U-L-L-S.
15	Q Great. And have you ever been deposed
16	before?
17	A No.
18	Q Okay. So just in terms of ground rules,
19	we're here so that I can ask you some questions
20	about what you know about the case. I'll ask you
21	questions and you'll answer them unless you're
22	instructed by counsel not to do so.
23	Is that fair?
24	A That's fair.
25	Q Okay. It's important we make a clear



1	record, so please wait for me to ask my question and
2	I'll wait for you to answer. Is that fair?
3	A That's fair.
4	Q If you don't understand a question, will
5	you tell me?
6	A Yes.
7	Q Great. And if you answer a question, I'm
8	going to assume that you understood it.
9	Is that fair?
10	A That is fair.
11	Q This isn't an endurance test. If you need
12	to take a break for any reason, let me know. I'll
13	try to accommodate you as soon as I can. I just ask
14	that you answer any question that's pending before
15	we take a break. Is that fair?
16	A That's fair.
17	Q Okay. Now, do you understand that you are
18	testifying under oath today?
19	A Yes.
20	Q And what's your understanding of
21	testifying under oath?
22	A That I need to tell the truth.
23	Q Okay. And why is it important that you
24	tell the truth when you're under oath?
25	A Because you need to understand the facts

1	as I know them and they need to be true.
2	Q Okay. And you agree that you're going to
3	tell the truth today?
4	A I do.
5	Q Okay. Is there any reason that you can't
6	answer my questions truthfully today?
7	A No.
8	Q Okay. Has anyone told you not to tell the
9	truth at this deposition?
10	A No.
11	Q Okay. Has anyone threatened you or told
12	you that bad things would happen if you told the
13	truth?
14	A No.
15	Q Has anyone told you that good things would
16	happen if you didn't tell the truth?
17	A No.
18	Q Okay. How did you prepare for this
19	deposition?
20	A I read through e-mails and just
21	familiarized myself and spoke with counsel.
22	Q What e-mails did you read through?
23	A E-mails that I received.
24	Q Okay. And who did you receive those
25	e-mails from?



1	A	E-mails from my supervisor.
2	Q	Okay. Who is your supervisor?
3	A	My supervisor was Liza Bundesen.
4	Q	Bundesen?
5	A	Mm-hmm.
6	Q	Is that the only person who sent you
7	e-mails t	hat you reviewed?
8	A	Yes.
9	Q	Okay. Did you review any e-mails that
10	you've se	ent?
11	A	Yes.
12	Q	Okay. What e-mails that you sent did you
13	review?	
14	A	I reviewed e-mails that I sent to Chief
15	Grants Ma	nagement Officers.
16	Q	Okay. And, just, could you tell me what a
17	Chief Gra	ants Management Officer is?
18	A	It's an officer that is in the Funding
19	Institute	es and Centers that is authorized to make
20	NIH award	ls on behalf of NIH and HHS.
21	Q	Okay. And when you sent those e-mails,
22	would the	ey have been sent to all the Chief Grants
23	Managemer	nt Officers or just to some of them?
24	A	Some of the e-mails were sent to all of
25	them.	



1	Q And some of them were sent to less than
2	all of them?
3	A Correct.
4	Q Okay. And so for those that were sent to
5	less than all of them, who were those sent to?
6	A The I don't recall the institutes that
7	they were sent to, I apologize.
8	Q Do you recall the people?
9	A I recall one person.
10	Q Okay. Who is that?
11	A Maggie Young.
12	Q Maggie Young?
13	A Mm-hmm.
14	Q And Maggie Young is the Chief Grants
15	Management Officer for?
16	A The Child Health Institute.
17	Q Okay. Is that NICHD?
18	A Correct.
19	Q Okay. So you reviewed e-mails from your
20	supervisor, Liza Bundesen. You reviewed e-mails
21	that you sent to Chief Grants Management Officers.
22	Did you review any other documents?
23	A In e-mail form? Yes, I did.
24	Q Okay. What other so you reviewed other
25	documents in e-mail form? Is that what you just



1 said? 2 Yes, I was trying to -- when you said, Α 3 "other documents," I was trying to understand what you meant. 4 5 0 Sure. No, that's fair. So what other documents in e-mail form did 6 7 you review? I reviewed the -- I don't know what it's 8 Α 9 called, where you -- where I'm supposed to come and 10 provide documentation, or provide documentation for 11 the -- this session. 12 No, that's fair. Okay. 0 Sure. 13 Α For this deposition. 14 I'll go ahead and hand you what has been 0 15 marked Exhibit 1. 16 (Bulls Deposition Exhibit 1 was introduced into the record.) 17 18 MR. McGINTY: Give a copy to counsel. 19 (Document tendered to Ms. Andrapalliyal) 20 BY MR. McGINTY: 21 Is this the document that you were just 0 2.2 referring to? 23 Α Yes. 24 Okay. And just for the record, this is 0 25 the Subpoena Duces Tecum that was served upon you



1 for today's testimony and a production of documents, 2 right? 3 Α Correct. 4 0 Okay. 5 MS. ANDRAPALLIYAL: I just want to, sorry, 6 state for the record we do have a standing objection 7 to the testimony here today. This Subpoena Notice and Deposition Notice were served in accordance with 8 9 expedited discovery that the Court ordered in 10 connection with its order denying the Court's motion 11 for -- or, the Plaintiff's Motion for Contempt. And 12 that motion concerns a grant that NIH terminated. 13 That grant has been since reinstated, and 14 so it's our position that those discovery 15 requests -- and I say discovery in general -- has 16 That being said, we understood that been mooted. 17 this deposition is moving forward today, but we just 18 wanted to make that objection for the record. 19 MR. McGINTY: Okay. I won't respond to 20 that right now, but if we need to follow up, we will. 21 2.2 BY MR. MCGINTY: 23 So you said that you reviewed other 0 Okay. 24 documents in e-mail form. And when you answered 25 that question as to what documents in e-mail form



1	you reviewed, I think you said this Subpoena that I
2	just put in front of you marked as Exhibit 1.
3	Is that right?
4	A That's right.
5	Q Okay. I'm going to get to the Subpoena in
6	a little bit, but are there any other documents,
7	other than the ones you've talked about, e-mails
8	from your supervisor, e-mails that you sent, this
9	Subpoena document, any other documents that you
10	reviewed in preparation for today's deposition?
11	A No other documents.
12	Q Okay. And did you talk to anybody in
13	preparation for today's deposition?
14	A Yes.
15	Q Okay. Who did you talk to?
16	A I spoke with the Office of General Counsel
17	and DOJ.
18	Q Okay. And did you talk to anybody else?
19	A My husband.
20	Q Okay. What did you tell your husband?
21	A I need you to take me.
22	Q Okay. Anything else?
23	A No.
24	Q Okay. You didn't talk to anybody else
25	about today's deposition?



1	А	The counsel.
2	Q	Oh, yeah, yeah. What I meant is, you
3	talked to	DOJ, you talked to OGC, Office of General
4	Counsel?	
5	A	Yes.
6	Q	And you talked to your husband?
7	A	I talked to my husband. And I alerted my
8	superviso	r, my current supervisor, that I had to
9	come to t	he deposition.
10	Q	Okay. And who is that?
11	A	Jon Lorsch.
12	Q	Jon Lorsch? Can you spell that for me.
13	A	L-O-R-S-C-H.
14	Q	Okay. And did you talk substantively
15	about wha	t your testimony might be today?
16	A	No.
17	Q	Okay. Did he ask any questions?
18	A	No.
19	Q	Okay. Let's turn to the Subpoena that's
20	been mark	ed as Exhibit 1. So you got a copy of
21	this?	
22	A	Yes.
23	Q	Okay. And when did you get a copy?
24	A	I'm not sure.
25	Q	All right. If you could turn to page 5 of



Case 1:25-cv-10787-BEM Document 38-8 Filed 04/25/25 Page 17 of 246

1	Exhibit 1, there's a numbered list titled, "Requests
2	for Production." Do you see that?
3	A Yes.
4	Q Did you review that before today?
5	A Yes.
6	Q Okay. And what efforts did you make to
7	collect the documents that were asked for here?
8	A I went through my e-mails and tried to
9	find anything that I could provide.
10	Q Okay. And did you find e-mails that would
11	match the descriptions in this list?
12	MS. ANDRAPALLIYAL: Objection, calls for a
13	legal conclusion.
14	BY MR. McGINTY:
15	Q You can answer.
16	(Witness reviews document)
17	THE WITNESS: Yes.
18	BY MR. McGINTY:
19	Q Okay. What e-mails were those?
20	A The e-mail that I sent to oh. Well,
21	the e-mails that I received related to the
22	termination.
23	Q Mm-hmm.
24	A The e-mails that I sent to the Chief
25	Grants Management Officers related to the



1	termination, the letter of termination, and a
2	response responses to requests for me to make the
3	termination.
4	Q Okay. When you say, "the termination,"
5	you're talking about termination of a grant where
6	Dr. Kym Ahrens was the principal supervisor at
7	Seattle Children's Hospital. Is that what you're
8	talking about?
9	A I'm talking about that includes, yes, the
10	grant.
11	Q Okay. And anything else?
12	A I don't recall.
13	Q Okay. Did you only look for e-mails, or
14	did you look for any other kinds of documents?
15	A E-mails.
16	Q Only e-mails?
17	A (Nodding head)
18	Q Okay. Is that because no other documents
19	exist or because you didn't look?
20	A The e-mails had other documents attached.
21	Q Okay. So let's just go through, I guess.
22	Let's start with Number 1. This request calls for
23	all drafts in your possession, custody, or control
24	of the following documents included as an exhibit to
25	the declaration of Kym Ahrens and William McGinty.



1		Did you get copies of those documents so
2	you could	verify that you had to see if you had
3	other cop	ies of those versions of documents?
4	A	No.
5	Q	You didn't get copies of those?
6	A	I don't recall.
7	Q	Okay. So Number 2 asks for all drafts in
8	your poss	ession, custody, or control of the document
9	titled "S	taff Guidance - Award Assessments for
10	Alignment	with Agency Priorities - March 2025."
11		Do you know what document that's talking
12	about, St	aff Guidance - Award Assessments for
13	Alignment	with Agency Priorities?
14	A	Yes.
15	Q	Okay. And do you have a copy of that?
16	A	Yes.
17	Q	Okay. And did you give that to counsel?
18	A	Yes.
19	Q	Okay. How many versions of that exist?
20	A	At the time I gave it to counsel or today?
21	Q	Today.
22	A	Probably two or three.
23	Q	Two or three versions of that exist?
24	А	Maybe yeah, I'll say three.
25	Q	Three? Three that exist.



1	And how many versions existed when you
2	gave it to counsel?
3	MS. ANDRAPALLIYAL: Objection. That's
4	privileged information.
5	I'm going to instruct you not to answer.
6	BY MR. McGINTY:
7	Q Okay. When is the most recent version of
8	that document dated?
9	MS. ANDRAPALLIYAL: Objection. To the
10	extent it's calling for draft information,
11	privileged, I'm going to instruct you not to answer.
12	MR. McGINTY: She just testified that
13	there's three versions of the document. She
14	testified there's three versions of the document.
15	BY MR. McGINTY:
16	Q Are any of those were any of those used
17	to implement NIH policy?
18	A They were used to provide guidance. And
19	there's the one document, that was used to provide
20	guidance. The rest of them have been draft versions
21	trying to update the guidance, so.
22	Q Okay. Were they distributed to NIH staff?
23	MS. ANDRAPALLIYAL: Objection. To the
24	extent we're talking about drafts, I'm going to
25	
20	instruct you not to answer on privileged grounds.



1	MR. McGINTY: The question doesn't call
2	for the content of any document. You substantiate
3	your objection on privilege?
4	MS. ANDRAPALLIYAL: Well, the deliberative
5	process privilege doesn't just cover the contents of
6	the document, but it covers the communications that
7	go into the deliberative process. And so timing and
8	who received what, that's part of the process that
9	should be protected.
10	BY MR. McGINTY:
11	Q So it's your testimony today that only one
12	version of that document was ever used by NIH staff
13	for purposes of implementing NIH policy?
14	A I don't know if they used it. It was
15	provided to them to provide guidance to them on how
16	to implement or assess their portfolios. So
17	Q Okay.
18	A I don't know.
19	Q It was given to them so that they could
20	assess their portfolios in conformance with the
21	guidance?
22	A Yes.
23	Q So it was used by them to assess their
24	portfolios. Is that right?
25	A That is correct.



1	Q Okay.
2	MR. McGINTY: Do you maintain your
3	privilege objection, Counsel?
4	MS. ANDRAPALLIYAL: I maintain the
5	privilege objection as to drafts. I don't maintain
б	it as to the final version.
7	MR. McGINTY: Okay.
8	BY MR. McGINTY:
9	Q How many versions of that document were
10	used to, for staff to assess their portfolios?
11	A Can you repeat that question.
12	Q Yeah. I guess I'm trying to understand is
13	how many versions of that document were actually
14	used for the purposes of NIH doing its work,
15	including assessment of portfolios? Was it all
16	three, was it only two, was it only one?
17	A So they only received instructions to use
18	the first version. The second and third versions
19	are versions that we worked on together as they had
20	questions and I answered them through the Staff
21	Guidance.
22	Q Okay. But did they use those versions to
23	assess their portfolios?
24	A I don't know if they used those versions
25	to assess their portfolios.
	الا ^{ست} اريخ



1	Q Okay. Were they instructed to?
2	A They were instructed to they were
3	instructed to use the Staff Guidance to assist them
4	in addressing, because they had questions, to assist
5	them in addressing their questions and concerns. So
6	if that is considered.
7	Q If that is considered?
8	A If that's considered giving, telling them,
9	or using it as Staff Guidance to assess their
10	portfolio, then yes.
11	Q Okay. So, and how many so it sounds
12	like, if I'm understanding this right, and tell me
13	if I'm wrong, it sounds like there was a version of
14	the document that was sent out to staff, they were
15	instructed to use this to assess their portfolios,
16	if they had questions, the document changed in
17	response to their questions. They continued to use
18	the updated version to assess their portfolios.
19	Am I right so far?
20	A They were uncomfortable with using all of
21	the new, you know, the additional pieces because we
22	were still awaiting additional guidance. So they
23	had questions about the original, we addressed those
24	questions. And staff were still a little hesitant
25	about using some staff were hesitant about using



Γ

1	it, but they wanted to have it so that when they
2	were able to use it, they could.
3	Q Okay. So some staff were using it and
4	some staff didn't want to. Am I understanding that
5	right?
6	A Yes.
7	Q Okay. And right now we're talking about
8	the second version?
9	A Yes.
10	Q Okay. And then there were continued
11	questions about this, and so you got more questions
12	about it, and a third version was created. Is that
13	right?
14	A Yes, yes.
15	Q Okay. And this third version, was that
16	used by staff to assess their portfolios?
17	A I don't know.
18	Q You don't know. Okay. Why not?
19	A Because we were still they were still
20	waiting for me to issue the final guidance.
21	Q And that has yet to be done?
22	A And that has yet to be done.
23	Q Okay. So the first one has been used to
24	assess portfolios. The second one was used by some
25	people to assess portfolios. The third one you

1	don't know. And there's a final that's forthcoming?
2	A Yes. It's been an evolving document. And
3	so, like I said, some of them were some of the IC
4	staff were comfortable in using the document, some
5	of the staff were, decided that they were going to
6	stop and wait for the final document. So it's been
7	a bit of back and forth.
8	Q Okay. And "IC," Institute/Centers?
9	A Institutes and Centers.
10	Q Thank you.
11	A You're welcome.
12	Q Let's see. And then item Number 3 asks
13	for all communications made to or by you related to
14	documents identified in Requests for Production 1
15	and 2.
16	It sounds like there was lots of
17	communications to and by you about all of these
18	documents. Is that right?
19	A Yes.
20	Q Okay. And did you collect all of those
21	communications?
22	A I believe I did.
23	Q Okay. And you gave them to counsel?
24	A I believe I did.
25	Q Okay. Let's see. And then all documents



Γ

1	in your possession, custody, or control, including
2	communications made to or by you, related to
3	termination of NIH Grant No and then there's a
4	grant number there 5R21HD107311. That's the
5	document we were just talking about with Kym Ahrens
6	as the principal investigator. Is that right?
7	A I do recognize the grant number, yes.
8	Q Okay. And it sounds like there's all
9	kinds of documents that would be responsive to that
10	one, too?
11	A Correct.
12	Q Okay. And you gave those to counsel?
13	A I
14	MS. ANDRAPALLIYAL: Objection. Just a
15	standing objection here to the extent that we're
16	going through all these requests that are calling
17	for a legal conclusion where you're asking her
18	whether she has collected all of the documents
19	responsive to these requests.
20	MR. McGINTY: Are you instructing the
21	witness not to answer?
22	MS. ANDRAPALLIYAL: No.
23	BY MR. McGINTY:
24	Q Could you repeat your last answer for me.
25	A Can you repeat the question.



Γ

1	Q Yes. I think I just asked you if you gave
2	them to counsel.
3	A I believe so.
4	Q Okay. So next one asks for all documents
5	in your possession, custody, or control related to
6	NIH's claims that research programs based on gender
7	identity are often unscientific, have little
8	identifiable return on investment, and do nothing to
9	enhance the health of many Americans. Many such
10	studies ignore, rather than seriously examine,
11	biological realities.
12	Did you look for documents related to that
13	request?
14	A Yes.
14 15	A Yes. Q Did you find any?
15	Q Did you find any?
15 16	Q Did you find any? A It was in the termination letter. That
15 16 17	Q Did you find any? A It was in the termination letter. That was the language in the termination letter that was
15 16 17 18	Q Did you find any? A It was in the termination letter. That was the language in the termination letter that was provided to me.
15 16 17 18 19	<pre>Q Did you find any? A It was in the termination letter. That was the language in the termination letter that was provided to me. Q Okay. Anything else?</pre>
15 16 17 18 19 20	Q Did you find any? A It was in the termination letter. That was the language in the termination letter that was provided to me. Q Okay. Anything else? A No.
15 16 17 18 19 20 21	Q Did you find any? A It was in the termination letter. That was the language in the termination letter that was provided to me. Q Okay. Anything else? A No. Q Okay. Number 6 asks for all documents in
15 16 17 18 19 20 21 22	<pre>Q Did you find any? A It was in the termination letter. That was the language in the termination letter that was provided to me. Q Okay. Anything else? A No. Q Okay. Number 6 asks for all documents in your possession, custody, or control related to</pre>
15 16 17 18 19 20 21 22 23	Q Did you find any? A It was in the termination letter. That was the language in the termination letter that was provided to me. Q Okay. Anything else? A No. Q Okay. Number 6 asks for all documents in your possession, custody, or control related to NIH's claim that it is the policy of NIH not to



1	A Yes.
2	Q And did you search for documents like
3	that?
4	A I provided the documents that likely had
5	this in it, but I was not searching for this
6	specific document, if that makes sense.
7	Q Okay. You were looking for documents that
8	had that quoted language?
9	A Not the quoted language. I looked for
10	documents that surrounded the termination, and if
11	the termination was based on this, it had that in
12	it. I wasn't looking specifically for this, if that
13	makes sense. I gave what I had and what I received,
14	and I that's what I gave.
15	Q Okay. I guess my question is:
16	What this is asking for is documents
1 🗗	
17	that's related to the claim that it is the policy of
18	that's related to the claim that it is the policy of NIH not to prioritize these research programs, so
18	NIH not to prioritize these research programs, so
18 19	NIH not to prioritize these research programs, so did you look for any documents about NIH policy?
18 19 20	<pre>NIH not to prioritize these research programs, so did you look for any documents about NIH policy? A No, I looked for documents related to the</pre>
18 19 20 21	<pre>NIH not to prioritize these research programs, so did you look for any documents about NIH policy? A No, I looked for documents related to the termination.</pre>
18 19 20 21 22	<pre>NIH not to prioritize these research programs, so did you look for any documents about NIH policy? A No, I looked for documents related to the termination. Q Okay. Did you look for any documents</pre>



1	Q Okay. Thank you.
2	So moving on to Number 7. This one asks
3	for all documents in your possession, custody, or
4	control related to NIH's claims that this award
5	related to transgender issue no longer
6	effectuates agency priorities.
7	So did you look for any documents about
8	NIH priorities in response to this question?
9	A I looked for the termination documents
10	that may have included that language, but I did not
11	look for that language.
12	Q Okay. You didn't look for any documents
13	about whether or not it is the policy, or, excuse
14	me, the priority of NIH to fund studies and research
15	related to transgender issues?
16	A No, I provided the documents that was
17	provided to me that may have included that. I did
18	not search for that.
19	Q Okay. The next one asks for all documents
20	in your possession, custody, or control that include
21	descriptions of policies, procedures, or guidance
22	regarding termination of NIH grants dated between
23	January 20, 2025 and March 6, 2025. Do you see
24	that?
25	A Mm-hmm.



1	Q Did you look for those kinds of documents?
2	A Yes, I provided all of the documents that,
3	regarding the termination.
4	Q Okay. And would this have included the
5	document that we were just talking about a minute
6	ago, the Staff Guidance Award Assessments? Would it
7	have included that one?
8	A Yes.
9	Q Okay. Are there any other documents about
10	agency priorities or policies that are dated in that
11	range having to do with grant termination?
12	A No, not that I recall.
13	Q Okay. The next one asks for all documents
14	in your possession, custody, or control including
15	communications, policy statements, or guidance
16	documents related to or referencing two Executive
17	Orders. Do you see that there?
18	A Yes.
19	Q And did you search for those documents?
20	A I provided the documents that led up to
21	the termination. That's all I provided.
22	Q Okay. In response to this request
23	specifically?
24	A In response to the request for me to
25	provide all documentation that led up to, all the



Γ

1	way through the termination. That's what I
2	provided.
3	Q Okay. How about documents that relate to
4	or reference these two Executive Orders, did you
5	search for that?
6	A If it was a part of the termination
7	package communication, I did provide it. But I
8	don't know that I searched for the Executive like
9	I didn't provide the Executive Order, I don't
10	believe.
11	Q Okay. So you searched for documents that
12	would have related to the termination we've been
13	talking about, but not necessarily anything else?
14	A Correct.
15	Q Okay. Did you search for any documents or
16	any communications between you and any person
17	affiliated with the Department of Government
18	Efficiency?
19	A I provided all the e-mails, all of the
20	communications, and if that was a part of it, that
21	is part of that package. I didn't look for any
22	communications with Department of Government
23	Efficiency.
24	Q Okay. Were there such communications?
1	g okay. Were enere such communications:
25	A There was no communication between, that I



	Bulls, Michelle - April 03, 2025
1	can, that I know of, directly between me and anyone
2	in the Department of Government Efficiency. They
3	may have been copied on the e-mail, but not with me.
4	Q Okay. Sitting here today, can you
5	recollect any e-mails that they were copied on?
6	A Yes, one.
7	Q Okay. Can you describe that e-mail for
8	me?
9	A I believe that was the e-mail that
10	included a list of grants to be terminated.
11	Q Okay. So you got an e-mail. Was it from
12	someone at the Department of Government Efficiency?
13	A No.
14	Q No. They were copied on one. Who was
15	sending that e-mail?
16	A The e-mail that I received was from,
17	between me and my supervisor, and there was a string
18	below it. So I wasn't directly on the e-mail with
19	that individual, it was forwarded to me with a list
20	of the terminations.
21	Q I see. And who was your supervisor at the
22	time?
23	A Liza Bundesen.
24	Q That was Liza Bundesen?
25	A Yeah.



1	Q	And she was given a list of terminations?
2	А	Correct.
3	Q	And that list came from someone at the
4	Departmer	nt of Government Efficiency?
5	A	That list came from Rachel Riley.
6	Q	Okay.
7	А	And her address was from HHS Office of the
8	Secretary	7•
9	Q	Thank you. And the Department of
10	Governmer	nt Efficiency was how were they involved
11	in that e	e-mail?
12	А	Copied.
13	Q	They were cc'd?
14	А	I believe.
15	Q	Okay. So Rachel Riley at HHS sent it to
16	Liza Bund	lesen, who sent it to you. Is that right?
17	А	Yes.
18	Q	Okay. Can you remember anybody else who
19	was inclu	uded on that e-mail?
20	А	Not that particular e-mail. Because one
21	of the e-	-mails came from Dr. Memoli, so those were
22	two separ	rate strings, but both termination e-mails.
23	Q	Oh, okay. So there's another set of
24	terminat	ions. Am I understanding that right?
25	A	It was the same yes, yes.



1	Q Okay. And that one came from Dr. Memoli?
2	A Yes.
3	Q But that was did it come from the same
4	person at HHS?
5	A Yes, it came from the same person at HHS
6	to Dr. Memoli that was forwarded to Liza.
7	Q I see. And who is the person in the
8	Department of Government Efficiency who was copied?
9	A I believe his name was Brad.
10	Q Brad. Don't remember the last name?
11	A I don't.
12	Q Okay, fine. Okay.
13	So it sounds like there's at least two
14	e-mails that copied someone at the Department of
15	Government Efficiency. One was forwarded to you by
16	Dr. Bundesen, one was forwarded to you by
17	Dr. Memoli. Are there any others?
18	A Dr. Memoli didn't forward the e-mail
19	directly to me.
20	Q Oh.
21	A He forwarded it to Liza Bundesen, who
22	forwarded it to me.
23	Q I see. Thank you for that clarification.
24	A You are welcome.
25	Q Are there any others?



1	A No.
2	Q Okay. Just the two?
3	A (Nodding head)
4	Q Okay.
5	A Yes.
6	Q Thank you so much. I did not ask you to
7	verbally answer the questions, and I should have
8	done so, so thank you so much for remembering to do
9	that.
10	A You're welcome.
11	Q We also asked for a copy of your CV and
12	your resume. Did you give that to counsel?
13	A Yes.
14	MR. McGINTY: Counsel, do you have any of
15	those documents to provide today?
16	MS. ANDRAPALLIYAL: Yes. I believe we've
17	provided you a copy of Ms. Bulls' CV.
18	(Document tendered to Mr. McGinty)
19	MR. McGINTY: Thank you. Okay. Let's go
20	ahead and mark this Exhibit 2.
21	(Bulls Deposition Exhibit 2 was marked for
22	identification.)
23	MR. McGINTY: Counsel, would it be
24	possible to get a second copy of this?
25	MR. BOMBARD: For the witness?



1	MR. McGINTY: I was going to hand the
2	witness the marked copy, and I would like to be able
3	to follow along, if possible.
4	MR. BOMBARD: Oh.
5	(Document tendered to Mr. McGinty)
б	MR. McGINTY: Thank you.
7	BY MR. McGINTY:
8	Q Okay. I just handed you what has been
9	marked as Exhibit 2. Do you recognize this
10	document?
11	A Yes.
12	Q And what is it?
13	A My resume.
14	Q Okay. Feel free to reference this. I'm
15	just going to ask you to go through your job
16	experience and education history since the time you
17	were 18, if that's possible. And to the extent you
18	want to reference what's on the CV and point things
19	out to me, I'd appreciate it.
20	A Starting forward or backward?
21	Q Starting forward, please. Let's start,
22	let's go chronological order from the time you were
23	18.
24	A From the time I was 18, graduated, some
25	community college, cosmetology school, cosmetology



1	license. Joined the government in a Pathways
2	Program. Worked in the government from, I guess,
3	1989 I can't recall, but maybe, yeah 1989
4	through now.
5	I worked through Grants Management Clerk,
6	Grants Management Specialist, Grants Management,
7	Officer at NIH. Went into Policy within the Office
8	of Policy for Extramural Research Administration as
9	an analyst. Left NIH and went to the Indian Health
10	Service to head up their policy office.
11	Left the Indian Health Service to go to
12	HHS Office of Grants to head up the policy office
13	for HHS. And came back to NIH as the Deputy
14	Director of the Office of Policy for Extramural
15	Research Administration, and then ultimately was
16	appointed as the Director.
17	Q Okay. So you started if I understand
18	you correctly, you started with the government
19	through a Pathways Program in 1989. And then you
20	became a Grant Management Clerk in NIH; is that
21	right?
22	A In the National Heart, Lung, and Blood
23	Institute.
24	Q Okay. And when was that?
25	A I don't recall.
	253.627.6401 schedule@balitigation.cd



1	Q	Okay. Sometime early '90s?
2	A	Yes, around well, I started as a Grants
3	Clerk	
4	Q	Oh, I see.
5	A	at '89.
6	Q	So that would be the '89. Okay. And then
7	you becan	ne a Specialist?
8	A	A Grants Management Specialist.
9	Q	Grants Management Specialist.
10	Approxima	ately when?
11	A	Early '90s.
12	Q	Early '90s. And then Grants Management
13	Officer s	sometime
14	A	Mid '90s.
15	Q	Mid '90s sometime?
16	A	Late '90s, yes.
17	Q	Okay. And then you started as a Policy
18	Analyst i	n OPERA?
19	A	Correct.
20	Q	What were your job duties when you were
21	the Polic	y Analyst in OPERA?
22	A	I worked in the Division of Grants Policy
23	represent	ing NIH on federal-wide working groups for
24	Grants Ad	lministration. I worked on the Grants
25	Policy St	atement, the NIH Grants Policy Statement.



Reviewed and analyzed policies and the regulations
and provided guidance to the Institutes and Centers.
Q And approximately when was this that you
were an OPERA Policy Analyst?
A 2001 to, like, 2004 or '5.
Q Okay. And then approximately then you
moved to, you said, the Indian Health Service?
A Correct.
Q And you were you said you headed up
their Grants Office. Did I understand that right?
A Their grants policy functions.
Q So what were you doing there?
A Implementing, helping to identify policies
under HHS that directly conflicted with the
Indian I don't even know. I'm Title 25 where,
you know, it was the Indian Determination,
Self-Determination Act identified how to implement
grant administration functions within the department
that would not disrupt the tribal programs, provided
technical assistance on how to maintain compliance
to the tribes with grant regulations and grant
policies.
Represented Indian Health Service through
the department on working with, you know, the Tribal
Affairs Office, just trying to make sure that we



1	acknowledged the rights of the tribes and making
2	certain that we provided clear and concise tribal
3	consultation guidance and that kind of thing.
4	Q Okay. And how long were you there?
5	A I was there for five years maybe?
6	Q Okay. And then you moved to the HHS
7	Office of Grants Policy. Did I understand that
8	right?
9	A Yes. The HHS Office of Grants, and I was
10	in the I was the director for the Policy
11	Division.
12	Q Okay. And so if I'm tracking right, we're
13	off to the mid 2000s now?
14	A I don't know where we are.
15	(Whereupon, laughter)
16	BY MR. McGINTY:
17	Q Well, when did you move to the HHS Office
18	of Grants Policy from the Indian Health Service?
19	A I moved there, I want to say, 2009.
20	Q 2009. Okay. And what were you doing when
21	you moved to the HHS Office of Grants Policy?
22	A Providing grants administration guidance
23	for all of the departments under HHS.
24	Q Okay. That's a lot of departments.
25	A Yes, Ops is, yeah, Operations Division.



	· · · · · · · · · · · · · · · · · · ·
1	Q So what would that entail?
2	A Meeting with the operating divisions,
3	talking to them about, you know, they had questions
4	about various grants, HHS policy
5	departmental-wide policies. And I would answer the
6	questions, help them implement the policies, have
7	meetings to go over guidance.
8	Q Okay. And you started there around 2009.
9	How long were you there?
10	A Probably about two and a half, almost
11	three years.
12	Q Two and a half years. And then you became
13	the did I understand, from there you became the
14	Deputy Director of OPERA Grants Management. Is that
15	right, or am I saying that wrong?
16	A OPERA. No, just OPERA.
17	Q OPERA. Just OPERA. Okay. Great.
18	So Deputy Director of OPERA around 2011?
19	A Yes.
20	Q Okay. And when were you appointed the
21	Director?
22	A I believe it was 2012.
23	Q 2012. Okay. So let's talk about your
24	role as the Director of OPERA. What are your duties
25	in that role?



Γ

1	A To provide so I have Compliance
2	no oversee Compliance for NIH policies. Oversee
3	the grants administration functions. Provide
4	oversight to the Institutes and Centers on grants
5	administration. Oversee the Federal Financial
6	Reporting Center where all of the financials are
7	submitted and analyzed.
8	And I oversee all of the closeout
9	functions for, administrative and financial, for
10	NIH. Administrative compliance, foreign
11	interference, and research misconduct compliance and
12	that kind of thing.
13	Q Okay. When you say "oversee," what does
14	that mean?
15	A Provide oversight, like, provide the
16	HHS-wide central level direction and then provide
17	that to the Institutes and Centers for them to
18	implement within their Institutes and Centers, and
19	provide them guidance as needed on implementation.
20	Help them with compliance functions when there's
21	noncompliance.
22	Work with them on different administrative
23	matters that come up either through the
24	administrative business effects of the grants when
25	recipients are noncompliant, or help them develop



1	corrective action plans for recipients when they're
2	not compliant. And, also, oversee how they are
3	implementing, "they" meaning the Institutions and
4	Centers are implementing our guidance, going and
5	looking at their compliance using a compliance
6	model to test to see whether or not they're, you
7	know, following the guidance that we provide, and
8	when they don't, providing them with updates on how
9	they need to manage. Meeting with them on a
10	consistent basis twice a month to discuss policy and
11	compliance issues and to obtain guidance from them
12	on better ways that we can manage NIH grants.
13	Q Okay. So you meet with who do you meet
14	with twice a month?
15	A I meet with the Institutes and Centers,
16	the so I service the Agency Chief Grants
17	Management Officer. And then we have the Institutes
18	and Centers Chief Grants Management Officers that
19	actually issue the awards and oversee the fiscal
20	management of the awards.
21	Q Okay. And so it's the two times meeting
22	with the Chief Grant Management Officers. Is that
23	right?
24	A Twice, twice a month.
25	Q Twice a month. And you talk about,



3

4

5

6

7

8

1 basically, all of the things that you just went 2 over?

A Correct.

Q Okay. And in issuing the guidance that you just talked about, when you issue that guidance, is that different or the same as the Staff Guidance that we were just talking about a minute ago on Exhibit 1?

It's the same in that we communicate about 9 Α 10 the guidance and they get to ask questions. It's 11 different because typically we talk about things 12 that we all are working on, and in the grants 13 management arena, and not this kind of thing. So, 14 yes, the guidance is provided, we talk about it, so 15 that's is the same.

16 Q Okay. And it's different insofar as --17 how is it different? I guess I didn't quite 18 understand.

A It's different because we're typically clear on what we are supposed to be doing with grants administration. And then this particular situation we were just talking about, you know, how do we manage, how do we identify categories and make sure that we are very clear in providing that, those next steps. We want everyone to do things



1 consistently. And sometimes with other guidance, 2 3 institutes have different practices and procedures. 4 So we give the guidance and allow them to go on and do what they do within their individual ICs as long 5 as it matches their processes. In this, it was a 6 very intentional discussion of we all should do it 7 the same way. 8 9 And when you say, "in this," you mean the Ο 10 Staff Guidance --The Staff Guidance, correct. 11 Α 12 -- that we were talking about on Exhibit 0 13 1? 14 Α Yes. 15 Okay. One of the divisions within OPERA 0 16 is the Division of Grants Policy. Is that right? 17 Α Correct. What's that division, what does that do? 18 Ο 19 Implements the NIH Grants Policy Α 20 Statement, implements the Grants Administration 21 Manuals, answer policy questions, work with programs 22 to make sure that the program policies are enter --23 that the Grants Administration regulations govern 24 the program policies. 25 Okay. And if I understood your previous Q



1	description, you were a policy analyst. Were you in
2	the Division of Grants Policy?
3	A I was.
4	Q Okay. And with your current role, what's
5	your role to that division?
6	A I supervise the division Director.
7	Q Okay. What's your role with respect to
8	grant termination, just generally speaking?
9	A I, generally speaking, with noncompliance
10	I work with the Institutes and Centers to help them
11	determine how to develop corrective actions and help
12	gain compliance with the recipient. I and then
13	for other areas, I work with the institutes to
14	complete bilateral terminations, but I don't
14 15	complete bilateral terminations, but I don't terminate, typically.
15	terminate, typically.
15 16	terminate, typically. Q So you're saying there's two kinds of
15 16 17	terminate, typically. Q So you're saying there's two kinds of terminations. Generally speaking, there's a
15 16 17 18	<pre>terminate, typically. Q So you're saying there's two kinds of terminations. Generally speaking, there's a noncompliance termination, there's a bilateral</pre>
15 16 17 18 19	<pre>terminate, typically. Q So you're saying there's two kinds of terminations. Generally speaking, there's a noncompliance termination, there's a bilateral termination?</pre>
15 16 17 18 19 20	<pre>terminate, typically. Q So you're saying there's two kinds of terminations. Generally speaking, there's a noncompliance termination, there's a bilateral termination? A Correct.</pre>
 15 16 17 18 19 20 21 	<pre>terminate, typically. Q So you're saying there's two kinds of terminations. Generally speaking, there's a noncompliance termination, there's a bilateral termination? A Correct. Q Could you describe the difference between</pre>
 15 16 17 18 19 20 21 22 	<pre>terminate, typically. Q So you're saying there's two kinds of terminations. Generally speaking, there's a noncompliance termination, there's a bilateral termination? A Correct. Q Could you describe the difference between those two?</pre>
 15 16 17 18 19 20 21 22 23 	<pre>terminate, typically.</pre>



1	because we can't come can't identify a new
2	principal investigator or whatever the case may be.
3	That's just one example.
4	And noncompliance terminations, though
5	there have they are where the recipient is
6	unilateral, right, that we, NIH, cannot identify or
7	cannot come up with a corrective action plan to help
8	move the project along, and so the decision of the
9	agency would be to terminate.
10	Q Are you generally involved in
11	noncompliance terminations?
12	A I'm generally involved in noncompliance
13	discussions, yes.
14	Q So if a noncompliance termination were to
15	happen, you would probably know about it?
16	A Correct.
17	Q Okay. Prior to when President Trump was
18	inaugurated, in the time that you were Deputy
19	Director or Director at OPERA, how many noncompliant
20	terminations were there?
21	A So deputy director, I don't recall. As
22	the director, maybe one or two. It doesn't happen
23	often.
24	Q Okay. And, help me. I think you've been
25	director for quite a while. I think you said since



1	2011. Did I get that right?
2	A 2012.
3	Q 2012. So since 2012, there's been one or
4	two noncompliance terminations until about
5	January 20th, 2025. Is that right?
6	A Yeah. And it's probably more than one,
7	for sure, and less than a handful. So I don't
8	recall, so I apologize, but I just know that that's
9	not what we normally do. And, yes, the answer to
10	the question is whether actually
11	Q What were you going to say?
12	A No, I need you to repeat the question
13	again, because I want to make sure I don't restate
14	it incorrectly.
15	Q Sure. No, that's fair, that's fair.
16	My question was just between when you were
17	appointed director in 2012 until January 20, 2025,
18	there's been, I think you clarified, more than one
19	but less than ten noncompliance terminations. I
20	think that's what your testimony was.
21	A My testimony was it doesn't happen often,
22	more than one and probably less than five.
23	Q More than one, less than five. Okay.
24	And since January 20, 2025, to the present
25	date, how many noncompliance terminations have there



1 been? 2 Α Zero. Oh, okay. None at all. Were they all the 3 Q 4 bilateral terminations you were just talking about? We had some bilateral terminations between 5 Α 6 January, yes. 7 Q Okay. And I don't recall the number, but not any 8 Α 9 noncompliance. 10 So then the thread we were talking about 0 11 with Dr. Kym Ahrens, it's been reinstated now, but 12 when it was terminated, what kind of termination was 13 that? 14 A termination that was provided to me, to Α 15 this -- yeah. 16 It was neither noncompliant nor was 0 Okav. 17 it bilateral? 18 Α Correct. 19 Okay. It was a different kind of 0 20 termination? 21 Α Correct. 2.2 How many of that kind of termination was Ο 23 there between when you were appointed director of 24 OPERA until January 20, 2025? 25 Α Zero.

1	Q Zero. That never happened before?
2	A I'm sorry, let me restate. There was one
3	termination that happened that way, but it was
4	the grant was reinstated as well. That, yes.
5	Q Okay. Which one was that?
6	A That was one under the first Trump
7	Administration for the Eco Health Alliance.
8	Q Okay. Do you know why that one was
9	reinstated?
10	A No.
11	Q Okay. Okay. You just stated that this
12	particular kind of termination, like for a
13	Dr. Ahrens, was provided to you. Who provided it?
14	A Liza Bundesen, my supervisor.
15	Q Okay. And I think you said it was
16	provided by someone in HHS, I forget her name,
17	Rachel something?
18	A Rachel Riley.
19	Q Rachel Riley?
20	A Correct.
21	Q Okay. And just to clarify, Rachel Riley
22	provided that list to Liza Bundesen, and that
23	included the termination to Dr. Ahrens?
24	A Correct.
25	Q Okay.



1	MR. McGINTY: Mark this Exhibit 3, please.
2	(Bulls Deposition Exhibit 3 was marked for
3	identification.)
4	BY MR. McGINTY:
5	Q I'm handing you what's been marked
6	Exhibit 3.
7	MR. McGINTY: Counsel.
8	(Document tendered to Ms. Andrapalliyal)
9	BY MR. McGINTY:
10	Q I'm sorry, just one more follow-up
11	question about the terminations that were provided
12	to you.
13	My understanding is there was an e-mail
14	from Rachel Riley and on which someone named Brad
15	from DOGE was copied on that e-mail, and that
16	applied to the termination for Dr. Ahrens, right?
17	A I don't recall if that's the same e-mail.
18	Q Okay. So we'd have to take a look at that
19	e-mail to know?
20	A Yes.
21	Q Okay. Do you recognize what I've just
22	handed you as Exhibit 3?
23	A Yes.
24	Q And what is this?
25	A The Executive Order.
	Normal Z



1	Q Which one?
2	A 14168, Defending Women from Gender
3	Ideology Extremism and Restoring Biological Truth to
4	the Federal Government.
5	Q Okay. When did you first become aware of
6	this Executive Order?
7	A I believe the date that it came, that it
8	was issued.
9	Q Okay. So on January 20th, 2025?
10	A Yes.
11	Q Okay. Have you talked with anyone about
12	this document?
13	A Talked with the Department of Office of
14	Grants.
15	Q And what did you tell them?
16	A I didn't tell them anything.
17	Q Okay. So you talked with the Department
18	of Office of Grants. Is that a department within
19	NIH?
20	A NO, HHS.
21	Q That's a department within HHS. Okay.
22	And so, who at the Department of excuse
23	me. You'll have to tell me that department name
24	again.
25	A Department of Grants.



1	Q Department of Grants. Who at the
2	Department of Grants were you talking to about this
3	Executive Order?
4	A The leadership there.
5	Q And who is that?
6	A The Deputy Assistant Secretary for Grants
7	Dale Bell.
8	Q Did you say Dale Bell?
9	A Bell.
10	Q B-E-L-L?
11	A Yes.
12	Q And anyone else?
13	A And the various operating divisions that
14	were there to ask, you know, just to hear the
15	conversation to it was a meeting just to talk
16	about the fact that the Executive Orders had come
17	out and that they would provide guidance as they
18	could.
19	Q When was that meeting?
20	A I don't recall.
21	Q Was it in the week after the Executive
22	Order came out?
23	A It may have been I don't recall. It
24	was definitely not long after it came out, so it
25	might have been a week or two. I don't recall. I



1 don't want to... 2 0 Go ahead. 3 I don't want to make up a date. Α 4 Sure, yes. Late January, early February? 0 5 Α February, probably, late January or 6 February, probably. 7 Okay. And what was said at that meeting? Q That they -- that there were Executive 8 Α 9 Orders that had come out, recognizing that the 10 operating divisions wanted to obtain guidance and 11 that they would give us guidance as soon as they 12 could. That was the first discussion. 13 And they didn't tell you to do Q Okay. 14 anything with respect to the Executive Order at that 15 time? 16 Α No. 17 Ο Who else was at that meeting? You said 18 Dale Bell and all the operating divisions. Who is 19 that? 20 The Agency Chief Grants Management Α 21 Officers. 2.2 From all of HHS? 0 Is see. 23 From all of HHS. Α 24 Okay. And were there any subsequent 0 25 meetings?



Case 1:25-cv-10787-BEM Document 38-8 Filed 04/25/25 Page 55 of 246

State of WA, et al. vs Trump, et al. Bulls, Michelle - April 03, 2025

1	A Yes.
2	Q Okay. With we're talking about with
3	HHS and Dale Bell?
4	
	A The same group.
5	Q Okay. And when was the next one?
6	A Probably at two or two weeks after the
7	first one.
8	Q So maybe mid February sometime?
9	A Maybe. Might maybe before. I'm not
10	sure. It was shortly after.
11	Q Okay. What happened at the second
12	meeting?
13	A We were provided a document we asked
14	questions. We asked for guidance on, like, a I
15	don't want to say it's frequently-asked questions,
16	but it was really to give us information on how we
17	should address the Executive Orders, because we
18	needed to know how, what we needed to do with them,
19	and so they provided guidance on that.
20	Q And what was the guidance they provided?
21	A We were asking whether or not because
22	by the time we met the second time, I think the TROs
23	had come out, and so they were going to tell us
24	whether, you know, what we needed to do with those.
25	Q So was this a meeting about this Executive



1	Order in particular that's been marked as Exhibit 3,
2	or was it all these Executive Orders?
3	A All of the Executive Orders.
4	Q Okay. Was this Executive Order marked as
5	Exhibit 3 specifically discussed?
6	A No.
7	Q Okay. And so you said it was Dale Bell at
8	HHS, all the Operating Directors, Chief Grants
9	Management Officers. Anybody else at that meeting?
10	A Yes, we had Office of General Counsel.
11	Q Okay. Anyone from the Department of
12	Government Efficiency?
13	A Not that I know of. I don't know.
14	Q How was the meeting held?
15	A Umm.
16	Q Was it on Zoom?
17	A Yes.
18	Q It was on Zoom?
19	A Teams, yes.
20	Q It was on Teams. Do you know if there
21	were notes or a transcript made of the meeting?
22	A I don't know.
23	MS. ANDRAPALLIYAL: Objection. You know,
24	OGC was present at this meeting so the contents of
25	this meeting are protected under the attorney-client



1	privilege, and so I'm going to instruct Ms. Bulls
2	not to answer.
3	BY MR. McGINTY:
4	Q Did anyone ask for client advice at the
5	meeting, attorney-client advice?
6	MS. ANDRAPALLIYAL: Objection, calls for a
7	legal conclusion.
8	BY MR. McGINTY:
9	Q You can answer.
10	A Can you repeat the question.
11	Q Sure. Did anyone ask for legal advice at
12	the meeting?
13	A Yes.
14	Q Okay. Asking did you get any direction
15	from Dale Bell about how to implement an Executive
16	Order that did not constitute a request or the
17	provision of the request?
18	MS. ANDRAPALLIYAL: Objection, calls for a
19	legal conclusion.
20	BY MR. McGINTY:
21	Q You can answer.
22	A I don't know that I understand the
23	question.
24	Q Okay. So you had two meetings with
25	Dale Bell. At the second time you had the meeting,



1	the temporary restraining orders had come out, at
2	least as to some of the Executive Orders.
3	Do you know if at that time the temporary
4	restraining orders as to this particular Executive
5	Order had come out?
6	A I don't recall, because we didn't talk
7	about the details of all of the Executive Orders.
8	What we talked about was we were wanting to know if
9	we could fund grants.
10	Q I see. What was the answer to that
11	question?
12	MS. ANDRAPALLIYAL: Objection. This
13	conversation was attorney-client privileged. I'm
14	going to instruct Ms. Bulls not to answer.
15	BY MR. McGINTY:
16	Q After the meeting, did you stop funding
17	grants?
18	A No.
19	Q Do you have any more meetings with
20	Dale Bell?
21	A Yes.
22	Q Okay.
23	A With the group, yes.
24	Q What was the next one?
25	A Probably at our chief GMO Council which is



1	a, you know, a meeting that we always have where we
2	were just yeah. That was the third meeting.
3	Q Okay. And was it about the same topic,
4	how to implement
5	A We did discuss this.
6	Q Okay.
7	A Not this exhibit, but the we discussed
8	the responses that we received for our questions
9	from our questions during the previous meeting.
10	Q Okay. And your questions were: Could you
11	fund grants?
12	MS. ANDRAPALLIYAL: Objection. Because
13	this is an attorney-client communication, it's
14	privileged. I'm going to instruct Ms. Bulls not to
15	answer insofar as it was an attorney-client
16	conversation or communication.
17	MR. McGINTY: If I understand the
18	objection correctly, you're only objecting insofar
19	as it was an attorney-client privileged
20	communication.
21	MS. ANDRAPALLIYAL: Correct.
22	MR. McGINTY: Do you want to have
23	Can we go off the record for a second.
24	(Discussion off record)
25	(Recess taken - 10:07 to 10:20 a.m.)



1	(The record was read aloud as follows:
2	"QUESTION: Did anyone ask for client
3	advice at the meeting, attorney-client
4	advice?
5	"MS. ANDRAPALLIYA: Objection, calls for a
6	legal conclusion.
7	"QUESTION: You can answer.
8	"THE WITNESS: Can you repeat the
9	question.
10	"QUESTION: Sure. Did anyone ask for
11	legal advice at the meeting?
12	"THE WITNESS: Yes.
13	"QUESTION: Did you get any direction from
14	Dale Bell about how to implement the
15	Executive Order that did not constitute a
16	request or the provision of the request?"
17	MS. ANDRAPALLIYAL: Thank you.
18	So I do want to maintain our objections on
19	attorney-client privilege here.
20	MR. McGINTY: Okay.
21	BY MR. McGINTY:
22	Q Before the break, we were talking about
23	these meetings with Dale Bell and I asked you if
24	there's any part of that meeting that you can
25	testify about, because counsel's objection and



1	instruction not to answer was an instruction not to
2	answer to the extent that attorney-client privileged
3	communications would have been implicated. You've
4	now had an opportunity to talk to your lawyer about
5	that
6	A Correct.
7	Q sorry, we spoke over each other.
8	Is that right?
9	A Correct.
10	Q Okay. Is there any part of that meeting
11	that you can testify about today?
12	MS. ANDRAPALLIYAL: Objection. So
13	objection on the basis of attorney-client privilege,
14	but a separate objection on the basis of
15	deliberative process privilege to the extent that
16	there were deliberative communications at this
17	meeting.
18	THE WITNESS: Dale Bell coordinated the
19	meeting, but the meeting was specifically to obtain
20	legal guidance on what we could do as agencies under
21	the TROs. So he actually coordinated the meeting,
22	but the meeting was definitely about obtaining legal
23	guidance. That was the sole purpose of the meeting.
24	BY MR. McGINTY:
25	Q Okay. We're talking about the second



1 meeting now? We're talking about the second meeting, 2 Α 3 yes. 4 Because at that time the TROs had 0 Okav. 5 come out --6 Α Right. 7 Q -- as to some of the Executive Orders but not necessarily all of them. Is that right? 8 9 That's right. Α 10 Okay. Was there any other meetings 0 11 coordinated by Dale Bell? The third meeting which he coordinates 12 Α 13 often which as the Chief Grants Management Officer 14 counsel meeting. 15 0 Okay. 16 Α Yeah. 17 Q And what was that meeting about? 18 That meeting was about other, you know, Α 19 Grants Management matters. Additional questions did 20 come up about we wanted additional information and 21 quidance from OGC. 2.2 Okay. Was any direction or instruction Ο 23 from Dale given to you about this Exhibit 3? 24 MS. ANDRAPALLIYAL: Objection to the 25 extent that it calls for the provision of



Γ

1	deliberative information that's protected on the
2	deliberative process privilege.
3	BY MR. McGINTY:
4	Q Do you understand the objection?
5	A Yes.
6	Q Okay. Is there anything you can tell me
7	about that meeting, about any instruction you were
8	given about Executive Order 14168, Exhibit 3?
9	A The meeting was not about this particular
10	Executive Order. It was about all of the Executive
11	Orders and whether we could continue to, you know,
12	move forward with yeah, it wasn't about this. It
13	was about all of them.
14	Q Okay. My question was: Were you given
14 15	Q Okay. My question was: Were you given any instruction about how to implement this
15	any instruction about how to implement this
15 16	any instruction about how to implement this particular Executive Order?
15 16 17	any instruction about how to implement this particular Executive Order? A The answer is no.
15 16 17 18	any instruction about how to implement this particular Executive Order? A The answer is no. Q Okay. Were there any of these meetings
15 16 17 18 19	any instruction about how to implement this particular Executive Order? A The answer is no. Q Okay. Were there any of these meetings with Dale Bell where you were given specific
15 16 17 18 19 20	<pre>any instruction about how to implement this particular Executive Order? A The answer is no. Q Okay. Were there any of these meetings with Dale Bell where you were given specific instruction about how to implement the Executive</pre>
15 16 17 18 19 20 21	<pre>any instruction about how to implement this particular Executive Order? A The answer is no. Q Okay. Were there any of these meetings with Dale Bell where you were given specific instruction about how to implement the Executive Order marked as Exhibit 3?</pre>
15 16 17 18 19 20 21 22	any instruction about how to implement this particular Executive Order? A The answer is no. Q Okay. Were there any of these meetings with Dale Bell where you were given specific instruction about how to implement the Executive Order marked as Exhibit 3? MS. ANDRAPALLIYAL: Objection to the
15 16 17 18 19 20 21 22 23	any instruction about how to implement this particular Executive Order? A The answer is no. Q Okay. Were there any of these meetings with Dale Bell where you were given specific instruction about how to implement the Executive Order marked as Exhibit 3? MS. ANDRAPALLIYAL: Objection to the extent that it calls for deliberative information to



1	THE WITNESS: There were discussions, but
2	no Dale did not provide final guidance. It was
3	just us talking about additional questions that we
4	had with regard to the Executive Orders. He did not
5	provide final guidance.
6	BY MR. McGINTY:
7	Q Okay. How many of these meetings with
8	Dale Bell did you have about the Executive Orders,
9	about?
10	A Three.
11	Q Just three?
12	A And the meaning the last meeting
13	included the Executive Orders because the Chief
14	Grants Management Officer still had questions, but
15	the meeting was a broader meeting. The second
16	meeting was a meeting that he actually coordinated
17	specifically.
18	Q I see. It sounds like these meetings with
19	Dale Bell happened in a recurring way?
20	A Correct. The meetings the Chief Grants
21	Management counsel meetings happened in a recurring
22	way, not meeting about Executive Orders.
23	Q Got it. How often did the recurring
24	meetings happen?
25	A They should be happening once a month.



1	Q Do they happen once a month?
2	A We try to have them once a month.
3	Q Okay. Sometimes they get canceled or
4	postponed?
5	A Correct.
б	Q Okay. I believe the question that
7	prompted the question of these meetings was just who
8	have you communicated with about this document, and
9	specifically I guess I'll clarify that.
10	Who have you communicated with at NIH
11	about this document for the purposes of NIH policy
12	and procedure?
13	A I haven't communicated about this
14	document. I've communicated about just overarching
15	funding and the Executive Orders.
16	Q Okay. Including this document?
17	A Yes.
18	Q Okay. And who have you communicated with
19	about that?
20	A The Chief Grants Management Officers.
21	Q Okay. And what have you told them?
22	MS. ANDRAPALLIYAL: Objection insofar as
23	it calls for privileged deliberative information
24	about action that hasn't been finalized yet.
25	THE WITNESS: We, as we talked earlier, we



1	are I'm answering I'm trying to establish the
2	process by which they can continue. So there's been
3	no final guidance. We've been talking about the
4	Executive Orders.
5	BY MR. McGINTY:
6	Q Okay. Can you turn to page this is
7	from the Federal Register, so I guess it would be
8	page 8616, and look at Section 3(e).
9	Do you see that?
10	A Yes.
11	Q And it says, the last sentence of Section
12	3(e):
13	"Agencies shall take all necessary steps,
14	as permitted by law, to end the Federal
15	funding of gender ideology."
16	Do you see that?
17	A Yes.
18	Q Has NIH taken any action to implement that
19	sentence of Section 3(e)?
20	MS. ANDRAPALLIYAL: Objection, calls for a
21	legal conclusion.
22	BY MR. McGINTY:
23	Q You can answer.
24	A Discussions are have been had, about
25	identifying agency priorities.



1	Q Okay. What is the relationship between		
2	agency priorities and that last sentence of Section		
3	3(e)?		
4	MS. ANDRAPALLIYAL: Objection, calls for		
5	speculation.		
6	BY MR. McGINTY:		
7	Q You can answer.		
8	A To be honest, I do feel like I'm now using		
9	my own thoughts to tell you that, and I don't know		
10	that that is the correct way to answer that		
11	question.		
12	Q Well, you told me that discussions had		
13	been had about identifying agency priorities. Was		
14	that your testimony?		
15	A That is my testimony.		
16	Q Okay. Where do those agency priorities		
17	come from?		
18	A The director of the agency.		
19	Q Okay. And what has the director of the		
20	agency told you about those agency priorities?		
21	A The director hasn't told me anything. The		
22	director is developing a memo to communicate agency		
23	priorities, but there's nothing final, so we don't		
24	have agency priorities final yet.		
25	Q Well, grants have been terminated on the		

	· · ·	,
1	basis of	agency priorities, haven't they?
2	A	Yes.
3	Q	But you don't have agency priorities that
4	are final	?
5	A	I have letters that I've been asked to
6	send.	
7	Q	Okay.
8		MR. McGINTY: Can I mark this as Exhibit
9	4, please	2.
10		(Bulls Deposition Exhibit 4 was marked for
11		identification.)
12	BY MR. Mc	GINTY:
13	Q	I'm passing to you what has been marked
14	Exhibit 4	, and do you recognize this document?
15	A	Yes.
16	Q	And what is it?
17	A	A termination letter.
18	Q	This is one of those letters that you've
19	been aske	ed to send that you were just talking about?
20	A	Yes.
21	Q	And you signed this letter, right?
22	A	Yes.
23	Q	Okay. And why did you send this letter?
24	A	I was asked to send it.
25	Q	Who asked you to send it?



1	A	My supervisor.
2	Q	Okay. And who is that?
3	А	At the time, Liza Bundesen.
4	Q	Okay. How did she ask you to send it?
5	А	Via e-mail.
6	Q	Did she tell you why she was asking you to
7	send it?	
8	А	Yes.
9	Q	Okay. And what did she say?
10	А	That we were asked to terminate grants.
11	Q	Did she tell you why you were asked to
12	terminate	grants?
13	А	She did not.
14	Q	Okay.
15	А	Can I correct the statement?
16		The e-mail that I received from
17	Liza Bunde	sen indicated that we needed to terminate
18	the grants	, and the language in the letters were
19	provided s	o I didn't question, I just followed the
20	directive.	
21	Q	Okay.
22	А	She didn't say: Terminate the grant
23	because of	. She said: The list below. So I just
24	wanted to	be clear about that.
25	Q	Okay. And did you provide this e-mail to



1	counsel?	
2	A	Yes.
3	Q	Okay. And "the list is below," list of
4	what?	
5	A	Awards to be terminated.
6	Q	Okay. And is that the same list that you
7	were talk:	ing about earlier that came from
8	Rachel Ri	ley?
9	A	That was on the same e-mail, yes.
10	Q	Okay. And Brad may have been copied on
11	that e-mai	il?
12	Α	I don't know if Brad was on that e-mail
13	string.	
14	Q	Okay.
15	А	I can't recall.
16	Q	Brad was on one of the e-mail strings?
17	Α	Correct.
18	Q	Do you remember if it was Brad Smith?
19	А	I know for sure Brad.
20	Q	Okay. Definitely Brad. It might have
21	been Brad	Smith, it might have been Brad someone
22	else?	
23	Α	Yes.
24	Q	Okay. And you said the language was
25	provided.	What do you mean by "the language was



1 provided"? 2 Α The letter. There were template letters. 3 So the entirety of the letter language? Q 4 Α Correct. 5 0 Okav. So take a look at the first 6 paragraph here: 7 "Funding for Project Number," and then there's a number, " is hereby terminated 8 9 pursuant to the 2022 National Institutes 10 of Health Grants Policy Statement," and 11 C.F.R., a CFR section. "This letter 12 constitutes a notice of termination." 13 You did not write that language? 14 Α No. 15 0 You didn't write any word in this letter? Just the signature. 16 Α 17 Okay. You wrote your name? Q 18 I mean, I -- yes, I wrote my Α Correct. 19 name and signed it. 20 Okay. And you don't know why this letter 0 21 was sent? 22 Α To terminate the grant. 23 Okay. But you don't know what agency 0 24 priorities are intended to be served by terminating 25 this grant?



Γ

1	A I didn't ask the question and I was not
2	told, I sent the letter as it was.
3	Q Okay. Did Rachel Riley provide the
4	templates that you used?
5	A Yes.
б	Q So it says here actually, can you read
7	the fourth paragraph, the one that starts with,
8	"This award no longer effectuates."
9	A "This award no longer effectuates agency
10	priorities. NIH is obligated to
11	carefully steward grant awards to ensure
12	taxpayer dollars are used in ways that
13	benefit the American people and improve
14	their quality of life. Your project does
15	not satisfy these criteria. Research
16	programs based on gender identity are
17	often unscientific, have little
18	identifiable return on investment, and do
19	nothing to enhance the health of many
20	Americans. Many such studies ignore,
21	rather than seriously examine, biological
22	realities. It is the policy of NIH not
23	to prioritize these research programs."
24	Q Okay. And this was part of the template
25	letter that Rachel Riley provided?



1	A Yes.
2	Q Are you aware of let me strike that.
3	Did NIH have any ability to alter this
4	language in any way?
5	A Did we have the ability?
6	MS. ANDRAPALLIYAL: Objection, assumes
7	facts not in evidence.
8	BY MR. McGINTY:
9	Q Was this edited in any way from the
10	template letter that Rachel Riley provided?
11	A No.
12	Q Okay. It says, "Your project does not
13	satisfy these criteria." Do you see that there?
14	A Yeah.
15	Q Are you aware of any assessment of
16	Dr. Ahrens' grant in particular that was made to see
17	if her grant satisfied the criteria?
18	A No.
19	Q Would you have been aware of such
20	assessment if one had been made?
21	A I don't know.
22	Q Okay. Would you have been aware of such
23	an assessment if one had been made by NIH?
24	A Yes.
25	Q And it says, "Research programs based on



1	gender identity are often unscientific with little
2	identifiable return on investment, and do nothing to
3	enhance the health of many Americans."
4	Did NIH do any assessment of this
5	particular grant to see if it was unscientific?
6	A I don't know. The letter was provided and
7	it was sent. I don't know what happened before
8	that.
9	Q Well, did NIH do any assessment?
10	A I don't know.
11	Q You don't know if NIH did an assessment to
12	see if Dr. Ahrens' grant was scientific or not?
13	A Are you talking about I don't
14	understand your question, sorry.
15	Q Well, it says in this letter, and I
16	understand you didn't write it, but you signed it,
17	"Research programs based on gender identity are
18	often unscientific." And that was the reason this
19	particular grant was terminated.
20	Is that right?
21	A That's what the letter says.
22	Q That's what the letter says. So I'm
23	trying to figure out whether or not there was any
24	basis to think that Dr. Ahrens' grant was
25	unscientific.



1	A	I don't know.
2	Q	Okay. And do you know if there was any
3	assessment	to see if it had an identifiable return
4	on investm	lent?
5	А	No, I don't know.
б	Q	Do you know if NIH did one?
7	A	I don't know.
8	Q	Okay. Would you have been aware if NIH
9	did one?	
10	A	I'm not sure.
11	Q	Okay. And it also says, "and do nothing
12	to enhance	the health of many Americans."
13		Do you know if NIH did any assessment to
14	see if Dr.	Ahrens' grant would enhance the health of
15	many Ameri	cans?
16	A	I don't know.
17	Q	Okay. Was this the only template language
18	that Rache	l Riley provided?
19		MS. ANDRAPALLIYAL: Objection. To the
20	extent tha	t you're calling for draft language that
21	wasn't fin	alized, that's privileged, and I instruct
22	the witnes	s not to answer.
23	BY MR. McG	INTY:
24	Q	I'll clarify.
25		Did Rachel Riley provide any other



1	template letters that were sent?
2	A Yes.
3	Q Okay. What were those template letters
4	about?
5	A In that list, I don't recall.
6	Q How about any list for letters that had
7	been sent?
8	A DEI activities, this language. I think
9	one on China. I don't know. That's it that I can
10	recall, and I'm sure I'm blanking right now.
11	Q So what you remember is the gender
12	identity language, the DEI language, and the China
13	language.
14	Was there language on vaccine hesitancy
15	that was used?
16	A In that batch, no.
17	Q Any batch that's been sent?
18	A Yes.
19	Q And that was provided by Rachel Riley,
20	too?
21	A Yes. Well, actually, that was provided by
22	Dr. Memoli. I don't know if Rachel Riley provided
23	that to him, I apologize.
24	Q Okay. So Dr. Memoli wrote the one on
25	or provided you with the one on vaccine hesitancy?



1	А	Provided my supervisor with the
2	instructio	on.
3	Q	And you don't know if that came from
4	Rachel Ri	ley or not?
5	A	I don't.
6	Q	This letter that's been marked as
7	Exhibit 4	has similar language as the Executive
8	Order tha	t's in Exhibit 3. Do you agree with that?
9		MS. ANDRAPALLIYAL: Objection, calls for
10	speculatio	on.
11	BY MR. Mc	GINTY:
12	Q	You can answer.
13	Α	Are you asking me if I I haven't
14	compared.	
15	Q	Okay. Let's take a look at Executive
16	Order 141	68. Do you see in Section 2 where it says:
17		"These sexes are not changeable and are
18		grounded in fundamental and
19		uncontrovertible reality"?
20	A	Yes.
21	Q	And do you see in the letter of
22	February	28th where it says:
23		"Many such studies ignore rather than
24		seriously examine biological realities"?
25	A	Yes.

Γ

1	Q That seems pretty similar, doesn't it?
2	MS. ANDRAPALLIYAL: Objection, calls for
3	speculation, calls for a legal conclusion.
4	BY MR. McGINTY:
5	Q You can answer.
6	A Looking at it today, it looks the same.
7	Q Going back to the language in the Order,
8	you write: It's true or, rather, you write that
9	"Research programs based on gender identity" or
10	in this letter it says "are often unscientific,
11	have little identifiable return on investment, and
12	do nothing to enhance the health of many Americans."
13	Has NIH done any study whatsoever to see
14	if that's true?
15	A I don't know.
16	Q Would you know if they had done?
17	A I'm not sure.
18	Q Okay. When did it become the policy of
19	NIH not to prioritize research programs based on
20	gender identity?
21	A I don't know.
22	Q So earlier I thought you testified that
23	one of your jobs at NIH was supervising the Division
24	of, I think you said, Grants Policy. Is that
25	correct?



1	A Correct.
2	Q So would you know what the grant policies
3	are at NIH?
4	A I would.
5	Q And you don't know when it became the
6	policy of NIH to deprioritize the funding of
7	transgender issues?
8	A I do not.
9	Q Why not?
10	MS. ANDRAPALLIYAL: Objection, calls for
11	speculation.
12	THE WITNESS: Final priorities have not
13	been provided. I don't know.
14	MR. McGINTY: Okay. Happy coincidence,
15	mark this as Exhibit 5, please.
16	(Bulls Deposition Exhibit 5 was marked for
17	identification.)
18	BY MR. McGINTY:
19	Q I'm handing you what's been marked
20	Exhibit 5. And I'll represent to you that this is
21	an article from the journal Nature that I've printed
22	out. And I want to direct your attention to pages 4
23	and 5.
24	There are some cutouts here, or maybe
25	callout boxes, but seems to be a portion of the



	· · ·	
1	Staff Guid	dance - Award Assessments for Alignment
2	with Ageno	cy Priorities.
3		Do you see that?
4	А	Yes.
5	Q	Is this the document that we were talking
6	about befo	ore when we were talking about Exhibit 1?
7	А	Yes.
8	Q	And you have this is a real document,
9	it exists	in NIH, right?
10	A	It's a real document.
11	Q	Okay. And how have you used it?
12	A	To provide guidance to the ICs.
13	Q	Okay. Where did it come from?
14	A	What do you
15	Q	Who wrote it?
16	A	I wrote it, along with my deputy, yes.
17	Q	Okay. You wrote this document?
18	A	Yes.
19	Q	Okay.
20	A	I developed it.
21	Q	Along with your deputy. Who is that?
22	Α	Kristen Ta.
23	Q	Can you spell that for me.
24	A	Т-А.
25	Q	Great. So this includes, on page 5, that



Г

1	transgender issues language. Do you see that?
2	A Yes.
3	Q Did you write this?
4	A Yes.
5	Q Okay. I'm trying to understand, because
6	earlier on Exhibit 4 you said you didn't write any
7	word on that letter, and that included this
8	transgender issues language, didn't it?
9	A I didn't write any word on that letter.
10	Q Okay. So where did this "transgender
11	issues" language come from?
12	A The categories from that letter.
13	Q I see. I think I see. Let me confirm.
14	You were given template letters, you cut
15	and past from those template letters into this Staff
16	Guidance document?
17	A Correct.
18	Q What's the purpose of this Staff Guidance?
19	A To help ICs to figure out how to fund or,
20	you know, yes, provide funds and how to protect the
21	categories. If the DEI was the sole purpose, then,
22	you know, they don't make awards categories to us,
23	where we were trying to make sure that they worked
24	with the recipient to come to a mutual negotiation.
25	Q Okay. So this



1	A This is guidance.
2	Q Guidance to?
3	A The ICs.
4	Q To the ICs for the purposes of making
5	decisions about future awards?
6	A Making decisions on their portfolio,
7	including current awards, just their entire
8	portfolio.
9	Q Including current awards and future
10	awards?
11	A Correct.
12	Q Okay. And so would this guidance instruct
13	ICs to terminate some awards?
14	MS. ANDRAPALLIYAL: Objection, calls for a
15	legal conclusion and calls for speculation.
16	BY MR. McGINTY:
17	Q You can answer.
18	A This is, again, draft guidance. And the
19	guidance is to provide the ICs with an opportunity
20	to know the various categories and how to address
21	those.
22	Q Okay. Let's go through those categories.
23	What is Category 1?
24	A Category 1 just requires for them to
25	the sole purpose of the award is DEI, like we just



Γ

1	were talking about. The sole purpose of the award
2	is DEI, just a diversity supplement.
3	Q Okay. And, first of all, what does DEI
4	mean?
5	A Diversity, equity, and inclusion.
6	Q Okay. Yeah, but what makes an award DEI
7	or not?
8	A Oh.
9	MS. ANDRAPALLIYAL: Objection, calls for
10	speculation.
11	THE WITNESS: I don't have the
12	programmatic expertise to make that determination in
13	terms of the research and how it's reviewed. This
14	is for ICs to use and make those determinations.
15	BY MR. McGINTY:
16	Q Okay. Is there any NIH policy for ICs to
17	make a determination as to whether an award is a DEI
18	award or not?
19	A There are some awards that are
20	specifically, the sole purpose of the award is DEI.
21	So there has to be a programmatic rationale which is
22	outlined in either the Notice of Funding
23	Opportunity.
24	Q And are those the only awards that would
25	fit into Category 1?



Г

1	A DEI awards?
2	Q Well, I'm trying to figure out yeah,
3	yes.
4	A Yes, those would be the the award
5	cannot stand without the sole purpose of making
6	the award was to support DEI activities.
7	Q Okay. And you're not sure whether or not
8	an award is DEI or not?
9	A The guidance is for them to take a look,
10	to use it to make determinations within their
11	portfolio as to whether or not it's a DEI award.
12	Q Okay. So this talks about diversity
13	supplements or conference grants where the purpose
14	of the meeting is diversity. That's what you are
15	talking about here?
16	A That's what I'm talking about.
17	Q And is that the only kind of award that
18	would fit into Category 1?
19	MS. ANDRAPALLIYAL: Objection, calls for
20	speculation.
21	THE WITNESS: It's the example given.
22	BY MR. McGINTY:
23	Q Okay. Are there other kinds of awards
24	that would fit into Category 1?
25	MS. ANDRAPALLIYAL: Objection, calls



1 speculation. 2 THE WITNESS: That's for the IC to 3 determine. 4 BY MR. McGINTY: 5 0 Okay. How is the IC supposed to determine that? 6 Looking at their portfolio and looking at 7 Α why the grant was made. 8 9 Is there a definition of DEI anywhere? 0 10 Α I don't know. 11 Would you know? 0 12 I would know. Α 13 Okay. Okay. So in Category 1 they're Q 14 supposed to terminate the award, right --15 Α Yes. 16 -- and not fund it? Ο 17 Category 1 is that they cannot fund the Α 18 award. 19 And then, so what's Category 2? Okav. Ο 20 Where the DEI activity is ancillary to the Α 21 entire purpose of the award, so it just has pieces 22 that can be excised, but the award can still -- it's 23 still, you know, viable without the DEI activities. 24 0 Okav. And what are they supposed to do 25 with a Category 2?

253.627.6401



Г

1	A The assessments that we talked about
2	earlier, take those and determine whether or not and
3	assess their portfolio to see how they can save the
4	award.
5	Q Okay. And, again, there's no definition
6	of DEI that you're aware of that they would use to
7	do that?
8	A I'm sure there's a definition of DEI
9	within the various, what do you call it,
10	activities no, grant activities. I don't know if
11	there's a DEI standard definition across the a
12	policy definition, but definitely a programmatic
13	definition.
14	Q What's the difference between those two
15	things?
16	A Well, a policy definition would be from
17	the central and, you know, it would be more
18	administrative, so I don't have administrative DEI.
19	But for the purposes of the research, there might be
20	programs where there is either, you know, statutory
21	language that defines DEI or that the program
22	defines it, DEI, which is more on the scientific,
23	programmatic side.
24	Q Okay. So if I'm understanding you
25	correctly, there might be a definition within each



1	one of the ICs that defines DEI?	
2	A It might be a scientific definition that	
3	is used by all ICs.	
4	Q And you wouldn't be aware of it?	
5	A Not in the sense of issuing the Staff	
6	Guidance. In other words, I needed them to take	
7	that the guidance is for them to use and to make	
8	those assessments, not for me to tell them.	
9	Q Did anyone tell you to write this	
10	guidance?	
11	A Yes.	
12	Q Who told you to write the guidance?	
13	A The guidance was well, nobody told me	
14	to write it. The guidance was requested.	
15	Q Okay. By whom?	
16	A By the Grants Management officials and	
17	yeah, by the Grants Management officials.	
18	Q Grants Management, are these the same as	
19	the	
20	A The Chief Grants Management Officers	
21	within the funding, IC.	
22	Q Okay. And why did they ask for the	
23	guidance?	
24	A So they could begin making, you know,	
25	begin looking at how they can issue awards.	



1	Q Did something happen to make them think	
2	that they needed guidance?	
3	A I think people were	
4	MS. ANDRAPALLIYAL: Objection, calls for	
5	speculation.	
6	THE WITNESS: Yeah, I'm thinking, you	
7	know. I don't yeah, that's really an assumption.	
8	BY MR. McGINTY:	
9	Q Well, I'm just trying to figure this out,	
10	right, because people don't ask for guidance for no	
11	reason.	
12	Did anyone tell you why they wanted the	
13	guidance?	
14	A Yes, so that they could know, to make sure	
14 15	A Yes, so that they could know, to make sure that they were able to know what awards to fund and	
15	that they were able to know what awards to fund and	
15 16	that they were able to know what awards to fund and how to make determinations on how funding would be	
15 16 17	that they were able to know what awards to fund and how to make determinations on how funding would be made under the DEI activities.	
15 16 17 18	that they were able to know what awards to fund and how to make determinations on how funding would be made under the DEI activities. Q Was there any communication prior to this	
 15 16 17 18 19 	<pre>that they were able to know what awards to fund and how to make determinations on how funding would be made under the DEI activities. Q Was there any communication prior to this guidance indicating that DEI activities would not be</pre>	
 15 16 17 18 19 20 	<pre>that they were able to know what awards to fund and how to make determinations on how funding would be made under the DEI activities. Q Was there any communication prior to this guidance indicating that DEI activities would not be funded?</pre>	
 15 16 17 18 19 20 21 	<pre>that they were able to know what awards to fund and how to make determinations on how funding would be made under the DEI activities. Q Was there any communication prior to this guidance indicating that DEI activities would not be funded? A There was a funding pause that was placed</pre>	
 15 16 17 18 19 20 21 22 	<pre>that they were able to know what awards to fund and how to make determinations on how funding would be made under the DEI activities. Q Was there any communication prior to this guidance indicating that DEI activities would not be funded? A There was a funding pause that was placed on the agency, so they wanted to understand what</pre>	
 15 16 17 18 19 20 21 22 23 	<pre>that they were able to know what awards to fund and how to make determinations on how funding would be made under the DEI activities.</pre>	



1	А	Yes.
2	Q	Did you talk with any of your supervisors
3	about thi	s guidance?
4	A	Yes.
5	Q	And who did you talk to?
6	А	Liza Bundesen.
7	Q	Did you talk with Dr. Memoli?
8	А	No.
9	Q	Okay. All right. How about any future
10	version o	of this guidance?
11	А	Liza briefed Dr. Memoli.
12	Q	Okay. And how many conversations have you
13	had with	Dr. Bundesen about it?
14	А	I don't recall how many. It was frequent.
15	Q	Okay. And what did you talk about?
16		MS. ANDRAPALLIYAL: Objection. To the
17	extent th	nat the question is calling for the
18	provisior	n of deliberative information, I would
19	instruct	the witness not to answer.
20	BY MR. Mo	CGINTY:
21	Q	Did Dr. Bundesen draft any part of this?
22	A	No.
23	Q	Did she review a draft?
24	A	Yes.
25	Q	And did she approve it?



Г

1	A It wasn't final, it was still ongoing, so		
2	the portions that she reviewed, she we just		
3	discussed.		
4	Q Okay. How did you go about writing this		
5	guidance?		
6	MS. ANDRAPALLIYAL: Objection. To the		
7	extent the question is calling for deliberative		
8	information, I instruct the witness not to answer.		
9	BY MR. McGINTY:		
10	Q Did you examine any existing NIH policies?		
11	A I'm sure I did. I'm sure I looked at the		
12	policy statement and the Grants Policy Statement,		
13	just to see if there was anything in there that we		
14	could use.		
15	Q And there's no citation to the Grants		
16	Policy Statement in here, is there?		
17	A No.		
18	Q Okay. Did you look at anything else?		
19	MS. ANDRAPALLIYAL: Objection. To the		
20	extent the question is calling for specific and		
21	deliberative information, I instruct the witness not		
22	to answer.		
23	BY MR. McGINTY:		
24	Q Did you examine any Executive Orders prior		
25	to writing this guidance?		



Г

1	A Of course I read the Executive Orders.
2	Q And you said, "of course." Why did you
3	say of course?
4	A Because I needed to be aware.
5	Q Why did you need to be aware?
6	A Because that's information that I needed
7	to know, or at least review, as the discussions were
8	taking place.
9	Q Because it's obvious, isn't it, that the
10	Executive Orders are causing this to happen?
11	MS. ANDRAPALLIYAL: Objection, legal
12	conclusion, calls for facts not in evidence, calls
13	for speculation.
14	BY MR. McGINTY:
15	Q You can answer.
16	A I don't know that it's obvious, but I
17	definitely read the Order, all of the Orders.
18	Q So going back to page 5 of this Nature
19	article and the guidance that you wrote, looking at
20	Appendix 3, and it says:
21	"Language provided to NIH by HHS providing
22	examples for research activities that NIH
23	no longer supports."
24	Do you see that?
25	A Yes.



1	Q	And it says:
2		"China: Bolstering Chinese universities
3		does not enhance the American people's
4		quality of life or improve America's
5		position in the world. On the contrary,
6		funding research in China contravenes
7		American national security interests and
8		hinders America's foreign-policy
9		objectives."
10		Do you see that?
11	A	Yes.
12	Q	This language was provided by
13	Rachel R	iley?
14	A	Yes.
15	Q	And then it says:
16		"DEI: Research programs based primarily
17		on artificial and non-scientific
18		categories, including amorphous equity
19		objectives, are antithetical to
20		scientific inquiry, do nothing to expand
21		our knowledge of living systems, provide
22		low returns on investment, and ultimately
23		do not enhance health, lengthen life, or
24		reduce illness. Worse, so called
25		diversity, equity, and inclusion (DEI)



1	studies are often used to support
2	unlawful discrimination on the basis of
3	race and other protected characteristics,
4	which harms the health of Americans.
5	Therefore, it is the policy of NIH not to
6	prioritize such research programs."
7	That language also was provided by
8	Rachel Riley?
9	A Yes.
10	Q And, finally, the transgender language
11	that we looked at before which was also provided by
12	Rachel Riley?
13	A Yes.
14	Q And it was provided by her in the form of
15	template letters to terminate grants?
16	A Yes.
17	MR. McGINTY: Mark this as Exhibit 6,
18	please.
19	(Bulls Deposition Exhibit 6 was marked for
20	identification.)
21	BY MR. McGINTY:
22	Q I'm handing you what's been marked
23	Exhibit 6, and I'll represent to you that this was
24	also published in the Nature journal, and I've
25	printed it off of their website.

	•	
1		Do you recognize this document?
2	A	Yes.
3	Q	And what is it?
4	А	The draft Staff Guidance.
5	Q	And this is a little bit later than the
6	Exhibit 5	we were just looking at, right?
7	А	Correct.
8	Q	This one is dated March 25, 2025. Is that
9	right?	
10	A	Yes, yes.
11	Q	Did you write this one, too?
12	A	Yes.
13	Q	And when did you write this one?
14		MS. ANDRAPALLIYAL: Can we go off the
15	record, p	lease.
16		(Discussion off record)
17		(Recess taken - 11:06 to 11:31 a.m.)
18	BY MR. Mc	GINTY:
19	Q	You understand you're still under oath?
20	А	Yes.
21	Q	Okay. So continuing to look at what we
22	marked as	Exhibit 6, I think earlier you testified
23	that you	wrote this document.
24	А	Yes.
25	Q	And why did you write this document?



1	A To help the Institutes and Centers with
2	trying to figure out how to make awards, give them
3	guidance.
4	Q Okay. Give them guidance on making awards
5	and also terminating awards, right?
6	A Making awards and making assessments on
7	which categories they need to use to make those
8	assessments.
9	Q Okay. So this says, under Category 1,
10	"Add the action to the master spreadsheet"?
11	A Yes.
12	Q What's the master spreadsheet?
13	MS. ANDRAPALLIYAL: Objection. To the
14	extent the question calls for information that's
15	deliberative, I'm instructing the witness not to
16	answer.
17	BY MR. McGINTY:
18	Q How does NIH keep track of the grants it
19	has terminated?
20	A We do track it in a spreadsheet.
21	Q Okay. And what's on that spreadsheet?
22	MS. ANDRAPALLIYAL: Objection. To the
23	extent that the question is calling for information
24	that's deliberative and not final, I'm instructing
25	the witness not to answer.

1	BY MR. Mc	GINTY:
2	Q	Okay. Does the spreadsheet contain
3	informati	on about grants that have been terminated?
4	A	Yes.
5	Q	Okay. And do you use a spreadsheet to
6	keep trac	k of that?
7	A	Yes.
8	Q	Okay. Does the spreadsheet indicate the
9	reason th	at the grants were terminated?
10	A	Based on the categories, yes.
11	Q	Okay. And that's the Category 1, 2, 3,
12	4 you hav	ve here?
13	A	No. The categories that were provided in
14	the termi	nation letters.
15	Q	Okay. And which categories are those?
16	A	The categories of the DEI
17	Q	Okay. So going
18	A	China.
19	Q	back to
20	A	Yeah.
21	Q	what I think had been marked Exhibit 5,
22	page 5 of	Exhibit 5?
23	A	Yes.
24	Q	So you're looking at China, DEI, and
25	transgend	ler issues?



		1 00, 2020
1	A	Yes.
2	Q	Are there any other categories that
3	designate	the reason that a grant was terminated?
4	A	Vaccine hesitancy is the one additional
5	one.	
6	Q	Any others?
7	A	No.
8	Q	Okay. And how do you know which of those
9	categorie	s to terminate a grant under?
10	A	Based on the letters that are provided
11	to you	know, the list. We receive a list.
12	Q	That's the list you get from Rachel Riley?
13	A	That's the list that I get from my
14	superviso	r or, yeah, it's forwarded.
15	Q	Okay. And does that list show which
16	category :	reason to terminate the grant for?
17	A	Yes.
18	Q	Okay. How does it do that?
19	A	It has a category section.
20	Q	What's the form of this list?
21	А	It's a spreadsheet.
22	Q	It's a spreadsheet. Okay.
23	А	So our spreadsheet matches that
24	spreadshe	et.
25	Q	Did you, like, copy and paste into it?



1	MS. ANDRAPALLIYAL: Objection. To the
2	extent the information sought is deliberative and
3	not final in nature, I'm instructing the witness not
4	to answer.
5	BY MR. McGINTY:
б	Q Okay. So you get a spreadsheet that tells
7	you which grants to terminate and the reasons why?
8	A Yes.
9	Q And what are those reasons?
10	A Based on the categories.
11	Q Is it verbatim what I'm seeing her, China,
12	DEI
13	MS. ANDRAPALLIYAL: Objection. To the
14	extent that this is calling for deliberative
15	information that has not been finalized, I'm
16	instructing the witness not to answer.
17	BY MR. McGINTY:
18	Q Speaking only about grants that have
19	actually been terminated, the spreadsheet that you
20	get, what does it say for the reason that the grants
21	have been terminated?
22	A The categories, you know, DEI,
23	transgender, you know.
24	Q Is that verbatim?
25	A I don't I can't tell you verbatim, but



Γ

1	it doesn't include all of this detail that was
2	provided in the termination letter. It just gives
3	the title, the category.
4	Q So it says China, DEI, or transgender?
5	A Yes, and vaccine
6	Q And vaccine?
7	A hesitancy.
8	Q Okay. When you get that list and you get
9	the template letters, do you get a letter for each
10	grant that you're going to terminate, or do you have
11	to do some kind of, like, word merge?
12	MS. ANDRAPALLIYAL: Objection. The
13	question is calling for provision of deliberative
14	information which is privileged. I'm instructing
15	the witness not to answer.
16	BY MR. McGINTY:
17	Q Okay. But it's your testimony that the
18	reason that the grant is going to be terminated is
19	provided to you. Is that right?
20	A That's right.
21	Q And you don't have any input into that?
22	A I don't.
23	Q Okay. And you're testifying that the
24	template letter for each reason is provided to you.
25	Is that right?



1	A Yes.
2	Q And you don't have any input into that
3	either?
4	A I don't.
5	Q Okay. And how many of these lists have
б	you gotten to terminate grants?
7	MS. ANDRAPALLIYAL: Objection. To the
8	extent this information is deliberative and
9	nonfinal, I'm instructing the witness not to answer.
10	BY MR. McGINTY:
11	Q How many lists have you gotten for grants
12	that have been terminated?
13	A More than five.
14	Q And how many grants have you terminated on
15	the basis of these lists?
16	A Lots of grants. I don't know the number.
17	Q More than a hundred?
18	A More than a hundred.
19	Q More than a thousand?
20	A No.
21	Q Somewhere between a hundred and a
22	thousand?
23	A Somewhere between five hundred and a
24	thousand.
25	Q Somewhere between five hundred and a



1	thousand.
2	A Mm-hmm.
3	MR. McGINTY: This is Exhibit 7, I think
4	we are on.
5	(Bulls Deposition Exhibit 7 was marked for
6	identification.)
7	BY MR. McGINTY:
8	Q Do you recognize this document?
9	A Yes.
10	Q And you wrote this document, right?
11	A I wrote it with Dr. Lauer, yes.
12	Q Okay. And what is it?
13	A It's the supplemental it's the
14	beginning of the guidance providing agency I mean
15	ICs with guidance on how to unpause funding.
16	Q And it does say that there is a
17	restriction. What's the restriction that it gives
18	guidance about?
19	A On spending funding related to DEI
20	activities on grants.
21	Q Was there a definition of DEI activities
22	provided with this memo?
23	MS. ANDRAPALLIYAL: Objection. To the
24	extent the information sought is deliberative and
25	not final, I'm instructing the witness not to

1	answer.
2	BY MR. McGINTY:
3	Q How are ICs supposed to determine if
4	something fell within DEI activities?
5	A They have scientific, the scientific
6	background and they know their programs, so the
7	Grants Management officials work with the program
8	officials to identify DEI activities where it's not
9	clear in the statute.
10	Q Are you aware of any statute that talks
11	about that?
12	MS. ANDRAPALLIYAL: Objection, calls for a
13	legal conclusion and assumes facts not in evidence.
14	BY MR. McGINTY:
15	Q You can answer.
16	A The Minority Health Disparity Institute
17	does have language about minority health and that
18	kind of thing. So I don't know if it's I don't
19	think it ties directly, but I think that is being
20	used. And that's an assumption, that's not facts.
21	Q Okay. You said the Minority Health and
22	Research Institute? Did I get that right?
23	A Minority Health Disparity.
24	Q Minority Health Disparity Institute.
25	What's the purpose of the Minority Health



Г

1	Disparity Institute?
2	A I don't know.
3	Q Okay. So this March 25 Guidance says it
4	is rescinding the March 13 Guidance. Is that right?
5	A Yes.
б	Q So the March 25 Guidance kind of takes the
7	place of this March 13?
8	MS. ANDRAPALLIYAL: Objection. This is a
9	draft so I'm instructing the witness not to answer
10	as to deliberative information that has not been
11	finalized.
12	BY MR. McGINTY:
13	Q The March 25 Guidance has an issue date of
14	March 25, right?
15	A It does say that, but it is not final.
16	Q Has this been given to ICs?
17	A It was shared for feedback.
18	Q Oh, with whom?
19	A The ICs.
20	Q Okay.
21	A Yeah.
22	Q And the ICs have not implemented it yet?
23	A I cannot say that they have implemented
24	the guidance. What they've been told is that we
25	cannot give them final guidance until we receive the



1	final details from the director.
2	Q So earlier you talked about, I think,
3	three versions of this document. This March 25 one,
4	which version is this?
5	A The latest.
6	Q This is the latest?
7	A Mm-hmm, yes.
8	Q And the one that's in the Nature article,
9	which one is that?
10	A It looks like it might be
11	MS. ANDRAPALLIYAL: Objection. To the
12	extent that the question is seeking deliberative
13	information that has not been finalized yet, I'm
14	instructing the witness not to answer.
15	BY MR. McGINTY:
16	Q You said the first one was used by ICs to
17	implement policy, right?
18	A To implement guidance on how to unpause
19	funding.
20	Q Was the one in the Nature article used by
21	ICs to implement guidance on how to unpause funding?
22	A The it expanded on the original
23	guidance as we received the draft memo on the
24	priorities. We wanted to make sure that when the
25	as the memo came out, that they had an understanding



1	of the next steps in the guidance. So the guidance
2	just expanded based on the anticipation of receiving
3	the memo.
4	Q Okay. So this February 13th one is the
5	first. Is that right?
6	A Yes.
7	Q And then the one in the Nature article is
8	the second. Is that right?
9	A Yes.
10	Q Okay. And the March 25 one is the last
11	one?
12	A I believe so, yes.
13	Q Okay.
14	MS. ANDRAPALLIYAL: Objection to the
15	draft. So I object to the extent that the
16	information sought is seeking final information that
17	has not been finalized yet.
18	MR. McGINTY: I think privilege has been
19	waived, Counsel.
20	MS. ANDRAPALLIYAL: The deliberative
21	process privilege does not have a subject matter
22	waiver component to it.
23	(Reporter requests clarification)
24	MS. ANDRAPALLIYAL: The deliberative
25	process privilege does not have a subject matter
	(<u>∠</u> = === <u>></u>)



1	waiver component to it.
2	MR. McGINTY: Would you mark this. I
3	think we're on 8.
4	(Bulls Deposition Exhibit 8 was marked for
5	identification.)
6	BY MR. McGINTY:
7	Q I'm handing you what's been marked
8	Exhibit 8. Do you recognize this document?
9	A Yes.
10	Q And what is this?
11	A A memo that Dr. Lauer and I sent asking,
12	alerting folks that we were evaluating our agency
13	priorities for the new administration.
14	Q And this one says, "We recognize that NIH
15	programs fall under recently issued temporary
16	restraining orders," and there's a list of some
17	cases, right?
18	A Mm-hmm.
19	Q Why was that included in here?
20	MS. ANDRAPALLIYAL: Objection. The
21	question calls for attorney-client communications,
22	it's privileged. I'd instruct the witness not to
23	answer.
24	BY MR. McGINTY:
25	Q By issuing this guidance you were alerting



1	the programs that there were temporary restraining
2	rules that apply, right?
3	A Yes.
4	Q Okay. In any of the subsequent guidance
5	did you alert the programs that there were temporary
6	restraining orders that applied?
7	MS. ANDRAPALLIYAL: Objection. The
8	question seeks deliberative information. I instruct
9	the witness not to answer.
10	BY MR. McGINTY:
11	Q Let's see. Going back to what I think is
12	Exhibit 6, March 25 Guidance, were ICs given any
13	guidance to avoid the termination of grants to
14	institutions providing gender affirming care in
15	plaintiff states in this case?
16	MS. ANDRAPALLIYAL: Objection,
17	information seeks the question seeks information
18	that's deliberative, not final, and potentially
19	attorney-client privileged, so I'm instructing the
20	witness not to answer.
21	BY MR. McGINTY:
22	Q Has NIH terminated grants to institutions
23	that provide gender affirming care in the plaintiff
24	states in this case?
25	MS. ANDRAPALLIYAL: Objection, calls for a



1	legal conclusion.
2	BY MR. McGINTY:
3	Q You can answer.
4	A I don't I don't know of an institute or
5	center that has terminated a grant based on this
6	information in this guidance.
7	Q Okay. That's because you get the lists of
8	grants to terminate from outside of NIH, right?
9	A Yes, it yes, the list comes from
10	outside of NIH.
11	Q So what has this guidance been used to do,
12	if anything?
13	A To anticipate the memo of the priorities.
14	ICs have not been instructed to terminate grants.
15	Q So grant terminations are coming
16	exclusively from outside of NIH?
17	A Yes.
18	Q Okay. Let's see.
19	(Bulls Deposition Exhibit 9 was marked for
20	identification.)
21	BY MR. McGINTY:
22	Q Exhibit 9, do you recognize this document?
23	A Yes.
24	Q And just for the record, we're on
25	Exhibit 9. And what is it?



1	A	It's a Notice of Award.
2	Q	And who is it a Notice of Award to?
3	A	Seattle Children's Hospital.
4	Q	And this is the same grant that we were
5	talking a	bout, I think, on Exhibit 2, maybe
6	Exhibit 3	?
7	A	Yes.
8	Q	Now, could you just run through the table
9	that appe	ars on page 1 of this exhibit.
10	A	The table?
11	Q	Yeah, there's some numbers there. I'm not
12	entirely	sure how to follow it.
13		What does this table indicator mean?
14		MS. ANDRAPALLIYAL: Objection, assumes
15	facts not	in evidence.
16	BY MR. Mc	GINTY:
17	Q	Do you know how to interpret this table?
18	A	What? There it looks like tables. Are
19	you talki	ng about this table?
20	Q	Sorry. I mean the table entitled,
21	"Summary	Federal Award Financial Information."
22	A	Okay.
23	Q	Sorry. Sorry for my confusion.
24	A	Okay. Yes, I can tell you that the
25	it's the	budget start date you know, the budget



1	period start date from when the grant started and
2	the end date for when the grant ended. Then, you
3	know, it has the obligation of funds and it's the
4	deobligation.
5	Q And what is that, deobligation?
6	A Removing funding, the existing funding,
7	from the grant.
8	Q Okay.
9	A And then the total amount that's obligated
10	is the amount that was left on the award, it looks
11	like. So it looks like they didn't deobligate the
12	entire. There was money left for the recipient.
13	And the project period end date which is, at the
14	time, the entire life cycle of the grant project.
15	Q And so how much was deobligated?
16	A I I can only assume the amounts here.
17	I didn't deobligate it, but I'm looking at the
18	table.
19	Q According to this table, how much was
20	deobligated?
21	A Yeah, well my math is bad so.
22	It's the 200 200,453, 162,636, and the
23	37,000 it looks like it was those all have minus
24	signs, so that tells me that they deobligated that
25	amount, and the remaining left is the 40,000.



1		(Reporter requests clarification)
2		THE WITNESS: 40,091.
3	BY MR. Mc	CGINTY:
4	Q	Okay. Thank you.
5		So who issued this letter?
6	А	Margaret Young. It's not a letter. It's
7	a Notice	of Award.
8	Q	Okay.
9	А	Yeah. I just wanted to make that
10	distincti	ion.
11	Q	No, I appreciate it.
12		So Margaret Young issued this Notice of
13	Award?	
14	A	Yes.
15	Q	Who is Margaret Young?
16	А	She is the Chief Grants Management Officer
17	of Child	Development, NICHD.
18	Q	Okay. If you would turn to page 5.
19	А	Yes.
20	Q	There's some language here under
21	"Terminat	ion" and "Transgender Issues."
22		Could you read the language under
23	Terminati	ion?
24	А	"This award related to Transgender
25		Issues no longer effectuates agency
		Name Z



1	priorities. It is the policy of NIH not
2	to further prioritize these research
3	programs. Therefore, the award is
4	terminated."
5	Q Who wrote that language?
6	A That language was taken from the
7	termination letter that I sent on the 28th. The
8	termination letter went out, had that language, and
9	then I instructed her to issue the Notice of Award
10	using the same language.
11	Q Okay. Why did you instruct her to do
12	that?
13	A That's the process for terminating awards,
14	is issuing the letter and then the institute will
15	well, this process is the issuing of the termination
16	letter, but the award is the official document.
17	Q So why did you instruct Margaret Young to
18	take the language from the termination letter?
19	A Because we were asked to terminate the
20	awards, of the award, other awards.
21	Q Could you have used different language?
22	MS. ANDRAPALLIYAL: Objection. To the
23	extent the question is calling for the provision of
24	deliberative information that wasn't actually
25	finalized into this letter, I'm instructing the



1	witness not to answer.
2	BY MR. McGINTY:
3	Q Did anyone tell you to use this language
4	exactly?
5	A I consulted with OGC.
6	Q Office of General Counsel?
7	A Correct.
8	Q And under "Transgender Issues," this
9	language is also identical to the language from the
10	termination letter?
11	A Yes.
12	Q And did anyone tell you to use this
13	language exactly?
14	A No. The language matched the language in
14 15	A No. The language matched the language in the letter, so I just followed the guidance from the
15	the letter, so I just followed the guidance from the
15 16	the letter, so I just followed the guidance from the letter and advised that the award matched the
15 16 17	the letter, so I just followed the guidance from the letter and advised that the award matched the letter.
15 16 17 18	<pre>the letter, so I just followed the guidance from the letter and advised that the award matched the letter. Q It's kind of</pre>
15 16 17 18 19	<pre>the letter, so I just followed the guidance from the letter and advised that the award matched the letter. Q It's kind of A I didn't have any other language to give.</pre>
 15 16 17 18 19 20 	<pre>the letter, so I just followed the guidance from the letter and advised that the award matched the letter. Q It's kind of A I didn't have any other language to give. Q It's kind of a funny typo under</pre>
 15 16 17 18 19 20 21 	<pre>the letter, so I just followed the guidance from the letter and advised that the award matched the letter. Q It's kind of A I didn't have any other language to give. Q It's kind of a funny typo under "Termination." "Transgender issues" is capitalized</pre>
 15 16 17 18 19 20 21 22 	<pre>the letter, so I just followed the guidance from the letter and advised that the award matched the letter. Q It's kind of A I didn't have any other language to give. Q It's kind of a funny typo under "Termination." "Transgender issues" is capitalized on the "T." Do you know why that is? Under</pre>



1	THE WITNESS: No, I don't know.
2	BY MR. McGINTY:
3	Q Could it have been copied and pasted from
4	something?
5	MS. ANDRAPALLIYAL: Objection, calls for
6	speculation.
7	THE WITNESS: I don't know.
8	BY MR. McGINTY:
9	Q Is it standard practice to capitalize the
10	"T" on these Notice Awards?
11	MS. ANDRAPALLIYAL: Objection, calls for
12	speculation.
13	THE WITNESS: The "T"?
14	BY MR. McGINTY:
15	Q On "Transgender issues."
16	A I've not issued an award for a letter that
17	before.
18	Q Have you told anyone to capitalize that
19	"T"?
20	A The language was taken from the letter.
21	(Bulls Deposition Exhibit 10 was marked
22	for identification.)
23	BY MR. McGINTY:
24	Q I'm handing you what's been marked
25	Exhibit 10. Do you recognize this document?



1	А	A Notice of Award.
2	Q	And it's the same grant as we were talking
3	about in	Exhibit 9, isn't it?
4	А	Yes.
5	Q	And taking a look at that, "Summary
6	Federal A	ward Financial Information," could you tell
7	me what t	hat summary means?
8	A	It looks like the deobligations were
9	reversed.	
10	Q	Do you know why the deobligations were
11	reversed?	
12		MS. ANDRAPALLIYAL: Objection, asks for
13	speculati	on.
14		MR. McGINTY: I asked if she knew.
15		THE WITNESS: If I knew why?
16	BY MR. Mc	GINTY:
17	Q	Why the deobligations were reversed.
18	А	To reinstate the grant.
19	Q	Do you know why this grant was reinstated?
20	A	No, but I was asked to reinstate the
21	grant.	
22	Q	Who asked you to reinstate it?
23	A	I want to say my supervisor. This is the
24	acting su	pervisor.
25	Q	And who is that?
	1	

1	А	Dr. Lorsch.
2	Q	Dr. Lorsch?
3	A	Yeah.
4	Q	Do you know when that happened?
5	Α	Probably around the same day or the day
6	before of	the issue date of the letter.
7	Q	And this grant was originally terminated
8	in respons	se to one of those lists you got, right?
9	A	Yes.
10	Q	Has any other grant been reinstated since
11	you got a	Notice to Terminate on one of those lists?
12	A	Yes.
13	Q	Which ones are those?
14	A	I think it's a COVID grant, the COVID OT
15	of the tra	ansaction.
16	Q	COVID OT. Do you know what grantee?
17	A	I don't know.
18	Q	Go to page 5 in Exhibit 10.
19		MS. ANDRAPALLIYAL: Can we go off the
20	record, p	lease.
21		(Discussion off record)
22		MR. McGINTY: Back on the record.
23	BY MR. Mc	GINTY:
24	Q	So we're on page 5, and it says:
25		"Revised Award: This grant has been



1	restored and the termination clause
2	rescinded effective immediately. This
3	grant will continue under the original no
4	cost extension."
5	What does that mean?
6	A It means that the grant was restored, you
7	know, and that the termination was rescinded, and
8	when the grant was terminated, it was in a no cost
9	extension. And we were just saying that we wanted
10	the recipient to know that they can continue in
11	their extension.
12	Q Okay. It does say:
13	"The previous terms and conditions of
14	award remain in effect as stated below."
15	What does that mean?
16	MS. ANDRAPALLIYAL: Objection, assumes
17	facts not in evidence.
18	BY MR. McGINTY:
19	Q You can answer.
20	A I don't know what that means. It just
21	I don't know.
22	Q Okay. Because it says "Termination," and
23	it has the same language related to transgender
24	issues. It says:
25	"Transgender issues: Research programs



1	based on gender identity are often"	
2	(Reporter requests Mr. McGinty to read	
3	slower)	
4	MR. McGINTY: Sorry, of course.	
5	BY MR. McGINTY:	
6	Q It has the same language from the letter	
7	we were talking about earlier.	
8	A Yes.	
9	Q Do you know why that language is still	
10	there?	
11	A I don't.	
12	Q Is this grant subject to being defunded	
13	again because of what it researches?	
14	MS. ANDRAPALLIYAL: Objection, calls for	
15	speculation.	
16	THE WITNESS: No.	
17	BY MR. McGINTY:	
18	Q It's not?	
19	A Not that I am not that I would say, no	•
20	Q Is it part of your duties as the Director	
21	of OPERA to interpret Notice of Awards like this?	
22	A Yes.	
23	Q So how would you interpret this Notice of	
24	Award when it says, "The previous terms and	
25	conditions will remain in effect as state below,"	



Г

1	and it still has the "Termination" and "Transgender
2	issues" language?
3	A I would interpret it that someone didn't
4	delete the language, because when we typically
5	revise awards, the previous terms and conditions
6	still apply. So I believe that it was in error.
7	Q And going back to page 1, was that also
8	issued by Margaret Young?
9	A Yes.
10	Q Did you ask Margaret Young to issue this
11	NOA?
12	A The recension of the termination, yes.
13	Q And did you give her any particular
14	instructions with respect to the "Termination" and
15	"Transgender issues" language?
16	A I told her to revise the award and restore
17	the grant and sent her the language to restore the
18	grant.
19	Q And that's the language which language
20	is that?
21	A "This grant has been restored and the
22	termination clause rescinded effective
23	immediately. The grant will continue
24	under the original no cost extension."
25	Q Did you get that language from anywhere?



1	А	No.
2	Q	You wrote that?
3	А	I wrote it.
4		MR. McGINTY: We can go off the record.
5	(Lunche	eon recess taken 12:03 to 1:08 p.m.)
6		MR. McGINTY: Back on the record. Go
7	ahead and	mark this, please.
8		(Bulls Deposition Exhibit 11 was marked
9		for identification.)
10	BY MR. Mc	GINTY:
11	Q	I'm handing you what's been marked
12	Exhibit 1	1. Do you recognize this document?
13	А	Yes.
14	Q	And what is it?
15	А	A termination letter.
16	Q	And this is another one that you wrote,
17	right?	
18	Α	This is another one that I issued that was
19	written.	
20	Q	I'll clarify. You signed this, right?
21	A	Correct.
22	Q	Okay. And you signed this on behalf of
23	Margaret 1	Young?
24	A	Yes.
25	Q	And that's the same Margaret Young that we



	<i>,</i>	,
1	were tal}	ing about earlier, the Chief Grants
2	Management Officer at NICHD?	
3	A	Yes.
4	Q	Why did you issue this on behalf of
5	Margaret	Young?
6	Α	I believe at that time because the letters
7	were com	ing out quickly that I just issued them on
8	behalf of	the IC Chief GMO, and then they would
9	handle th	ne Notice of Reward.
10	Q	Did you talk to Margaret Young, before you
11	issued it	, about issuing this letter?
12	Α	No.
13	Q	Is this another one of the letters that
14	you got :	in a list?
15	А	Yes.
16	Q	And that list was sent to you by your
17	superviso	pr?
18	A	Yes.
19	Q	Who at the time was?
20	A	March 12th? I can't recall.
21	Q	Okay. And do you recall whether or not
22	Rachel R	iley was cc'd on the e-mail you got that
23	terminate	ed this grant as well?
24	A	I don't recall
25	Q	Okay.



1	A Rachel being on there.
2	Q You'd have to look at the e-mail to know?
3	A Yes.
4	Q And you did get this in an e-mail from
5	your supervisor?
6	A An e-mail from my supervisor, a forwarded,
7	probably.
8	Q A forwarded e-mail from your supervisor
9	that had the spreadsheet that you were talking about
10	earlier?
11	A All of them have spreadsheets.
12	Q And that spreadsheet has the list of
13	grants to terminate?
14	A Yes. And a point of clarification, if I
15	may?
16	MS. ANDRAPALLIYAL: Sure.
17	THE WITNESS: Because the process was just
18	continuing to be a lot, we actually I did say to
19	the I asked the Chief Grants Management Officers
20	if they were okay with me just issuing the letter
21	and them issuing the Notice of Awards. And they did
22	say that they were okay with that. And I do have
23	some of that in writing.
24	BY MR. McGINTY:
25	Q Great. Thank you for that clarification.



1	A Yeah.
2	Q By way of further clarification, did you
3	have any input in saying whether or not this
4	particular grant was going to be terminated?
5	A No.
6	Q And did you have any input in the language
7	on this letter?
8	A No.
9	Q To your knowledge, did anyone at NIH have
10	input?
11	MS. ANDRAPALLIYAL: Objection. It calls
12	for the provision of deliberative information. I'm
13	instructing the witness not to answer.
14	MR. McGINTY: Counsel, deliberative
15	process exemption only applies where an action has
16	not been taken. I'm talking about terminating a
17	grant.
18	MS. ANDRAPALLIYAL: No, that's not true.
19	The deliberative process privilege applies to
20	pre-decisional communications that precede a final
21	action, so it does apply to actions that have
22	already been taken.
23	BY MR. McGINTY:
24	Q Is there anything other than this letter
25	that explains why the grant was being terminated?



		511 00, 2020
1	А	The spreadsheet.
2	Q	The spreadsheet explains why?
3	А	It doesn't explain, it just lists the
4	category	
5	Q	Okay. Is there anything other than this
6	letter an	nd the spreadsheet?
7	А	An e-mail.
8	Q	An e-mail?
9	А	Yes.
10	Q	An e-mail you got from your supervisor?
11	А	Yes.
12	Q	Anything other than this letter, that
13	spreadshe	eet, and the e-mail?
14	А	No.
15	Q	Okay. Were either the spreadsheet or the
16	e-mail sł	nared with the grant recipient?
17	А	No, not that I'm aware of.
18		MR. McGINTY: Mark this, please.
19		(Bulls Deposition Exhibit 12 was marked
20		for identification.)
21	BY MR. Mo	CGINTY:
22	Q	I'm handing you what's been marked
23	Exhibit 3	12. And do you recognize this document?
24	А	Yes.
25	Q	And what is it?



1	A	Termination letter.
2	Q	And this is another termination letter
3	that you	signed?
4	A	Yes.
5	Q	And this one is to the Regents of the
6	Universit	y of California, San Francisco. And it's
7	Project N	Jo. 1R01 AI186641-01
8		(Reporter requests clarification)
9		MR. McGINTY: I'm sorry. 1R01 AI186641-0.
10	BY MR. Mo	CGINTY:
11	Q	Is that correct?
12	A	Dash 01.
13	Q	And is this another one of the
14	terminati	ons that you got in a list?
15	A	Yes.
16	Q	From your supervisor?
17	A	Yes.
18	Q	And this letter is dated March 18?
19	A	Yes.
20	Q	And who was your supervisor at that time?
21	A	I believe it was Jon Lorsch at that time,
22	for sure.	
23	Q	Jon Lorsch?
24	А	Dr. Lorsch.
25	Q	Dr. Lorsch?



1	A Yeah.
2	Q And, to your knowledge, did anyone at NIH
3	have any input in whether or not this grant was
4	going to be terminated?
5	A I don't know.
6	Q Would you know?
7	A I don't know.
8	MS. ANDRAPALLIYAL: Objection, calls for
9	speculation.
10	BY MR. McGINTY:
11	Q You can answer.
12	A I wouldn't know.
13	Q And is there anything, other than this
14	letter, that explains why this grant was terminated?
15	A The spreadsheet, the e-mail.
16	Q Anything else?
17	A No.
18	Q Okay. Did you ever talk to Dr. Lorsch
19	about this termination?
20	MS. ANDRAPALLIYAL: Go ahead.
21	THE WITNESS: No.
22	BY MR. McGINTY:
23	Q Did he tell you why this grant was being
24	terminated?
25	MS. ANDRAPALLIYAL: Objection. Because



1	the question is seeking deliberative information, I	
2	instruct the witness not to answer.	
3	BY MR. McGINTY:	
4	Q Let's go back very quickly to Exhibit 11.	
5	I just want to make sure that the grant project	
6	number is on the record.	
7	Could you read that for me.	
8	A Can I read I'm sorry?	
9	Q The project number that was being	
10	terminated.	
11	A Oh. 5 U01 HD108779-04.	
12	Q Great. And to whom what was the	
13	institution this was issued to?	
14	A Regents of the University of Minnesota.	
15	Q Thank you.	
16	MR. McGINTY: Mark that one, please.	
17	(Bulls Deposition Exhibit 13 was marked	
18	for identification.)	
19	BY MR. McGINTY:	
20	Q I hand you what's been marked Exhibit 13.	
21	Do you recognize this document?	
22	A Yes.	
23	Q And what is it?	
24	A A termination letter.	
25	Q Okay. And this one is a grant to the	



Γ

1	Regents of the University of Colorado. Is that
2	right?
3	A That is correct.
4	Q And could you read the project number for
5	me, please.
6	A Sure. 1R21 HD115838-01.
7	Q And this is another one that was provided
8	to you in a list from your supervisor?
9	A Yes.
10	Q And the only thing to explain why that
11	grant was terminated is this letter, the spreadsheet
12	that was attached to that e-mail, and the e-mail
13	itself?
14	A The e-mail itself doesn't explain it, it
15	just asks me to terminate it. The spreadsheet
16	attached gives the category and the grant number.
17	Q Okay. And, to your knowledge, NIH didn't
18	do any assessment of this particular grant before it
19	was terminated?
20	A I don't know.
21	MR. McGINTY: Mark that, please.
22	(Bulls Deposition Exhibit 14 was marked
23	for identification.)
24	BY MR. McGINTY:
25	Q I hand you what's been marked Exhibit 14.



Г

1	Now, starting about halfway down the page, this
2	appears to be an e-mail from you. Is that right?
3	A Yes.
4	Q And what is this e-mail from you?
5	A A termination letter.
6	Q And did you start sending these in the
7	form of an e-mail at some point?
8	A Yes.
9	Q When was that?
10	A Likely around the same date of this
11	letter.
12	Q Which is March 21, 2025?
13	A Yeah, around that time.
14	Q And why did you do that?
15	A To be efficient.
16	Q Why did you need to be efficient?
17	A The letters were the spreadsheet had
18	many terminations on the list, so I did it to be
19	efficient.
20	Q It was easier to send it in e-mail form
21	because there were so many to do?
22	A Yeah.
23	Q And who is the institution that this grant
24	was issued to?
25	A University of Washington.



	·	
1	Q And what's the project number?	
2	A 5R01MD017573-03.	
3	Q Okay. And this one, I think you allu	ıded
4	to it already, but this one is also on the basi	s of
5	the spreadsheet that you got?	
6	A Yes.	
7	Q And who sent you that spreadsheet?	
8	A Probably it was forwarded to me by my	,
9	supervisor.	
10	Q Forwarded from whom?	
11	A From Dr. Memoli.	
12	Q Dr. Memoli?	
13	A Yeah, at this point. That's correct.	
14	Q And do you know if it was forwarded t	0
15	Dr. Memoli from anybody?	
16	MS. ANDRAPALLIYAL: Objection, calls	for
17	speculation, calls for a provision of deliberat	live
18	information.	
19	BY MR. McGINTY:	
20	Q You can answer.	
21	MS. ANDRAPALLIYAL: Objection. To th	le
22	extent that it calls for the provision of	
23	deliberative information, I would instruct the	
24	witness not to answer.	
25	MR. McGINTY: Can you explain the	



1	privilege attaching to an e-mail that the person
2	forwarded an e-mail.
3	MS. ANDRAPALLIYAL: To the extent that the
4	answer is that the answer would provide
5	information that is deliberative, I would instruct
6	the witness not to answer.
7	BY MR. McGINTY:
8	Q Did any of the to or from or cc fields on
9	that e-mail, or on the e-mails that were attached to
10	it, contain back-and-forth deliberative discussions?
11	A Not that I'm aware of.
12	Q Okay. Do you recall if the e-mail that
13	Dr. Memoli was forwarded from Dr. Memoli, was
14	forwarded from anybody else?
15	A I don't recall.
16	Q Okay. The only way to know that would be
17	from the e-mail?
18	A Yes.
19	Q Okay.
20	MR. McGINTY: Mark that.
21	(Bulls Deposition Exhibit 15 was marked
22	for identification.)
23	BY MR. McGINTY:
24	Q I pass you what has been marked
25	Exhibit 15. Do you recognize this document?



	· · ·	·
1	A	Yes.
2	Q	What is it?
3	A	It is a termination letter.
4	Q	And this is two-sided. I'm sorry, I
5	printed t	his double sided.
6	A	That's okay.
7	Q	And that's your signature at the end,
8	right?	
9	А	Yes.
10	Q	Okay. And this is another one of the
11	terminati	ons on the basis that was sent to you on
12	a spreads	heet?
13	A	Yes.
14	Q	And what's the institution that received
15	this gran	t?
16	A	University of Washington.
17	Q	And what's the project number?
18	A	1F31 AI181431-01A1.
19	Q	Okay. And the only thing that would
20	explain w	hy this grant was terminated is this letter
21	and the s	preadsheet?
22	A	Yes.
23		MS. ANDRAPALLIYAL: Sorry. Objection,
24	assumes f	acts not in evidence.
25	BY MR. Mc	GINTY:



1	Q What are the documents that would explain
2	why this grant was terminated?
3	A The letter, the e-mail that was forwarded
4	with the spreadsheet.
5	Q And that spreadsheet was forwarded to you
6	from your supervisor?
7	A Yes.
8	Q And who is your supervisor at the time?
9	A I believe it was Dr. Lorsch. There was a
10	transition period so.
11	Q So either Dr. Lorsch or?
12	A Dr. Bundesen.
13	Q Okay. Either Dr. Lorsch or Dr. Bundesen.
14	And would Rachel Riley have been on any of
15	the to or from fields of that e-mail?
16	A Not at that time, not during this time
17	period.
18	Q Anyone else from HHS?
19	A No.
20	Q So did so that stopped at some point?
21	A Yes. I didn't see the to, where it
22	originated. It was just coming from Dr. Memoli to
23	either Liza or Dr. Lorsch.
24	Q And when did you stop being able to see
25	where it originated?



1	A	I don't even recall because I stopped
2	looking	down on the e-mails at that point. It
3	was y	eah.
4	Q	Before or after March 10?
5	A	Probably after.
6	Q	Sometime after March 10?
7	A	Yes.
8		(Bulls Deposition Exhibit 16 was marked
9		for identification.)
10	BY MR. M	CGINTY:
11	Q	I'm showing you what's been marked
12	Exhibit	16. Do you recognize this?
13	A	Yes.
14	Q	And what is it?
15	A	A termination letter.
16	Q	And this is another one that you signed?
17	A	Yes.
18	Q	And who is the recipient of this grant?
19	A	University of Washington.
20	Q	And what's that project number?
21	A	5R01LM013301-05.
22	Q	And this is another one that came to you
23	in the f	orm of a spreadsheet listing the grants to
24	terminat	e?
25	А	Yes.

1	Q	And that was sent to you by your
2	superviso	r?
3	А	Yes.
4	Q	Which was who at this point?
5	A	Dr. Lorsch.
6	Q	That was Dr. Lorsch.
7		And you wouldn't have known who sent
8	Dr. Lorsc	h this spreadsheet?
9	А	Typically, like I said, I started seeing
10	just the	e-mail forwarded from sent to Dr. Lorsch
11	from Dr.	Memoli.
12	Q	Got it.
13	А	Yeah.
14	Q	So Dr. Memoli sent it to Dr. Lorsch. Is
15	that righ	t?
16	A	That is correct.
17	Q	Okay. And do you know who sent it to
18	Dr. Memol	i?
19	A	No.
20	Q	Okay. Because that information was cut
21	off of th	e e-mail?
22	A	I don't know if it was cut off, it just
23	wasn't th	ere.
24	Q	It wasn't on the e-mail?
25	A	No, it wasn't on the e-mail.



1	Q Okay.
2	(Bulls Deposition Exhibit 17 was marked
3	for identification.)
4	BY MR. McGINTY:
5	Q I'm handing what's been marked Exhibit 17.
6	Do you recognize this?
7	A Yes.
8	Q And what is this?
9	A A termination letter.
10	Q And who is the institution it was issued
11	to?
12	A University of Washington.
13	Q And what's the project number?
14	A 1G13LM014426-01.
15	Q And this is another one that you got in a
16	spreadsheet?
17	A Yes.
18	Q And it was sent to you by your supervisor?
19	A Yes.
20	Q And do you know who sent the spreadsheet
21	to your supervisor?
22	A During this period it was from Dr. Memoli
23	to I this is the foggy period, sorry.
24	Q Okay. You're not sure who your supervisor
25	was?



1	A I'm sure who my supervisor was. I'm just
2	not sure of the period when it was, the different
3	time frames.
4	Q That's fine. It was either Bundesen or
5	Lorsch?
6	A Right.
7	Q And do you know who sent it to Dr. Memoli?
8	A I don't recall during this time. Yeah,
9	I'm not sure if it was just forwarded from
10	Dr. Memoli to Liza or Jon to me. Because, remember,
11	during a period of time, it was on the from with
12	how do I say? The person that it was sent from at
13	the department was on there, and at a point that
14	stopped.
15	Q But when it was from someone from the
16	department, that was Rachel Riley?
17	A The two times, yes.
18	Q Okay. Was there anyone else from HHS it
19	was sent from?
20	A Not that I'm aware of.
21	Q Okay. So either it was Rachel Riley or
22	you didn't have the information?
23	A Correct.
24	Q Okay. And this letter and the other
25	letters we've been looking at, this is still the



1	same template letter that was provided to you?
2	A Yes.
3	Q You didn't write one word in this letter?
4	A No, just signed it.
5	Q Okay. And the only thing that would
б	explain why this grant was terminated is this letter
7	and the spreadsheet and the e-mail?
8	A Yeah, the spreadsheet that was attached to
9	the e-mail.
10	(Bulls Deposition Exhibit 18 was marked
11	for identification.)
12	BY MR. McGINTY:
13	Q I'm handing you what's been marked
14	Exhibit 18. Do you recognize this?
15	A Yes.
16	Q And what is it?
17	A A termination letter.
18	Q And this is another one that looks like it
19	was in e-mail form. Is that right?
20	A Yes, that's correct.
21	Q And who is the institution it was issued
22	to?
23	A University of Washington.
24	Q And what's the project number?
25	A 1R21AI183907-01A1.



[
1	(Reporter requests clarification)
2	THE WITNESS: "A" as in apple.
3	BY MR. McGINTY:
4	Q And this is another termination that you
5	issued on the basis of a spreadsheet that was sent
6	to you?
7	A Yes.
8	Q And that was sent to you who sent you
9	that spreadsheet?
10	A Dr. Lorsch.
11	Q Dr. Lorsch sent it to you. And Dr. Memoli
12	sent it to Dr. Lorsch?
13	A Correct.
14	Q And the only thing that would explain why
15	this grant was terminated is this letter and the
16	e-mail and the spreadsheet?
17	MS. ANDRAPALLIYAL: Objection, assumes
18	facts not in evidence.
19	BY MR. McGINTY:
20	Q What are the documents that would explain
21	why this grant was terminated?
22	A The letter, the forwarded spreadsheet that
23	had the categories in there.
24	Q Okay. Anything else?
25	A No.



1	MS. ANDRAPALLIYAL: Can we go off the	
2	record for a minute.	
3	MR. McGINTY: Why?	
4	MS. ANDRAPALLIYAL: I would like to confer	
5	with my co-counsel.	
6	MR. McGINTY: About what?	
7	MS. ANDRAPALLIYAL: I don't think I'm	
8	obligated to tell you that.	
9	MR. McGINTY: We just had a break. I	
10	think we're going to keep going.	
11	MS. ANDRAPALLIYAL: I'd like to stop, and	
12	I don't think that's I don't yeah, I'd like to	
13	stop, please.	
14	MR. McGINTY: Okay. Off the record.	
15	(Recess taken - 1:31 to 1:46 p.m.)	
16	MR. McGINTY: We can go back on the	
17	record.	
18	All right. I just want to note for the	
19	record that we took about a 15-minute break just	
20	now.	
21	BY MR. McGINTY:	
22	Q Ms. Bulls, did you confer with counsel at	
23	the break?	
24	A I asked a question.	
25	Q Did you talk to your lawyers?	



1	А	Yes.
2	Q	Okay.
3		MR. McGINTY: Can I ask the court reporter
4	how much	time we've been on the record.
5		(Whereupon, the reporter discloses time
6		spent on the record)
7		MR. McGINTY: A little less than four
8	hours?	
9		MADAM COURT REPORTER: Yes.
10		MR. McGINTY: I'll also note for the
11	record the	at we've been on the record for a little
12	less than	four hours.
13		(Bulls Deposition Exhibit 19 was marked
14		for identification.)
15	BY MR. Mc	GINTY:
16	Q	I'm handing you what's been marked
17	Exhibit 1	9.
18		MR. McGINTY: Counsel.
19		(Document tendered to Ms. Andrapalliyal)
20	BY MR. Mc	GINTY:
21	Q	Do you recognize this document?
22	A	Yes.
23	Q	And what is it?
24	A	A termination letter.
25	Q	Okay. And this is another one that you



1 signed, right? Α 2 Yes. 3 Okay. And who is the issuing Q 4 institution -- or the institution that received the termination letter? 5 University of Washington. 6 Α And what's that project number? 7 Q 1R01 TW012904-01. 8 Α 9 And this is another one that you got in a 0 10 spreadsheet from your supervisor? 11 Α Yes. 12 Okay. And where are the documents that Ο 13 explain why the grant was terminated? 14 Α The spreadsheet and the request for me to 15 terminate. And this letter right here, sorry. 16 No, that's fine, that's fine. Ο 17 And, again, this was language -- the 18 language in this letter was provided to you? 19 Α Yes. 20 And you didn't write one word in this 0 21 letter? 22 (Nodding head) Α 23 Sorry, I didn't hear your answer. 0 24 Α No. Sorry, no. 25 (Bulls Deposition Exhibit 20 was marked



1	for identification.)
2	BY MR. McGINTY:
3	Q I'm handing you Exhibit 20. And I'll note
4	that it is big and unwieldy and the pages are not
5	bound. So I'll ask you to be careful with your
6	handling it.
7	But do you recognize this document?
8	A Yes. Yes, I do.
9	Q And what is it?
10	A NIH Grants Policy Statement.
11	Q And how are you familiar with it?
12	A I'm familiar with it because I placed
13	information in it, I use it to advise recipients, I
14	use it to assess compliance, I read it.
15	Q Assess compliance with what?
16	A With the policies that are in the policy
17	statement to determine whether or not the recipients
18	are complying with the terms and conditions of the
19	award.
20	Q Okay. What's the purpose of the document?
21	A To provide, lay out the grant policy
22	requirements of that serve as the terms and
23	conditions of all NIH award administrative
24	requirements.
25	Q Turn to page Romanette ii. So this



		,
1	says s	ee where it says:
2		"Is intended to make available to NIH
3		recipients, in a single document, the
4		policy requirements that serve as the
5		terms and condition of NIH grant awards"?
6	А	Yes.
7	Q	And is that a true description of what
8	this docu	ment is for?
9	А	It is.
10	Q	Is this the most recent version of this
11	document?	
12	А	It is.
13	Q	Okay. Are there any operative amendments
14	to it?	
15	А	Can you explain your question.
16	Q	Sure. Has any document been issued that
17	changes t	he terms of this document?
18	А	The there have been Guide Notices that
19	have been	issued that we provide to, yes, to the
20	public.	
21	Q	To the public?
22	A	Yeah.
23	Q	How many of those have been issued?
24	A	I don't recall.
25	Q	Do you know if it changed the terms?



	-	
1	A	They do they add to the terms at times.
2	Q	Okay. Let's see, could you turn to page
3	I-53.	
4		Do you see here where it says:
5		"The more significant of the public policy
6		requirements for the purpose of peer
7		review are those concerning research
8		involving human subjects; inclusion of
9		genders, members of minority groups, and
10		individuals across the lifespan in
11		clinical research; and research involving
12		live vertebrate animals"?
13	А	No. Where are you reading from?
14		Oh, I see it.
15	Q	Okay. You found it?
16	A	Yes, I see it.
17	Q	What does that mean?
18		MS. ANDRAPALLIYAL: Objection, assumes
19	facts not	in evidence, calls for a legal conclusion.
20	BY MR. Mc	GINTY:
21	Q	You can answer.
22	A	The public policy requirement is this
23	is about :	making sure that the peer review of the
24	research	for humans and an human subject,
25	inclusion	of gender, members of minority groups.



1	It basically outlines the public policy
2	requirements that we should point to and consider
3	when we are making awards.
4	Q What does "inclusion of genders" mean?
5	MS. ANDRAPALLIYAL: Objection, calls for
6	speculation, assumes facts not in evidence.
7	BY MR. McGINTY:
8	Q You can answer.
9	A "Inclusion of genders" is inclusion of
10	gender, all genders.
11	Q Okay. All right. What do you mean by
12	"all genders"?
13	A It means whatever the gender whatever
14	is identified as the gender.
15	Q What does "members of minority groups"
16	mean as used in that section?
17	MS. ANDRAPALLIYAL: Objection, assumes
18	facts not in evidence, calls for speculation.
19	BY MR. McGINTY:
20	Q Well, Ms. Bulls, you helped draft this
21	document, right?
22	A (Nodding head)
23	Q Could you answer.
24	A Yes.
25	Q And part of your role is to help the ICs



1	understand what this document means, right?
2	A That is correct.
3	Q Is part of your role to help the public
4	understand what this document means?
5	A That is correct.
6	Q And so it's part of your regularly
7	occurring duties to interpret this document, isn't
8	it?
9	A It is.
10	Q Okay. So what does "members of minority
11	groups" mean here?
12	MS. ANDRAPALLIYAL: Objection, asked and
13	answered, and the document speaks for itself.
14	BY MR. McGINTY:
15	Q You can answer.
16	A "Members of minority groups" is identified
17	in the Notices of Funding Opportunities. The
18	details of those are typically laid out in the
19	eligibility criteria or the eligibility areas of the
20	Notices of Funding Opportunities. So it would tie
21	back to whatever the program issued in that NOFO
22	and identified in the NOFO.
23	Q So what's the public policy requirement
24	that they're talking about when they say, "The more
25	significant of the public policy requirements for



1 the purpose of peer review are those concerning research involving human subjects; members of 2 3 minority groups"? 4 Does that refer to the NOFO? 5 Α Yes, because the viewers look at the NOFO, and they review based on the information that's in 6 the Notices of Funding Opportunities. They have 7 their criteria. 8 9 And the NOFO will have the I see. 0 10 How does that relate to the members of criteria. 11 minority groups? I quess I'm just not following 12 vour answer. 13 Α So if it's a Notice of Funding Opportunity 14 that is specific to a minority health or minority HBCU, the research is linked to that, they will lay 15 out in the NOFO who is eligible to receive the 16 17 funding and lay out the criteria that they will use 18 for the recipient, or applicant at that time, to 19 be -- to apply for the funding, they lay out that 20 criteria. 21 And they have to be responsive. And then 22 it goes to peer review for them to review all of how 23 the applicant responded to the Notice of Funding 24 Opportunities. So that's how we look at that from 25 the peer review standpoint.



Γ

1	Q Got it. So this is explaining why you do
2	NOFOs and the way you do it?
3	A This is explaining the public policy
4	requirements that apply to those NOFOs, and the
5	guidance by which reviewers are looking at as the
6	scientists or the program officials write the NOFOs.
7	So it's kind of all baked into the Notice
8	of the Funding Opportunity, the purpose of the grant
9	itself. And then we, because before it is an
10	application, once it's an award, then they are bound
11	by the requirements here to follow that.
12	Q Does anything in this language that we
13	were just talking about suggest that research into
14	transgender or gender diverse health issues would
15	not be a priority for NIH?
16	MS. ANDRAPALLIYAL: Objection, calls for
17	speculation.
18	BY MR. McGINTY:
19	Q You can answer.
20	A Can you repeat the question.
21	Q Does anything about the language we've
22	been talking about imply that it's a priority of NIH
23	not to fund research into transgender issues?
24	A Not at the time that this was issued.
25	Q Nothing in this language said that?



1	A Nothing.
2	Q How about health disparities across racial
3	groups?
4	MS. ANDRAPALLIYAL: Same objection, calls
5	for speculation.
6	BY MR. McGINTY:
7	Q You can answer.
8	A Yes, same response. The language does not
9	say anything about that in this at this time, in
10	the April 2024.
11	Q Have any of the amendments you just talked
12	about to these policies and procedures changed the
13	NIH priorities for funding of transgender issues?
14	MS. ANDRAPALLIYAL: Objection to the
15	extent that your question is calling for the
16	provision of deliberative information that hasn't
17	finalized yet.
18	THE WITNESS: The
19	MS. ANDRAPALLIYAL: And instruct the
20	witness not to answer to the extent that the
21	question is asking for that information.
22	BY MR. McGINTY:
23	Q I'm asking only about effective policy.
24	I'm asking only about policies that are effective
25	right now, today, that are final.



1	My question is: Have there been any
2	amendments to this policy statement that would make
3	it so NIH does not have a priority of funding
4	transgender issues?
5	MS. ANDRAPALLIYAL: Objection, assumes
6	facts not in evidence.
7	THE WITNESS: No.
8	BY MR. McGINTY:
9	Q How about research for racial disparities?
10	A No.
11	Q How about research regarding vaccine
12	hesitancy?
13	MS. ANDRAPALLIYAL: Objection, calls for
14	speculation.
15	THE WITNESS: Your question is still the
16	same?
17	BY MR. McGINTY:
18	Q Yeah. The question is: Are there any
19	effective policies for NIH right now, today, that
20	are final that say that NIH deprioritizes funding
21	for vaccine hesitancy?
22	A No.
23	Q Okay. How about research that might
24	benefit institutions in China?
25	MS. ANDRAPALLIYAL: Same objection, calls



1 for speculation. 2 THE WITNESS: Not where there's not a, a 3 foreign interference or nondisclosure requirement or -- but at this time China is on the list of 4 5 countries of concern. BY MR. McGINTY: 6 7 0 Would you turn to I-73, please. Now what I want to ask you about is this list of, I think 8 9 it's five things that appears in the top third of 10 It's under a section that's starts on the page. 11 I-72, so if you need to familiarize yourself with 12 any portion, go right ahead. 13 But my question is, there's these five 14 sections here, could you just read those into the 15 record and tell me what they mean. MS. ANDRAPALLIYAL: Objections, calls for 16 17 speculation. 18 THE WITNESS: So I'm going to read it, but 19 then I also want to respond if that's okay. 20 BY MR. McGINTY: 21 0 Sure. 22 "Significance, Investigators, Innovation, Α 23 Approach, Environment." This section was written 24 by, by the experts in the peer review area. 25 Okay. So do you have an understanding of Q



1	what this means and how it's used in the grant
2	application and review process?
3	A I have an overarching understanding of
4	what that means.
5	Q Okay. I'm just going to be asking for
6	your understanding.
7	A Yeah.
8	Q For your understanding, what does
9	"Investigators" mean?
10	MS. ANDRAPALLIYAL: Objection, calls for
11	speculation.
12	THE WITNESS: Investigators that are
13	participating on the award that are leading the
14	scientific direction.
15	BY MR. McGINTY:
	DI MR. MCGINII.
16	Q And it has to do with how qualified the
16 17	
	Q And it has to do with how qualified the
17	Q And it has to do with how qualified the investigators are, right?
17 18	Q And it has to do with how qualified the investigators are, right? A Yes.
17 18 19	Q And it has to do with how qualified the investigators are, right? A Yes. MS. ANDRAPALLIYAL: Objection, misstates
17 18 19 20	<pre>Q And it has to do with how qualified the investigators are, right? A Yes. MS. ANDRAPALLIYAL: Objection, misstates the yeah, misstates the testimony.</pre>
17 18 19 20 21	<pre>Q And it has to do with how qualified the investigators are, right? A Yes. MS. ANDRAPALLIYAL: Objection, misstates the yeah, misstates the testimony. BY MR. McGINTY:</pre>
17 18 19 20 21 22	<pre>Q And it has to do with how qualified the investigators are, right? A Yes. MS. ANDRAPALLIYAL: Objection, misstates the yeah, misstates the testimony. BY MR. McGINTY: Q Does it have to do with how qualified the</pre>
17 18 19 20 21 22 23	<pre>Q And it has to do with how qualified the investigators are, right? A Yes. MS. ANDRAPALLIYAL: Objection, misstates the yeah, misstates the testimony. BY MR. McGINTY: Q Does it have to do with how qualified the investigators are who are applying?</pre>



1	Q What makes an investigator qualified?
2	MS. ANDRAPALLIYAL: Objection, calls for
3	speculation.
4	THE WITNESS: I don't feel comfortable
5	answering that because I don't review grants.
6	BY MR. McGINTY:
7	Q So you don't know what makes an
8	investigator qualified?
9	A I know what I would think an investigator
10	is qualified and how they are qualified. But I'm
11	not a scientist, so I wouldn't you know, what I
12	might see and someone else might see is two
13	different things. And so I don't want to I'm not
14	comfortable with answering that question.
15	Q Okay. So in your opinion what makes an
16	investigator qualified?
17	MS. ANDRAPALLIYAL: Objection, calls for
18	speculation, and the witness is not here to testify
19	in her personal capacity.
20	THE WITNESS: Yeah, I'm not an expert in
21	that.
22	BY MR. McGINTY:
23	Q You can answer.
24	A Yeah, I'm not an expert in
25	Q So you don't have an opinion?



1	A I have an opinion. I'm not comfortable
2	with giving my opinion outside of my official
3	capacity.
4	Q With all due respect, Ms. Bulls, you are
5	here today to testify, and you've not been
6	instructed not to answer. I'm asking for your
7	opinion.
8	A It has to be I would assume so in my
9	opinion, it would be the principal investigator is
10	the person that has the expertise in the scientific
11	area by which they were applying for the grant.
12	Q And what would give them expertise?
13	MS. ANDRAPALLIYAL: Objection, calls for
14	speculation.
15	MR. McGINTY: I'm asking her to explain
16	her opinion.
17	THE WITNESS: Their background, their
18	qualifications, their experience, publications.
19	BY MR. McGINTY:
20	Q If they had background and qualifications
21	and publications in the area that they're applying
22	for a grant for, that would make them more qualified
23	for that grant?
24	MS. ANDRAPALLIYAL: Objection, calls for
25	speculation, calls for testimony in the witness's



Γ

1	personal capacity which she is not here to do.
2	BY MR. McGINTY:
3	Q Is that right?
4	A Is what right? I'm sorry.
5	MR. McGINTY: Could you read back the
6	question, please.
7	(The record was read aloud as follows:
8	"QUESTION: If they had a background and
9	qualifications and publications in the
10	area that they're applying for a grant
11	for, that would make them more qualified
12	for that grant?")
13	THE WITNESS: I don't know that it would
14	make them more qualified, because they're the
15	grant is there's a competition across the board,
16	so they would be in the running to receive a grant.
17	BY MR. McGINTY:
18	Q Understood. Thank you.
19	What does "Environment" mean?
20	MS. ANDRAPALLIYAL: Objection, calls for
21	speculation.
22	THE WITNESS: The environment is the
23	where the project is going to be taking place, place
24	of performance.
25	BY MR. McGINTY:



1	Q And how is that evaluated in the grant
2	application and review process?
3	MS. ANDRAPALLIYAL: Objection, calls for
4	speculation.
5	THE WITNESS: I don't know so they look
6	at the grant application and they assess whether or
7	not the place of performance is an acceptable place
8	to conduct the research.
9	BY MR. McGINTY:
10	Q What would make it acceptable?
11	MS. ANDRAPALLIYAL: Objection, calls for
12	speculation.
13	THE WITNESS: Yeah, I can't answer that.
14	BY MR. McGINTY:
15	Q Do you have an opinion on what would make
16	it acceptable?
17	MS. ANDRAPALLIYAL: Objection. The
18	witness is not here to testify in her personal
19	capacity, offer her personal opinions.
20	THE WITNESS: No, I don't have an opinion.
21	BY MR. McGINTY:
22	Q Would you turn to IIA-3.
23	A IIA-3, you say?
24	Q No. IIA
25	A Oh, 3.



1	Q 3.
2	A Got you.
3	Q Could you read the second paragraph that
4	appears on IIA-3.
5	A "As noted in this section, some
6	requirements may necessitate the
7	submission of a separate document (e.g,
8	human subjects assurance, certification
9	of IRB approval, institutional exemption,
10	civil rights assurance"
11	Q I'm going to interrupt you. I meant the
12	second paragraph at the top of the page.
13	A Oh, I'm sorry.
14	Q No, you're fine.
15	A "This chapter addresses the public
16	Policy requirements, objectives, and other
17	appropriation mandates applicable to NIH
18	awards. The term 'public policy'
19	indicates that the requirement is based
20	on social, economic, or other objectives
21	or considerations that may be attached to
22	the expenditure of Federal funds by the
23	recipients, subrecipients, and
24	contractors, in general, or may relate to
25	the expenditure of Federal funds for



1		research or other specified activities."
2	Q	So if there were a social, economic, or
3	other obje	ective of distributing NIH funds, I would
4	expect to	find it in this Part 4 of this document,
5	right?	
6		MS. ANDRAPALLIYAL: Objection, calls for
7	speculatio	on.
8		THE WITNESS: Yes.
9	BY MR. Mc	GINTY:
10	Q	Can you turn to IIA-14. Would you read
11	that parag	graph under 4.1.2, Civil Rights
12	Protection	ns, please.
13	А	The entire paragraph?
14	Q	Yes, please.
15	А	I'm going to have to take some water.
16	Q	Please do.
17	А	"Recipients are required to administer
18		NIH-funded projects in compliance with
19		the federal civil rights laws that
20		prohibit discrimination on the basis of
21		race, color, national origin, disability,
22		age, and sex, which includes
23		discrimination on the basis of gender
24		identity, sexual orientation, and
25		pregnancy, and comply with the applicable



1	conscience protections."
2	Q That's the end.
3	A Oh. I thought you said I meant the
4	whole, I'm sorry, the whole section.
5	Q Oh, no, I just meant that first paragraph
6	under that section. I apologize.
7	A That's okay.
8	Q So recipients for NIH funding, they're
9	prohibited from discriminating on the basis of sex,
10	right?
11	A That's correct.
12	Q And prohibited from discriminating against
13	transgender people also?
14	MS. ANDRAPALLIYAL: Objection, calls for a
15	legal conclusion, calls for speculation.
16	THE WITNESS: That is correct.
17	BY MR. McGINTY:
18	Q And they are forbidden from discriminating
19	against gender diverse people, too?
20	MS. ANDRAPALLIYAL: Objection, calls for a
21	legal conclusion, calls for speculation, and assumes
22	facts not in evidence.
23	THE WITNESS: I would think so.
24	BY MR. McGINTY:
25	Q Does this section that we were just



1	looking at right here, does this imply that NIH has
2	any policy for not funding research into transgender
3	issues?
4	MS. ANDRAPALLIYAL: Objection, calls for
5	speculation.
6	THE WITNESS: Not at the time this was
7	issued.
8	BY MR. McGINTY:
9	Q So this language doesn't have any
10	implication that NIH does not fund transgender
11	related research?
12	MS. ANDRAPALLIYAL: Objection, calls for
13	speculation.
14	THE WITNESS: Not before this. Not before
15	this was issued.
16	BY MR. McGINTY:
17	Q Okay. And is there any effective
18	operative amendment to this NIH Policy Manual that
19	would change that so that NIH does have a policy of
20	defunding transgender issues?
21	A Not at this time. In draft form, but not
22	at this time publicly.
23	Q Okay. So there's drafts that are being
24	generated that will change that?
25	



1	extent that the question is calling for the
2	privileged and deliberative information that has not
3	been finalized, the witness is instructed not to
4	answer.
5	BY MR. McGINTY:
6	Q So right now, today, there is no published
7	NIH policy that says NIH does not fund transgender
8	related issues?
9	A No.
10	Q And if I understood your testimony
11	correctly, the only written policy that exists is
12	the form letters that you got in connection with
13	those spreadsheets terminating grants?
14	MS. ANDRAPALLIYAL: Objection, misstates
15	prior testimony.
16	THE WITNESS: The letters are not
17	considered policy.
18	BY MR. McGINTY:
19	Q The letters aren't policy?
20	A No, they're not considered policy.
21	Q So there's no policy that NIH has to
22	defund or to not fund transgender related research?
23	MS. ANDRAPALLIYAL: Objection, calls for
24	speculation, assumes facts not in evidence.
25	THE WITNESS: The question you asked



1	before was whether it was published, anything today,
2	and publicly available. No.
3	BY MR. McGINTY:
4	Q Is there a policy that NIH implements but
5	is not published that defunds transgender related
6	research?
7	A Not at this time.
8	Q So there's no policy that NIH implements
9	that defunds transgender related research?
10	A Not at this time.
11	Q When you say, "this time," what do you
12	mean?
13	A I'm saying that earlier I spoke to you
14	about the priorities memo. Once that memo is
15	finalized, that will be made publicly available, but
16	it's still in draft form, we're still going through
17	a process.
18	Q Okay. And is that memo implemented in any
19	way?
20	MS. ANDRAPALLIYAL: Objection, calls for a
21	legal conclusion, calls for speculation.
22	THE WITNESS: No, nothing final is
23	implemented related to the memo.
24	BY MR. McGINTY:
25	Q Okay.



1	A The draft memo.
2	Q So right now, today, NIH does not have a
3	policy of defunding or not funding transgender
4	related research?
5	MS. ANDRAPALLIYAL: Objection, calls for
6	speculation.
7	THE WITNESS: That is correct.
8	BY MR. McGINTY:
9	Q Okay. Now, following this, there's some
10	significant policies having to do with stem cell
11	research and fetal human cells. Is that correct?
12	A Yes.
13	MS. ANDRAPALLIYAL: I'm sorry, what page
14	are we on?
15	MR. McGINTY: Just the following pages,
16	IA-15, IA-16 [sic].
17	MS. ANDRAPALLIYAL: IIA-15?
18	MR. McGINTY: Yes, sorry.
19	BY MR. McGINTY:
20	Q Are these policies the kind of things
21	are these the kind of social, economic, and other
22	policy goals that this Section 4 is about?
23	MS. ANDRAPALLIYAL: Objection, calls for
24	speculation.
25	THE WITNESS: Can you repeat. I'm sorry,



Case 1:25-cv-10787-BEM Document 38-8 Filed 04/25/25 Page 165 of 246

State of WA, et al. vs Trump, et al. Bulls, Michelle - April 03, 2025

I was just --1 BY MR. McGINTY: 2 3 Let me find it. Okay. When we get Q Sure. 4 to IIA-28 --5 Α Okay. -- and IIA-29, there's policies about 6 0 human stem cell research and human fetal tissue 7 8 research? 9 Α Yes. 10 And earlier in this section we talked Ο 11 about the overriding umbrella section it had, which 12 was, its purpose with to set out the social, 13 economic, and public policy issues surrounding NIH 14 funding. Is that right? 15 Α That is right. 16 Okay. So I'm just asking if these sorts Ο 17 of sections, 4.1.13 and 4.1.14, are examples of those kinds of social, economic, and public policy 18 19 implications of NIH funding. 20 MS. ANDRAPALLIYAL: Objection, calls for 21 speculation. 22 THE WITNESS: I interpret them to be, yes. 23 BY MR. McGINTY: 24 0 Okav. And this references on IIA-28 25 Executive Order 13505, doesn't it?



1	A Yes.
2	Q So when the NIH policies are informed by
3	an Executive Order, it's referenced somewhere,
4	right?
5	MS. ANDRAPALLIYAL: Objection, calls for
6	speculation.
7	THE WITNESS: Yes.
8	BY MR. McGINTY:
9	Q Okay.
10	A Where there is correction, where there
11	is an Executive Order, yes.
12	Q Let's see. I'm looking for 4.1.15. Here
13	we go, "Human Subjects Protections."
14	Can you summarize this section for me.
15	What are the human subjects protections that NIH
16	implements in this policy manual?
17	A Making certain that there are assurances
18	and protocols in place to provide protections to
19	participants.
20	Q And it also requires that human trials
21	include all kinds of people, right?
22	A I just said, yes.
23	Q And why is that important?
24	MS. ANDRAPALLIYAL: Objection, calls for
25	speculation.



1	THE WITNESS: It's important to the
2	outcomes of science.
3	BY MR. McGINTY:
4	Q And that includes clinically important sex
5	gender differences, doesn't it?
6	MS. ANDRAPALLIYAL: Objection, calls for
7	speculation.
8	THE WITNESS: I don't see it as just one
9	thing. It includes all participants.
10	BY MR. McGINTY:
11	Q Which includes sex and gender differences,
12	right?
13	MS. ANDRAPALLIYAL: Objection, calls for
14	speculation.
15	THE WITNESS: It does. I would interpret
16	it to include that.
17	BY MR. McGINTY:
18	Q Okay. So is there anything here in this
19	4.1.15 Section that indicates it is not the policy
20	of NIH to defund or to not fund transgender related
21	research?
22	MS. ANDRAPALLIYAL: Objection, calls for
23	speculation.
24	THE WITNESS: No.
25	BY MR. McGINTY:



1	Q Okay. And, in fact, it's actually the
2	opposite, isn't it? This policy actually says that
3	transgender related research is important?
4	A That is what the policy says at this time,
5	yes.
6	Q And "at this time," you mean today?
7	A Yes.
8	Q So is there anything in this policy
9	anywhere that says that NIH does not fund
10	transgender related research?
11	MS. ANDRAPALLIYAL: Objection, assumes
12	facts not in evidence.
13	THE WITNESS: No.
14	BY MR. McGINTY:
15	Q And is there anything in any of the
16	effective amendments to this policy that says NIH
17	does not fund or defund transgender related
18	research?
19	A Publicly, no.
20	Q Publicly, no?
21	A No.
22	Q But NIH is terminating grants on the basis
23	that they fund transgender related research, isn't
24	it?
25	MS. ANDRAPALLIYAL: Objection, calls for



1 speculation. Termination letters 2 THE WITNESS: 3 terminate the grant. 4 BY MR. McGINTY: On the basis that they are studying 5 0 transgender related issues? 6 And others. And other issues that are --7 Α yeah. 8 9 Are those other issues anywhere in this 0 10 policy manual? 11 Α No. 12 Are those other issues anywhere in the Ο 13 effective amendments to this policy memo? 14 Α No. Are you familiar with the 2022 version of 15 0 16 this policy memo? 17 Α Yes. Given your job title, it might be an funny 18 0 19 question. 20 Is there anything in that 2022 version 21 that says that NIH has a policy of not funding or 2.2 defunding transgender related research? 23 Α No. 24 0 In fact, in that 2022 version, it's also 25 the opposite, the policy is actually to fund that



1	research, isn't it?
2	MS. ANDRAPALLIYAL: Objection, calls for
3	speculation.
4	THE WITNESS: It doesn't exclude.
5	BY MR. McGINTY:
6	Q Doesn't exclude, but research on
7	sex gender minorities is important under that 2022
8	Version 2, right?
9	MS. ANDRAPALLIYAL: Objection, calls for
10	speculation.
11	THE WITNESS: In the Institutes and
12	Centers where those priorities are, they are able to
13	fund and have been able to fund their research.
14	BY MR. McGINTY:
15	Q Have you ever been told not to talk about
16	either of the Executive Orders in your
17	communications about terminating grants?
18	MS. ANDRAPALLIYAL: Objection. To the
19	extent that to the extent the question is seeking
20	attorney-client and deliberative information, I'm
21	instructing the witness not to answer.
22	BY MR. McGINTY:
23	Q Can you answer that question?
24	MS. ANDRAPALLIYAL: Again, to the extent
25	the question is seeking deliberative or



4

5

6

7

8

1 attorney-client information, I instruct the witness
2 not to answer.
3 BY MR. McGINTY:

Q Without divulging any deliberative or attorney-client privileged information, have you ever been told not to talk about the Executive Orders in your communications about grant termination?

9 A That would divulge discussions with the
10 Office of General Counsel. And seeking clarity from
11 the funding -- you know, just in seeking clarity
12 between the priorities, we need to know if the
13 priorities, you know, the memo, so.

14 Q The memo that you are currently drafting?
15 A The memo that the agency head is drafting.
16 Q Outside of communications about drafting
17 that memo, has anyone told you not to talk about the
18 EOs when you talk to, for example, the Chief Grants
19 Management Officers?

20

A No.

MS. ANDRAPALLIYAL: Objection. The question calls for provision of deliberative, attorney-client information, so to the extent that that information is implicated, I would instruct the witness not to answer.



1	THE WITNESS: During the meetings about
2	staff guidance, no, nobody has told me not to talk
3	about that, but I just don't because it's yeah,
4	nobody said not to, though.
5	BY MR. McGINTY:
6	Q Have you ever told the Chief Grants
7	Management Officers not to refer to the Executive
8	Orders when they discuss grant terminations with
9	investigators?
10	A No.
11	MS. ANDRAPALLIYAL: Objection
12	THE WITNESS: No. Sorry.
13	MS. ANDRAPALLIYAL: Objection to the
14	extent that objection. The question is seeking
15	deliberative information so I'd instruct the witness
16	not to answer.
17	MR. McGINTY: Can you explain your
18	objection to me.
19	MS. ANDRAPALLIYAL: You're seeking
20	deliberative information that employees are using to
21	make a final policy decision, and so for that reason
22	it's deliberative communications protected by the
23	Daubert process privilege.
24	MR. McGINTY: I'm seeking a communication
25	that instructs agency behavior, not the information



1	of the policy.
2	MS. ANDRAPALLIYAL: I'm not sure I
3	understand the difference.
4	MR. McGINTY: The difference is one is
5	deliberative and one isn't.
6	MS. ANDRAPALLIYAL: But any communications
7	that are pre-decisional that go towards that final
8	decision are arguably
9	MR. McGINTY: And I'm asking about the
10	final decision not to talk about the EOs.
11	MS. ANDRAPALLIYAL: Can you repeat the
12	question, please.
13	MR. McGINTY: Sure.
14	BY MR. McGINTY:
15	Q Have you ever told any Grants Management
16	Officers not to talk about the EOs when they discuss
17	grant terminations
18	MS. ANDRAPALLIYAL: Objection, vague.
19	BY MR. McGINTY:
20	Q with the public.
21	There's no objection on the table. You
22	can answer.
23	A No.
24	Q Okay.
25	A The question is I would like to correct



1 that. The question has been are we terminating 2 3 on the basis of the EOs. And the answer is we are looking at the priorities, the agency priorities, 4 5 and that's what the letter has stated. So that, that's what I'm pointing them back to, the letter 6 7 and the priorities, not the EOs. If they asked. If that was a question 8 9 during a meeting. And the answer was the 10 termination is based on the agency's new priorities 11 as outlined in the termination letters. That's all 12 I provided. 13 The agency priorities are not published in 0 14 the Grants Management, the Grants Policy Statement, 15 or any amendments to it? 16 Α Correct. 17 The Agency's priorities, as far as you're 0 18 aware, only exist in form letters that you were 19 given by Rachel Riley? 20 MS. ANDRAPALLIYAL: Objection, asked and 21 answered. 22 THE WITNESS: By my supervisor, yes. 23 BY MR. McGINTY: 24 0 And there's no other place where Okav. 25 these agency priorities are published or made



1 available? MS. ANDRAPALLIYAL: Objection, asked and 2 3 answered. 4 THE WITNESS: No. 5 MR. McGINTY: Okay. I think we're about It might be time to take a 6 to move into a new area. 7 quick five or ten-minute break. Can we go off the 8 record. 9 (Recess taken - 2:29 to 2:50 p.m.) 10 MR. McGINTY: We can go back on the 11 record. 12 BY MR. McGINTY: 13 Now, I know you have a big stack of Q 14 exhibits right in front of you. And I'm going to ask you to find Exhibit 3 which is the February 28th 15 16 letter to Dr. Tham. 17 Exhibit 3, you said? Α 18 Oh, did I get the number wrong? Q 19 No, not that one. Maybe it's 4. 20 Α Okay. 21 0 Yeah, 4. Sorry. 22 Α Yeah. 23 So about a little more than halfway 0 Okay. 24 down the page it says here in this letter: 25 "It is the policy of NIH not to prioritize



1	these research programs."
2	Do you see that?
3	A Yes.
4	Q Okay. And "these research programs,"
5	meaning research programs based on gender identity,
б	right?
7	A Yes.
8	Q Now, I just asked you to go through a lot
9	of NIH policies, and your testimony was there is no
10	written final policy of NIH not to prioritize
11	research programs based on gender identity.
12	That was your testimony, right?
13	A Yes.
14	Q So when this letter says it is the policy
15	of NIH not to prioritize these research programs,
16	that's not referring to any written policy, is it?
17	MS. ANDRAPALLIYAL: Objection, assumes
18	facts not in evidence.
19	THE WITNESS: I don't know what it was
20	intended to mean because I didn't write it.
21	BY MR. McGINTY:
22	Q There is no effective and final NIH policy
23	that you are aware of not to prioritize research
24	programs based on gender identity. Is that right?
25	A That I know of, no.



1	Q And in your role as Director of OPERA,
2	would you expect to know about such a policy?
3	(Reporter requests clarification)
4	MR. McGINTY: Director of OPERA.
5	MS. ANDRAPALLIYAL: Objection, calls for
6	speculation.
7	THE WITNESS: I don't not necessarily.
8	BY MR. McGINTY:
9	Q In your role as Director of OPERA, what
10	kind of policies do you oversee?
11	A Grants administration policies and
12	grants internal policies for our grants managers,
13	which are called the NIH Grants Administration
14	Manuals, which is an internal document that supports
15	the external document which is the NIH Grants Policy
16	Statement.
17	Q So those are all policies that apply to
18	NIH as a whole?
19	A Yes.
20	Q So the policies that you might not be
21	aware of would be policies that would apply to one
22	IC, for example?
23	MS. ANDRAPALLIYAL: Objection, calls for
24	speculation.
25	THE WITNESS: I don't know.



1	BY MR. McGINTY:
2	Q Do you know of policies within the ICs
3	that you do not oversee?
4	A I don't know.
5	Q Okay. And just to be clear, there is no
6	NIH policy not to prioritize research programs based
7	on gender identity that you are aware of?
8	A That that is clear. No, not that I am
9	aware of.
10	Q Okay.
11	A Can I ask a point of clarification?
12	Q Please.
13	A You are saying NIH policies, and I don't
14	see priorities as something that I would oversee.
15	Q Sure.
16	A You know?
17	Q I understand. I guess my question comes
18	from the part of the sentence where it says, "It is
19	the policy of NIH not to prioritize these research
20	programs." So that's why I'm asking you about the
21	policies of NIH.
22	A Okay.
23	Q And you're not aware of any policy of NIH
24	not to prioritize those research programs?
25	A No, I don't have any (indiscernible).



1	(Reporter requests clarification)
2	THE WITNESS: I don't have any insight on
3	it.
4	BY MR. McGINTY:
5	Q Okay. So now let's go back to Exhibit 3.
6	A I don't know if I'll be able to find it
7	now.
8	(Witness reviews documents)
9	THE WITNESS: I just saw it. Where did it
10	go? It's running from me. Maybe I'll look closer.
11	I have to re-order.
12	(Witness reviews documents)
13	BY MR. McGINTY:
14	Q I understand the papers get shuffled.
15	Okay. And we are looking at page 8616 on
16	Exhibit 3, and looking at Section 3(e). The last
17	sentence there, it says:
18	"Agencies shall take all necessary steps,
19	as permitted by law, to end the Federal
20	funding of gender ideology."
21	Do you see that?
22	A Yes.
23	Q Has NIH, to your knowledge, terminated any
24	grants implementing that sentence?
25	MS. ANDRAPALLIYAL: Objection, calls for a



1	legal conclusion, calls for speculation.
2	THE WITNESS: We terminated it based on
3	the language in the letter.
4	BY MR. McGINTY:
5	Q Is it your testimony that the language in
6	the letter had no connection to the sentence that I
7	just read?
8	MS. ANDRAPALLIYAL: Objection, calls for
9	speculation, calls for a legal conclusion, assumes
10	facts not in evidence.
11	THE WITNESS: I don't know what the
12	intention was for the two. I don't know.
13	BY MR. McGINTY:
14	Q The language in the letter was given to
15	you. Is that right?
16	A Yes.
17	Q And you don't know why it was written. Is
18	that right?
19	A I don't know.
20	Q Okay. Let's go to Section 3(g) of this
21	same Executive Order.
22	A Okay.
23	Q It says:
24	"Federal funds shall not be used to
25	promote gender ideology. Each agency



1	shall assess grant conditions and grantee
2	preferences to ensure grants funds do not
3	promote gender ideology."
4	See that?
5	A Yes.
6	Q To your knowledge, has NIH terminated any
7	grants in implementing this section of this
8	Executive Order?
9	MS. ANDRAPALLIYAL: Objection, calls for a
10	legal conclusion, calls for speculation.
11	THE WITNESS: To my knowledge, the letter
12	terminates the grant and the language is in the
13	termination letter.
14	BY MR. McGINTY:
15	Q Okay. And the reason that the grants were
16	terminated, if I understand your prior testimony
17	correctly, is stated in the letter and it's stated
10	in the spreadsheet that states which grants you are
18	In the spreadbleet that states which states for are
18	going to terminate. Is that right?
19	going to terminate. Is that right?
19 20	going to terminate. Is that right? A Yeah, the spreadsheet, remember, I was
19 20 21	<pre>going to terminate. Is that right? A Yeah, the spreadsheet, remember, I was telling you, it has the categories, like, Y, you</pre>
19 20 21 22	<pre>going to terminate. Is that right? A Yeah, the spreadsheet, remember, I was telling you, it has the categories, like, Y, you know, D, I, that kind of thing.</pre>



1	Q Okay. That's not an internal NIH platform
2	for administrative information chain?
3	MS. ANDRAPALLIYAL: Objection, calls
4	for assumes facts not in evidence.
5	THE WITNESS: What would it be I don't
6	under is it a part of something I would use for
7	work? I mean
8	BY MR. McGINTY:
9	Q That's my understanding from just
10	googling. I searched START NIH, and that appears to
11	be an internal database. I'm just asking if you are
12	familiar with it?
13	A I don't know about it, no.
14	Q Okay.
15	A I'm trying you have me think like,
16	NIH like START.
17	Q S-T-A-R-T.
18	A Oh, okay. No.
19	(Bulls Deposition Exhibit 21 was marked
20	for identification.)
21	BY MR. McGINTY:
22	Q I'm handing you what's been marked
23	Exhibit 21. Do you know what that is?
24	A Oh, gosh.
25	MS. ANDRAPALLIYAL: Can I have a copy.



1	(Document tendered to Ms. Andrapalliyal)
2	THE WITNESS: It's a spreadsheet of all
3	the termin it looks like terminations. That's
4	what this says up here, but I'm not familiar with
5	this document.
6	BY MR. McGINTY:
7	Q You haven't seen this before?
8	A Is this the spreadsheet? A spreadsheet
9	that we have a master spreadsheet that kind of, I
10	think, has all of the terminations in it. But
11	that's not this I don't know if that is this.
12	Q You don't know by looking at it?
13	MS. ANDRAPALLIYAL: Objection, asked and
14	answered.
15	THE WITNESS: The spreadsheet that I have
16	doesn't look like this.
17	BY MR. McGINTY:
18	Q What does it look like?
19	A It has all the information in it, like the
20	grant number, the title, you know, that kind of
21	stuff. I don't know that it has, like it has the
22	administering IC.
23	What does this have? I thought that said
24	program official. It has it has a lot of this in
25	it. It does.



1	
1	Q Okay. Could you go over to "Termination
2	Reason," that column. See the first four rows it
3	says, "gender ideology (EA14168)"? Do you see that?
4	A This is small.
5	Q I have a modified version with some
6	columns taken out, it's a bit bigger. Would you
7	like to see that?
8	A Yes, please. Sorry.
9	(Bulls Deposition Exhibit 22 was marked
10	for identification.)
11	BY MR. McGINTY:
12	Q I'm handing you what's been marked
13	Exhibit 22.
14	A Yes.
15	Q And I will represent to you that this is a
16	version of Exhibit 21, and I've taken some columns
17	out so that the information on it is more legible.
18	A Thank you.
19	Q But if you ever need to refer back to
20	Exhibit 21 for any reason, let me know. I don't
21	mean to take information away from you, I just want
22	you to be able to see it.
23	A Exactly.
24	Q Okay. So the question I just had was, for
25	now, this first four rows, you see where it says



1	"Terminat	ion Reason"?
2	A	Yes.
3	Q	And it says "gender ideology," and then in
4	parenthes	is, 14168?
5	A	Yes.
6	Q	Is that the same thing that appears on
7	your inte	rnal spreadsheet that you didn't know
8	about?	
9	A	Not that I know about.
10	Q	Okay.
11	A	But I will say that there are different
12	spreadshe	ets that are being maintained, so I
13	don't	I don't know about all of them. I just
14	know abou	t mine.
15	Q	How do you know there are different
16	spreadshe	ets that are being maintained?
17	A	Well, because we are actually working
18	with, to	give data to HHS. Then we provide data to
19	maintain	ourselves so we know when the grant was
20	terminate	d. And HHS wants to be able to put that
21	informati	on, publicize that information.
22		So some of this information is made
23	available	, like, with the columns, the categories
24	that I wa	s telling you about. So I see the
25	categorie	s which is what determination reason looks



1	like, but I don't know that I've seen this in my
2	spreadsheet.
3	Q When you say "this," what do you mean?
4	A This gender so gender ideology, yes.
5	But the EA14168, I don't recall seeing that.
6	Q You didn't see that. Okay.
7	MR. McGINTY: Okay. I think we're done.
8	MADAME COURT REPORTER: May I just ask:
9	would you like to order a copy?
10	MS. ANDRAPALLIYAL: I would, but we would
11	also like to redirect.
12	MADAME COURT REPORTER: Oh, sorry.
13	MS. ANDRAPALLIYAL: But maybe we could
14	could we take a break before we do that. Maybe
15	reconvene at 3:30.
16	(Recess taken - 3:05 to 3:38 p.m.)
17	MS. ANDRAPALLIYAL: Okay. We're back on
18	the record.
19	EXAMINATION
20	BY MS. ANDRAPALLIYAL:
21	Q Good afternoon, Ms. Bulls.
22	A Good afternoon.
23	Q So I'll be asking you just a few questions
24	here today. And let me know if anything is unclear
25	or when you have any questions.



	· · ·
1	So I'll just start with the Subpoena that
2	was issued that we talked about in Exhibit 1. Do
3	you have the handy?
4	A Yes.
5	Q Okay. And will you turn to page 5 of that
6	document. And you see the second half of that page
7	number, "Requests for Production"?
8	A Yes.
9	Q Okay. Did you discuss these Requests for
10	Production with counsel?
11	A No.
12	Q Okay. Did you receive were you told by
13	counsel to collect documents in preparation for
14	these discovery requests?
15	A Yes.
16	Q Okay. Is it possible that counsel is
17	collecting documents in other ways apart from asking
18	you to collect documents?
19	MR. McGINTY: Objection, calls for
20	speculation.
21	THE WITNESS: It is possible.
22	BY MS. ANDRAPALLIYAL:
23	Q Okay. Are you aware of whether counsel is
24	collecting documents in other ways?
25	A I don't know.



1	Q	Okay. I'll turn to and I'm sorry, I
2	don't hav	e the exhibit number handy, but the one,
3	DEI Staff	Guidance.
4		MR. McGINTY: Which one?
5		MS. ANDRAPALLIYAL: The third one.
6		(Reporter requests clarification)
7		MS. ANDRAPALLIYAL: DEI Staff Guidance.
8		MR. McGINTY: The one dated March 25?
9		MS. ANDRAPALLIYAL: No, I guess, the first
10	one, plea	se.
11		MR. McGINTY: The first one, so the one
12	dated Feb	ruary 12th.
13		MS. ANDRAPALLIYAL: Okay, yes.
14		MR. McGINTY: So that would be Exhibit 8.
15		MS. ANDRAPALLIYAL: Exhibit 8, okay.
16	BY MS. AN	DRAPALLIYAL:
17	Q	Do you have Exhibit 8 handy, Ms. Bulls?
18	A	Yes.
19	Q	You have it?
20	A	Yes.
21	Q	Okay, great.
22		Now, what, in your understanding, was the
23	basis for	issuing this; in other words, what
24	policies	were the basis for issuing this Staff
25	Guidance,	to your knowledge?

1	A There wasn't a policy that was issued. It
2	was the temporary restraining orders that were
3	issued that caused us to develop this guidance.
4	There was a funding pause.
5	Q Mm-hmm.
6	A And the funding pause was in place, and we
7	were trying to figure out, you know, just make sure
8	that folks understood that the given, you know,
9	the recent court it says, "given the recent
10	court orders, this cannot be a factor in IC funding
11	decisions at this time."
12	So we're trying to talk about the fact
13	that leadership is going to be looking over agency
14	priorities.
15	Q Okay. Okay.
16	MS. ANDRAPALLIYAL: Okay. And then can we
17	go to and what was the second version, which
18	exhibit was that?
19	MR. McGINTY: The one dated February 13th.
20	MS. FRAAS: 7, I believe.
21	MR. McGINTY: Yeah, the one dated after
22	the one that said follow court order, it says don't
23	follow court orders. And that's February 13 and
24	that's Exhibit 7.
25	BY MS. ANDRAPALLIYAL:



1	Q Do you have that one handy?
2	A Yes, I do.
3	Q Okay. And, to your knowledge, what
4	were what, if any, policies or priorities were
5	the basis for this guidance?
6	A There were no policies. There were no
7	priorities for the guidance.
8	Q Okay. When you say there were no
9	priorities, do you mean there were no final
10	priorities, or something else?
11	A Final priorities. I issued this based on
12	the Secretarial directive related to DEI funding.
13	Q Okay.
14	A That was just to say that, that the
15	Secretary had issued a memo, or a Secretarial
16	directive.
17	Q Okay.
18	A So it wasn't agency priorities, but it was
19	a Secretarial directive.
20	Q Okay. So it was a Secretarial directive.
21	So when you say when you contrast with an agency
22	priority, what do you mean by that?
23	A It means, for me, that there was a
24	directive coming from HHS Office of the Secretary
25	that was issued to the NIH and the other operatives.



1	Q So by "agency," do you mean NIH? Are you
2	contrasting NIH with HHS when you are distinguishing
3	between
4	A Yeah, I am.
5	Q Secretarial directive and agency
6	priorities directive?
7	A Yeah.
8	Q Okay. Well, let me switch gears a little
9	bit.
10	If we can go to Exhibit go to Exhibit 4
11	which, I believe, is the December 28th termination.
12	Give me one second.
13	So looking at that document, but also
14	looking at the several other exhibits that we've
15	discussed earlier in this deposition regarding other
16	grant terminations, is it correct to say that your
17	prior testimony identified three documents that, in
18	your view, explained the terminations? And by those
19	three documents, I mean an e-mail you received,
20	spreadsheets you received, and a template letter.
21	A Yes.
22	Q Is that correct?
23	A That is correct.
24	Q Okay. Do you know if there are other
25	documents out that NIH has produced that would
	A remove P



1	explain these terminations but that you did not
2	receive?
3	A I do not know.
4	Q Okay. Is it possible?
5	A It is possible.
6	Q Now, can you remind us of your title
7	again.
8	A The Director of the Office of Policy for
9	Extramural Research Administration.
10	Q And what's the title of the person you
11	report to?
12	A The Deputy Director for Extramural
13	Research.
14	Q And who does that person report to?
15	A The Principal Deputy of Extramural
16	Research.
17	(Reporter requests clarification)
18	THE WITNESS: Extramural.
19	And, I believe, the person I reported to,
20	the Principal Director and Director, so.
21	BY MS. ANDRAPALLIYAL:
22	Q And the Principal Deputy is one title, and
23	then above that is the Director. Is that correct?
24	A That's correct.
25	Q Okay. And who does the Director report



1 to? 2 Α Secretary. 3 Secretary of HHS? Q 4 Α HHS. 5 0 Okav. Now, are you involved in the 6 discussion of what should be agency priorities in 7 funding research? 8 Α No. 9 Who would be involved in those 0 No? Okay. 10 discussions? 11 It would be the Deputy Director for Α 12 Extramural Research, the Principal Deputy, and the 13 Director of the Agency along with all of the 14 Institute and Centers Directors. 15 0 Okay. And who actually sets agency 16 priorities for funding, for funding research? 17 Α The Director along with the IC Directors. 18 Now, are you aware of whether the 0 Okav. 19 Acting Director has issued funding priorities? 20 Α I'm not aware. 21 Are you aware of draft priorities? 0 22 I am aware of draft priorities. Α 23 Of draft priorities that are currently 0 24 being developed? I'm aware -- I saw a draft document, but I 25 Α



1	don't know	w if it's still under development. I'm
2	not I d	don't have any insight. I just know that I
3	saw a dra:	ft document, definitely, yes.
4	Q	Do you know if any draft priorities have
5	been fina	lized?
6	Α	I don't know.
7	Q	Is it possible that they have and you
8	don't know	N?
9	Α	It is possible.
10	Q	Turning back to Exhibit 4, I know I'm
11	jumping a	round a little bit, I do apologize.
12		But turning back to Exhibit 4 to the grant
13	terminatio	on letter, at one point counsel for
14	Plaintiff	asked you to compare the language in that
15	letter to	the language in Exhibit 3, which is the
16	Executive	Order 14168. Is that correct?
17	Α	Yes.
18	Q	Okay. And specifically, I believe, asked
19	you to com	mpare the language in that letter to
20	Section 2	of the Executive Order. Is that correct?
21	Α	Yes.
22	Q	Okay. Section 2 on page 1, at the bottom
23	of page 1	•
24	A	Mm-hmm, yes.
25	Q	Okay. Now, do you have any basis, any



1	official basis, to know whether the language in that	
2	termination letter was included because of the	
3	Executive Order?	
4	A No.	
5	Q Do you have any reason to believe or	
6	you said at one point that the language looked	
7	similar.	
8	What was the basis for that, for that	
9	statement?	
10	A Just me looking at it today, yeah.	
11	Q Okay. Did anybody tell you that the	
12	letter was based on the Executive Order?	
13	A No.	
14	Q Do you have reason to believe that it was,	
15	that the letter was based on the Executive Order?	
16	A I don't know.	
17	Q Okay. The letter in Exhibit 4 says that,	
18	that this award no longer effectuates agency	
19	priorities. Is that correct?	
20	A Yes.	
21	Q Okay. And do you have reason to believe	
22	that those agency priorities are based on Executive	
23	Order 14168?	
24	A Can you restate.	
25	Q Sure. Do you have reason to believe, in	



	· · · · · · · · · · · · · · · · · · ·
1	your official capacity, that the language in the
2	letter saying that this award no longer effectuates
3	the agency priorities was based on Executive Order
4	14168?
5	A No.
6	Q Okay. Let me switch gears again and let
7	me go back to that third version of the Staff
8	Guidance in the record, the March 25th document.
9	Do you have that handy?
10	A Exhibit?
11	MR. McGINTY: For the record, I believe
12	this is Exhibit 6.
13	BY MS. ANDRAPALLIYAL:
14	Q Exhibit 6.
15	A Okay.
16	Q Okay. Thank you.
17	Now, Ms. Bulls, is that a final document
18	that you have there as Exhibit 6?
19	A No, it's not intended to be final.
20	Q Okay. Is there a watermark on that
21	document?
22	A Yes.
23	Q What does the watermark say?
24	A "Confidential."
25	Q Is there a header on that document?



1	A Yes.
2	Q What does the header say?
3	A "Internal: Not for Distribution Outside
4	of the Government."
5	Q Do you know why that watermark and that
6	header was included on this document?
7	A Yes.
8	Q Why?
9	A Because people were sending the document
10	out to places where it's being posted publicly.
11	Q And why is it a problem that this document
12	was being posted publicly?
13	A Because, one, it was a draft document,
14	and, two, it was an internal document, Guidance for
15	Staff, and
16	Q So when you say it was a draft document,
17	was it was it subject to change?
18	A Yes.
19	Q When you sent it out, what was the purpose
20	of sending this kind of document out?
21	A I sent it out and asked for folks to
22	because they had a lot of questions, and so I asked
23	them to take a look at the document to see if the
24	updated version of the document answered their
25	questions.

1	Q And what are the problems that arise if a
2	draft document is posted publicly?
3	A People have information that is not final,
4	it's internal, and it's still going through vetting
5	processes. So it gives the pre what do you I
6	mean it's like pre-information that's not available,
7	not even final, within the agency.
8	Q And is it possible that there are
9	inaccuracies in a draft document like that when it
10	hasn't been finalized?
11	A Yes, because it still has to go through
12	approval within the management and leadership levels
13	and be approved, or at least reviewed by OGC.
14	Q And is it possible that that kind of
15	document would be materially changed before it's
16	finalized?
17	MR. McGINTY: Objection, leading.
18	THE WITNESS: The document has changed
19	over time, and it's very different than where it
20	started. And, yeah, it's not the same document.
21	BY MS. ANDRAPALLIYAL:
22	Q So it has changed sorry.
23	Are you saying that it has changed over
24	time?
25	A Yes.



	•
1	Q Okay. And could it change further over
2	time?
3	A It will.
4	Q Okay.
5	MS. ANDRAPALLIYAL: I'm going to jump
6	around again, and we might need an exhibit number
7	again here. The reinstatement document?
8	Do you have that exhibit number, Counsel?
9	MR. McGINTY: I believe that's Exhibit 10.
10	BY MS. ANDRAPALLIYAL:
11	Q Do you have that handy, Ms. Bulls?
12	A I'm getting at it. We were doing fine
13	before the grants policy.
14	(Whereupon, laughter)
15	BY MS. ANDRAPALLIYAL:
16	Q Okay. Do you have a copy of that now,
17	Ms. Bulls?
18	A Yes, I do.
19	Q Okay, great. Could you turn to page 5 of
20	that document, please.
21	(Reporter requests clarification)
22	MS. ANDRAPALLIYAL: Yes, page 5 of this
23	reinstatement document.
24	BY MS. ANDRAPALLIYAL:
25	Q Okay. And could you remind us which part



1	of Section IV has the language that you drafted?
2	A This:
3	"Revised Award: This grant has been
4	restored and the termination clause
5	rescinded effective immediately. The
6	grant will continue under the original no
7	cost extension."
8	Q Okay. Now, below that there is sorry,
9	at the very end of that page there's a statement
10	that says:
11	"The previous terms and conditions of
12	award remain in effect."
13	Do you see that language down at the
14	bottom?
15	A Yes.
16	Q Now, is it part of your job
17	responsibilities to interpret these kinds of Revised
18	Notices of Award?
19	A I never see them.
20	Q You never see them? Okay.
21	A No.
22	Q Who is in charge of administering them?
23	A The Institute and Centers, so the Chief
24	Grants Management Officer is responsible for making
25	sure that the terms are correct.

1	Q Okay. So in your duties do you typically	
2	come across these Revised Notices of Award?	
3	A No.	
4	Q No? Okay.	
5	Do you have reason to believe that the	
6	language beginning on page, at the bottom of page 5	
7	in some way invalidates the reinstatement of the	
8	grant?	
9	MR. McGINTY: Objection, leading, lack of	
10	foundation.	
11	BY MS. ANDRAPALLIYAL:	
12	Q What does this Notice of Award do? What	
13	does this document do?	
14	MR. McGINTY: Objection, lack of	
15	foundation.	
16	BY MS. ANDRAPALLIYAL:	
17	Q Do you know what this document does?	
18	A The document communicates the terms and	
19	conditions to the recipient.	
20	Q Okay. A Notice of Award, what is a Notice	
21	of Award?	
22	A It's a funding instrument.	
23	Q Okay. And so, do you understand what	
24	this, what this Notice of Award is doing?	
25	A Yes.	



1	Q What is it doing?	
2	A It is giving funding information from the	
3	Institute and Center to the recipient.	
4	Q Okay.	
5	A And are you talking about this particular	
6	award, or all? Just	
7	Q I'm talking about this particular award.	
8	A This particular award is communicating	
9	that the grant has been restored and that the	
10	termination clause is rescinded.	
11	Q Okay.	
12	A This is the first part. Because there's a	
13	second part, too, so. That's the only one I know	
14	about.	
15	Q Okay. And by "second part," what do you	
16	mean by second part?	
17	A So when Institutions and Centers issue	
18	awards, they issue the original award and then they	
19	issue revisions on top of that.	
20	Q Okay.	
21	A So the top revision was the latest	
22	revision as of the issue date of 3/27.	
23	Q Okay. And so when you drafted this	
24	language regarding the revised award, what was the	
25	intent of that language?	



1	A To restore the grant and to rescind the
2	termination.
3	Q Okay. And did you mean to conditionally
4	restore the grant?
5	A No.
6	Q Okay. Did this language intend to subject
7	the reinstatement to, to the language that follows
8	regarding, yeah, the start at the top of page 6?
9	A No, my language was to restore the grant,
10	which is what I sent to the Chief GMO.
11	Q Okay.
12	A The other language looks like it was
13	adding money back to the grant, which I had that
14	was just an action from the Chief GMO to restore
15	funding back to the grant.
16	Q I see. You're talking about the second
17	revised
18	A revision, yes.
19	(Simultaneous speaking)
20	BY MS. ANDRAPALLIYAL:
21	Q statement. I see.
22	A Yeah, which was separate from the first
23	one.
24	Q I see, okay. And then can we move to the
25	manual, that big stack at the bottom. So can we



1	just go to the introduction on page ii.	
2	A Yes.	
3	Q What is your understanding of the point of	
4	this, of this manual? What is the purpose for this	
5	manual?	
6	A It's to provide NIH recipients with the	
7	policy requirements and lay out the standard terms	
8	and conditions of the award.	
9	Q So when you say that it's meant for NIH	
10	recipients, does that mean it's for people who have	
11	already received, or institutions that have already	
12	received NIH grant funding?	
13	A Yes.	
14	Q Okay. How often is this manual updated,	
15	in your experience?	
16	A It's typically updated annually.	
17	Q Annually?	
18	A Yes.	
19	Q Okay. And so when was this document most	
20	recently updated?	
21	A It was updated April 2024. Well, that's	
22	the publication date.	
23	Q And, in your experience, has NIH issued	
24	new funding priorities or policies outside of this	
25	policy statement or initially without modifying this	

policy statement? 1 Yeah, funding priorities are typically 2 Α 3 outside of it. And they're housed on the websites 4 of the Institutes and Centers. 5 Okay. 0 We usually just issue a Guide Notice to 6 Α 7 talk about, you know, what the public policies are, legislative mandates, but we don't get into the 8 9 funding, aside from the CRs. We have to issue a CR 10 Notice. 11 And what are Guide Notices? 0 Okav. You 12 used that term earlier. 13 Α Yeah, Guide Notices communicate NIH 14 policies in the interim, between the time that the policy statement is updated, because policies change 15 before the policy statement is revised. 16 So we use 17 that as an instrument to communicate the policies, 18 policy changes, that might impact the end grants 19 policy statement. 20 Do you know if there are new Guide Notices 0 21 being developed at this time based on any new agency 2.2 priorities for policies? 23 I don't know. Α 24 Okay. Ms. Bulls, I'm done with my 0 25 questions. Thank you so much for your time.



1	А	Thank you.
2		MR. McGINTY: I will have some follow-ups.
3	Take a fi	ve-minute break?
4		(Recess taken - 4:08 to 4:16 p.m.)
5		MR. McGINTY: Let's go back on the record.
6		FURTHER EXAMINATION
7	BY MR. Mc	GINTY:
8	Q	Thank you, Ms. Bulls, for hanging in
9	there. I	think we're almost done.
10	А	Okay.
11	Q	You were asked about Exhibit 1, the
12	Subpoena I	Duces Tecum that was sent to you.
13	А	Yes.
14	Q	Do you recall just now you were asked
15	about that?	
16	А	Yes.
17	Q	And you were asked if counsel directed you
18	to gather	those documents. Is that right?
19		MS. ANDRAPALLIYAL: Objection, misstates
20	prior tes	timony.
21		MR. McGINTY: Would you read that back.
22		(The record was read aloud as follows:
23		"QUESTION: And you were asked if counsel
24		directed you to gather those documents.
25		Is that right?")



1	MR. McGINTY: If you go back up to the
2	redirect, and I believe the question was about
3	counsel's representation to Ms. Bulls about
4	Exhibit 1.
5	(The record was read aloud as follows:
б	"QUESTION: So I'll be asking you just a
7	few questions here today. And let me
8	know if anything is unclear or when you
9	have any questions.
10	"So I'll just start with the Subpoena that
11	was issued that we talked about in
12	Exhibit 1. Do you have that handy?
13	"ANSWER: Yes.
14	"QUESTION: Okay. And will you turn to
15	page 5 of that document. And you see the
16	second half of that page is numbered
17	'Requests for Production'?
18	"ANSWER: Yes.
19	"QUESTION: Okay. Did you discuss these
20	Requests for Production with counsel?
21	"ANSWER: No.
22	"QUESTION: Okay. Did you receive were
23	you told by counsel to collect documents
24	in preparation for these discovery
25	requests?



1	"ANSWER: Yes.
2	"QUESTION: Okay. Is it possible that
3	counsel is collecting documents in other
4	ways apart from asking you to collect
5	documents? ")
6	MADAM COURT REPORTER: Is that what you
7	wanted?
8	MR. McGINTY: Yes, thank you.
9	BY MR. McGINTY:
10	Q So you were asked if counsel instructed
11	you to collect documents in response to those
12	requests, right?
13	A Yes.
14	Q And you did collect those documents,
15	right?
16	A Yes.
17	Q And other than your CV, are you aware of
18	any of those documents having been provided to
19	Plaintiff's counsel today?
20	A I don't know.
21	Q And you've been here all day. Did you see
22	counsel give those documents to us?
23	A No.
24	Q Let's see. When you were asked about
25	Exhibit 8, which is the February 12th Staff



1	Guidance if you could pull that up, that would be	
2	great.	
3	Now, this was from Dr. Lauer and from you.	
4	Is that right?	
5	A That is correct.	
6	Q And Dr. Lauer resigned the next day,	
7	right?	
8	A I don't remember.	
9	Q You don't remember. Did Dr. Lauer resign?	
10	A Yes, he did. He retired.	
11	Q Do you know if it had any connection with	
12	this Exhibit 8?	
13	A I'm sorry?	
14	Q Do you know if his retirement had any	
15	connection with this Exhibit 8?	
16	A No.	
17	Q Okay. When you were asked about	
18	Exhibit 7, if I remember correctly, you said that	
19	Exhibit 7 was in response to a Secretarial	
20	directive. Did I understand that right?	
21	A Yes.	
22	Q Was that Secretarial directive written	
23	down?	
24	A Yeah, it's in the document from the	
25	department. It was attached.	



Case 1:25-cv-10787-BEM Document 38-8 Filed 04/25/25 Page 210 of 246

1	Q I see. It is this February 10th document
2	here?
3	A Yes.
4	Q Okay. And that had to do with DEI
5	funding?
6	A Yes.
7	Q Is it common for those kinds of directives
8	to come from HSS?
9	MS. ANDRAPALLIYAL: Objection, calls for
10	speculation.
11	THE WITNESS: I don't know.
12	BY MR. McGINTY:
13	Q Okay. I'm going to ask a bit, a few more
14	questions about Exhibit 4, the February 28th letter.
15	And you were asked if you knew whether or
16	not there were other documents other than the
17	e-mail, the spreadsheet, and the template letter
18	that explained terminations like what we see on this
19	Exhibit 4.
20	Do you remember that?
21	A Yes, I do.
22	Q And, as I recall your testimony, you said
23	you didn't know if there were other documents that
24	might exist.
25	A I don't know if there are other documents.



1	Q If you wanted to find that out, who would
2	you ask?
3	MS. ANDRAPALLIYAL: Objection, calls for
4	speculation.
5	THE WITNESS: If I wanted to find out who
6	would I ask? My supervisor.
7	BY MR. McGINTY:
8	Q Okay. Who, right now, is who?
9	A Jon Lorsch.
10	Q Jon Lorsch.
11	A But at the time I think it was
12	Liza Bundesen.
13	Q Liza Bundesen might know?
14	A I don't know.
15	Q Can you think of anybody else who might
16	know whether or not other documents exist?
17	MS. ANDRAPALLIYAL: Objection, calls for
18	speculation.
19	THE WITNESS: No, I don't know. I don't.
20	BY MR. McGINTY:
21	Q How about Rachel Riley?
22	A I don't know.
23	Q Okay. Just confirming your testimony, you
24	got this template language word for word, right?
25	A Yes.

Q You didn't write one word in this?
A No.
Q And there's several letters like this. I
think you testified somewhere over five hundred and
less than a thousand for grants that you terminated
with those kind of template letters. Is that right?
A Yes.
Q Is that common?
MS. ANDRAPALLIYAL: Objection, calls for
speculation.
THE WITNESS: Is is what common?
BY MR. McGINTY:
Q Have you ever, before January 20th, 2025,
put your name on a letter like this without having
written a single word of it?
MS. ANDRAPALLIYAL: Objection, beyond the
scope of redirect.
BY MR. McGINTY:
Q You can answer.
A No.
Q And it's your testimony that you don't
know why any of this language was included, right?
MS. ANDRAPALLIYAL: Objection, misstates
MS. ANDRAPALLIYAL: Objection, misstates prior testimony.

1	Q Do you know why any of this language is
2	included?
3	A No.
4	Q Before January 20th, 2025, did you put
5	your name on a letter when you didn't know why any
6	of the words were included in it?
7	MS. ANDRAPALLIYAL: Objection,
8	argumentative.
9	THE WITNESS: Not that I can recall.
10	BY MR. McGINTY:
11	Q Is that something you might remember?
12	A I don't know.
13	Q You were asked if you were regularly
14	involved in discussions of what agency priorities
15	should be, and I think you said: Deputy Director,
16	Principal Director, the Director of the agency, and
17	the Institute Directors. Is that right?
18	A Yes.
19	Q Okay. And can you name those people for
20	me?
21	A The acting leader or, well, from when
22	these letters were written? Is that what you mean?
23	Yes.
24	Q I mean everybody from the first letter,
25	which I understanded is February 28, 2025, to the



1	most recent, which I think is March 27th.
2	Who are all the people in that time frame
3	who would be involved in discussions about what
4	agency priorities should be?
5	A I don't know. I don't know I know who
6	the people I know the people that were in the
7	positions, but I don't know if they were discussing
8	agency priorities. Because we were talking about
9	funding priorities, that's what I was saying to
10	counsel.
11	Q Oh, okay. In funding priorities, then.
12	A Funding priorities.
13	Q Then funding priorities, then.
14	A During the time that this letter was
15	issued, it would have been Liza, maybe, and
16	Dr. Memoli. I don't know of anyone else except for
17	the IC directors that probably were
18	Q Okay. And how many IC directors are
19	there?
20	A There are, I want to say, 20 well,
21	there's 27 different Institute and Centers, but
22	there's 24 ICs that administer funds. So I'm going
23	to just talk about the 24 that I know. And I'm not
24	sure the CSR has an IC director. Yeah, so, yes, 24.
25	Q Okay. If I am understanding you



1	correctly, the people who might be involved in those
2	discussions of what agency funding priorities should
3	be would be Liza Bundesen, Dr. Memoli, and then the
4	24 IC directors?
5	MS. ANDRAPALLIYAL: Objection, calls for
6	speculation.
7	MR. McGINTY: Following up on the question
8	you asked.
9	THE WITNESS: I'm sorry?
10	BY MR. McGINTY:
11	Q I'm following up on a question that
12	counsel asked.
13	A Oh, okay.
14	Q She asked you who are the people who would
15	be involved in agency priorities for funding, and
16	you said Deputy Director, the Principal Director,
17	the Director of the agency, and Institute Directors.
18	I'm just making sure I have a full list of who that
19	is.
20	A So you want the names of the individuals
21	or I don't understand the question.
22	Q If I get the names of the individuals that
23	would be great.
24	A The names I don't know the names of all
25	of them, so it's just Liza and Matt. Matt from this



1 letter. (Reporter requests clarification) 2 3 Matt, M-a-t-t, Matthew THE WITNESS: 4 Memoli. BY MR. McGINTY: 5 6 Plus the 24 IC directors? 0 7 Α Yes. And I think you said the acting director 8 0 9 generally does funding priorities. 10 Are funding priorities generally written 11 down somewhere? 12 They're on the -- it's not the acting Α 13 director, it's the Institute and Centers. And their 14 funding priorities and funding strategies are out on their individual websites. 15 16 Are you generally familiar with those? 0 17 Α No. I'm familiar with just the 18 overarching strategy, which is to push, because they 19 have different strategies, you send the recipients 20 back to the various Institute and Centers to look at 21 those. 2.2 And in this instance with respect 0 Okav. 23 to this February 28th letter we're looking at and 24 the other termination letters that reference the 25 policy of NIH not to prioritize certain research



1	programs, that didn't come from the Institute and		
2	Centers, did it?		
3	A	I don't know. I don't know.	
4	Q	Were they is any language like this on	
5	any of t	he Institute and Centers websites?	
6	A	Not that I know of.	
7	Q	And earlier it was your testimony that	
8	this was	sent to or sent from someone at HHS. So	
9	Rachel Riley?		
10	A	This particular language and e-mail, yes.	
11	Q	The language that we're looking at in	
12	Exhibit 4?		
13	A	Yes.	
14	Q	Do you have any reason to believe that the	
15	Institute and Centers sent that language up to HHS		
16	and it was distributed back down?		
17	A	I don't know.	
18	Q	How many Institutes and Centers have	
19	grants that were terminated with these kinds of form		
20	letters?		
21	A	Many, if not	
22	Q	All of them?	
23	A	most.	
24	Q	Sorry, I spoke over you. Can you say that	
25	again?		



1	A Many, if yeah, many.	
2	Q Is it all of them?	
3	A By now it might be. I don't know. I I	
4	honestly just don't know. But I believe that all of	
5	them have been impacted at this point.	
6	Q So it stands to reason that this is not a	
7	funding priority that's coming from the individual	
8	Institutes and Centers, doesn't it?	
9	MS. ANDRAPALLIYAL: Objection, calls for	
10	speculation.	
11	THE WITNESS: I don't know.	
12	BY MR. McGINTY:	
13	Q You were also asked if you have any	
14	official basis to know whether the language in these	
15	template letters relates in any way to the Executive	
16	Orders. Do you recall that testimony?	
17	A Yes.	
18	Q And you testified you don't have any	
19	reason to believe that or to know that on your	
20	official basis?	
21	A That is correct.	
22	Q If you wanted to figure that out, who	
23	would you ask?	
23 24	would you ask? MS. ANDRAPALLIYAL: Objection, calls for	



1		THE WITNESS: I would ask my supervisor.
2	BY MR. Mc	GINTY:
3	Q	Which in February 28 was Liza Bundesen?
4	А	Correct.
5	Q	Can you think of anybody else who might
6	know?	
7		MS. ANDRAPALLIYAL: Objection, calls for
8	speculation.	
9		THE WITNESS: I can't.
10	BY MR. Mc	GINTY:
11	Q	Is it possible that Rachel Riley knows?
12		MS. ANDRAPALLIYAL: Objection, calls for
13	speculati	on.
14		THE WITNESS: I don't know. It's
		THE WITNESS. I GOT C KNOW. IC S
15	possible.	I don't know.
	possible. BY MR. Mc	I don't know.
15	-	I don't know.
15 16	BY MR. Mc Q	I don't know. GINTY:
15 16 17	BY MR. Mc Q	I don't know. GINTY: You were asked about this March 25th
15 16 17 18	BY MR. Mc Q	I don't know. GINTY: You were asked about this March 25th Exhibit 6. And your testimony was it's still subject
15 16 17 18 19	BY MR. Mc Q Guidance,	I don't know. GINTY: You were asked about this March 25th Exhibit 6. And your testimony was it's still subject
15 16 17 18 19 20	BY MR. Mc Q Guidance, to change	I don't know. GINTY: You were asked about this March 25th Exhibit 6. And your testimony was it's still subject , right?
15 16 17 18 19 20 21	BY MR. Mc Q Guidance, to change A Q	I don't know. GINTY: You were asked about this March 25th Exhibit 6. And your testimony was it's still subject , right? Yes.
15 16 17 18 19 20 21 22	BY MR. Mc Q Guidance, to change A Q	I don't know. GINTY: You were asked about this March 25th Exhibit 6. And your testimony was it's still subject , right? Yes. Has this Guidance been relied on by any
 15 16 17 18 19 20 21 22 23 	BY MR. Mc Q Guidance, to change A Q Institute	I don't know. GINTY: You were asked about this March 25th Exhibit 6. And your testimony was it's still subject , right? Yes. Has this Guidance been relied on by any or Center to take any action?



1 ask? The Institute and Center. 2 Α 3 Q You have to ask each Institute and Center 4 directly? 5 Α I would. And you testified about Exhibit 10 which 6 0 was the March 27th Notice of Award. 7 8 Α Yes. 9 And I think your testimony here was that 0 10 it's not within your usual job duties to interpret 11 these kinds of Notices of Award. Is that right? 12 No, I don't usually interpret these Α Yes. 13 Notices of Awards. I don't -- my testimony, what I recall is that I said I don't normally see them so I 14 15 wouldn't interpret them. 16 You don't normally see them, let alone 0 17 interpret them? 18 Α Right. 19 Fair enough. Earlier when you were 0 20 looking at page 5 and page 6, your testimony was it 21 looked to you, maybe on the basis of just a lay 2.2 person's understanding, that this language under 23 termination and transgender issues may have been included by mistake. 24 25 Do you recall that testimony?



1	A I do recall that testimony, yeah.
2	Q If I wanted to get to the bottom of that,
3	who would I need to ask?
4	A You would need to ask the Institute or
5	Center, so Maggie. Margaret Young.
6	Q Margaret or Maggie Young?
7	A Yes.
8	Q How is Maggie spelled?
9	A M-A-G-G-I-E.
10	Q Great. Do you know if NIH has ever made a
11	promise not to terminate this grant in the future?
12	MS. ANDRAPALLIYAL: Objection, calls for
13	speculation.
14	THE WITNESS: No, I don't know that.
15	MR. McGINTY: Okay. Nothing further.
16	MS. ANDRAPALLIYAL: We're good. Thank
17	you.
18	MR. McGINTY: Oh, yeah. We do need the
19	rough transcript, I'll put that on the record.
20	MADAM COURT REPORTER: And you're ordering
21	the original
22	MR. McGINTY: We're ordering the original
23	and we'll probably expedite it.
24	MADAM COURT REPORTER: Okay.
25	And may I ask, are you ordering a copy,



<pre>2 too? 3 MS. ANDRAPALLIYAL: Yes, please. Yeah, 4 and on the same time frame, I guess, for both.</pre>	
4 and on the same time frame, I guess, for both.	
5 (Whereupon, at 4:38 p.m. the deposition of	
6 MICHELLE G. BULLS was concluded.)	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	



1	ACKNOWLEDGMENT	OF DEPONENT		
2	I, MICHELLE G. BULLS, do hereby			
3	acknowledge that I have read and examined the			
4	foregoing testimony, and the same is a true, correct			
5	and complete transcription of the testimony given by			
6	me and any corrections appear on the attached Errata			
7	sheet signed by me.			
8				
9				
10				
11	(DATE)	(SIGNATURE)		
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				



1	CERTIFICATE OF SHORTHAND REPORTER - NOTARY PUBLIC		
2	I, Bess A. Avery, Registered Merit		
3	Reporter, the officer before whom the foregoing		
4	deposition was taken, do hereby certify that the		
5	foregoing transcript is a true and correct record of		
6	the testimony given; that said testimony was taken		
7	by me stenographically and thereafter reduced to		
8	typewriting under my supervision; and that I am		
9	neither counsel for, related to, nor employed by any		
10	of the parties to this case and have no interest,		
11	financial or otherwise, in its outcome.		
12	IN WITNESS WHEREOF, I have hereunto set my		
13	hand and affixed my notarial seal this 7th day of		
14	April 2025.		
15			
16	My commission expires:		
17	November 14, 2028		
18			
19			
20	/s/BESS A. AVERY		
21	NOTARY PUBLIC IN AND FOR THE		
22	DISTRICT OF COLUMBIA		
23			
24			
25			
	Na constant N		













































